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Factor H (FH) is a 155-kDa plasma protein that regulates the alternative pathway of 
the complement system. Its 20 CCP modules, of 51-62 amino acid residues each, are 
linked by short stretches (“linkers’) of three to eight residues. We set out to test the 
hypothesis that long linkers towards the middle of FH play a role in ensuring that its 
architecture allows binding sites near its N- and C-termini to engage cooperatively 
with the main target, C3b, which is the key complement pathway-triggering product 
of C3 cleavage. 
In initial work, site-directed mutagenesis was used to test whether two mutations, 
R53H and R78G, located within CCP 1 and linked to the kidney disease atypical 
hemolytic uremic syndrome, are functionally deficient. Mutant versions and a native-
sequence version of CCPs 1-4 of FH (i.e. FH 1-4) were tested for their ability to act 
as a cofactor for the FI-mediated cleavage of C3b, and accelerate the decay of the C3 
convertase. It was shown that FH 1-4 R53H binds normally to C3b but has no 
regulatory activity while FH 1-4 R78G binds very poorly and is also deficient in co-
factor and decay-accelerating activities. 
In subsequent work, mutagenesis was used to make the eight-residue CCPs 12-13 
linker shorter (SL), or more flexible through introduction of glycine residues 
(3xGLY), within recombinant (r) module pair FH 12-13, and in rFH 10-15 and rFH 
8-15 as well as full-length rFH. NMR showed CCPs 12 and 13 remain intact 
following mutation of the linker but (in FH 12-13) are more flexibly mutually 
disposed, as expected. SAXS indicated that both FH 10-15 SL and FH 10-15 3xGLY 
nonetheless have similar compact structures to native sequence (WT) FH 10-15. On 
the other hand, FH linker mutants interact with C3b (according to surface plasmon 
resonance) somewhat less well than WT FH and in the case of FH SL, affinity is 
similar to that of FH 19-20, i.e. there is no evidence that both C3b-binding sites in 
this mutant bind to the target simultaneously. Nonetheless, the bacterial protein 
PspCN boosts binding of linker mutants to C3b by a similar factor (three-to-fivefold) 
to that observed for FH WT. Thus, while interactions between non-sequential CCPs 
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are important for FH architecture, a bend at the 12-13 linker is needed for full-length 
FH to adopt a fully biological activity confirmation. 
The use of EPR for structural studies of rFH and its mutants was explored. Free 
cysteines were engineered in so they could have spin labels site-specifically attached. 
Alternatively, a recognition site for transglutaminase was introduced so a spin label 
could be incorporated. These strategies were applied to rFH 12-13 and rFH 10-15 as 
a prelude to studies of full-length FH. Several suitably engineered proteins were 
prepared but only one paramagnetically labeled sample (of FH 12-13) made it for 
EPR; this yielded results commensurate with the NMR-derived structure.Taken 
together, these promising data lay the groundwork for a future, potentially very 
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Chapter 1 Introduction 
1.1 Complement System 
1.1.1 Historical perspective 
Initial reports of complement were published as early as the 1890s by Buchner and 
Bordet who independently described a heat-labile component in serum that aided or 
“complemented” the killing of bacteria by antibodies [1]. Later in the same decade, 
the term “complement” was introduced by Paul Ehrlich. For many years it was 
thought that the role of complement was limited to the innate immune response, and 
to being an effector arm of antibody-mediated immunity. More recently it was 
recognized that complement also augments adaptive immunity by influencing both 
B-cells and T-cells [2, 3]. Furthermore, it is now realized that the complement 
system contributes to homeostasis by elimination of endogenously generated 
hazardous materials [4]. 
1.1.2 Functions of the complement system 
The complement system is a highly integrated network of proteins located either in 
plasma or on cell surfaces; in 2010 Ricklin et al [4] estimated that 48 proteins form 
the “core” of the system [1, 4]. Complement performs three main physiological 
activities: integration of innate and adaptive immunity [5]; defending against 
infections [6, 7]; and disposing of immune complexes and waste from inflammatory 








Table 1.1 The three main physiological activities of the complement system (adapted from [1]).  
Activity Complement Protein Responsible For Activity 
Host defense against infection  
 Opsonization  Covalently bound C3b (and iC3b) and C4b; receptors 
on erythrocytes and phagocytes. 
 Chemotaxis and activation 
of Leukocytes 
 Anaphylatoxins (C3a, C4a and C5a); anaphylatoxin 
receptors on various cells. 
 Lysis of bacteria and cells 
 
 Membrane attack complex (C5b, C6, C7, C8 and C9). 
Interface between innate and 
adaptive immunity 
 
 Augmentation of antibody 
responses 
 C3b (and iC3b) and C4b bound to immune complexes 
and to antigen; C3-fragment receptors on B- cells and 
antigen-presenting cells. 
 Enhancement of 
immunologic memory 
 C3b and C4b bound to immune complexes and to 
antigen; C3-fragment receptors on follicular dendritic 
cells. 
Disposal of waste  
 Clearance of immune 
complexes 
 C1q; covalently bound fragments of C3 and C4. 
 Clearance of apoptotic 
cells 
 C1q; covalently bound fragments of C3 and C4. 
 MBL and Ficolins, bind apoptotic cells. 
  
 
The proteins that together make up the proteolytic cascade at the heart of the 
complement system were named C1 to C9, more or less according to when they were 
identified and in approximate accordance with the order in which they participate in 
the cascade. In addition, several proteases in the alternative pathway are called 
“factors”, namely factors B, D and I (and factor H, which is not a protease but is a 
cofactor for factor I). Upon activation, several of the proteins are cleaved and the 
resulting fragments are then assigned a lowercase letter, e.g. C3a and C3b. The 
proteins may be organized into three interconnected activation pathways (see Figure 




Figure 1.1 Three pathways of complement activation. The early stages of each pathway involve a 
series of proteolytic cleavages and macromolecular recognition events that allow an enzyme known as 
a “C3 convertase” to form. The event at which all three pathways merge is cleavage of C3 into C3a 
and C3b by the C3 convertases. Subsequently, C5 convertases assemble that catalyze activation of C5 
generating C5a and C5b.  The C5b fragment initiates self-assembly of terminal components to form 
the membrane attack complex (MAC). (Image redrawn form [1] and the MBL-MASP complex taken 
from Wallis group home page (http://www2.le.ac.uk/departments/biochemistry/staff/wallis/research) 




1.2 Activation pathways of the complement system 
Complement activation is initiated by the classical, lectin or alternative pathways 
(Figure 1.1). All of the pathways involve initially inactive components that become 
proteolytically cleaved into their active forms. Each pathway is initiated by different 
molecules, but they converge at C3 cleavage and thereafter all can lead to production 
of anaphylatoxins (C3a and C5a), opsonins (C3b, iC3b, C4b) and, ultimately, the 
MAC.  
1.2.1 The central role of complement components C3 and C3b  
As mentioned above all three activation pathways converge at the cleavage of C3 to 
C3b. This is therefore the pivotal event in a complement-mediated response.  
C3 (187 kDa) is part of the α2-macroglobulin family. It is composed of two chains - 
the α-chain (residues 650-1641, 110 kDa) and β-chain (residues 1-645, 75 kDa) - 
that are linked by a single disulphide bond and non covalent forces [11]. Electron 
microscopy [12] and crystal structures [13-15] (Figure 1.2) have revealed a large 
difference in the domain orientations between C3 and C3b. Of great significance is 
that the reactive thioester, which is buried in C3, becomes both exposed and 
activated in C3b allowing attachment to nucleophiles including hydroxyl groups on 
cell surfaces. The crystal structure of C3 (Figure 1.2 (A)) [13] revealed the presence 
of 13 domains. Eight of these are macroglobulin (MG) domains that form the core or 
body of the protein and have a key-ring arrangement; MG1-4 form one ring whilst 
MG5 and MG6 form a second half-ring which overlaps the first; MG7 and MG8 
extend the second half-ring. The five remaining domains are the linker (LNK) 
domain located between MG1, MG4 and MG5, the anaphylatoxins (ANA) domain 
(residues 650-726), the CUB domain, the thioester domain (TED) that is inserted 
within the CUB, and finally the C345C domain.  
C3b is generated from C3 by the proteolytic removal of the ANA domain from C3 
which results in a truncated α-chain (residues 727-1641) whilst the β-chain (residues 
1-645) is unaffected. The crystal structures of C3 and C3b (Figure 1.2) [14, 15] 
revealed for the first time, the details of the major rearrangement in domain 
orientations following excision of ANA. As mentioned above, the most important of 
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these rearrangements is the shift in position of the CUB and TED domain. Thus, in 
C3b the thioester (residues Cys988-Gln991 [16-18]) is exposed and hence poised to 
attach to the surface while in C3 these residues are buried at a position 85 Å away 
from where they are in C3b. The TED domain in C3b has also changed its 
conformation to be C3d-like [19] rather than C3-like [13] and the reactive residues 
of the thioester now form an acyl-imidazole intermediate that is highly reactive [20]. 
 
Figure 1.2 Crystal structures of C3 and C3b. (A) shows the crystal structure of C3 (PDB_ID 2A73, 
[13]) with the eight MG domains shown in different purple shades, ANA in cyan, CUB in red, TED in 
green with the thioester shown in red spheres, and C345C in orange. The crystal structure of C3b 
(PDB_ID 2I07, [14]) (B) shows the loss of the ANA domain and the large conformational change 
between the CUB and TED domains allowing the thioester to become solvent-exposed [13, 14].The 
structures were visualized using PyMOL (www.pymol.org). 
1.2.2 Classical pathway 
The classical pathway (CP) was, as the name suggests, the first pathway to be 
discovered.  It is activated by C1; C1 is a molecular complex consisting of C1q 
associated with two molecules each of the serine protease proenzymes C1r and C1s. 
C1 is mainly activated through binding to the Fc portions of antigen-bound IgG and 
IgM antibodies [21-23]. Once bound to a molecular pattern on a target surface, a 
conformational change occurs to C1q, which is composed of 18 chains arranged in 
tightly associated trimers and resembles a “bunch of six tulips” with collagenous 
“stems” and globular “heads” [24] (Figure 1.3). Binding by multiple globular heads 
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of C1q to antibodies in an antibody-antigen complex produces a rearrangement of 
the stems. The resultant mechanical forces that are experienced by the C1r chains - 
which weave in and out of the collagenous stems of C1q - causes mutual cleavage 
and consequent activation by one C1r molecule of the other. Activated C1r then 
cleaves and activates the two C1s molecules. Activated C1s performs cleavage of C4 
to C4b that (like C3b) can attach to surfaces via a covalent bond [24-26]. C4b is a 
platform for binding of C2, which in the context of the C4b:C2 complex is also a 
substrate for activated C1s. The resultant complex C4b.2a is the C3 convertase (C3-
cleaving enzyme) of the classical pathway. Some of the C3b molecules generated in 
the subsequent cleavage event remain bound (or re-bind) to C4b.2a, forming the C5 
convertase (C4b2a3b). This enzyme cleaves C5 into C5a and C5b; C5b binds to C6 
to initiate the terminal pathway and formation of the membrane-attack complex 
(MAC). 
 
Figure 1.3 Structure of C1 complex. C1 contains one molecule of C1q and two molecules of C1r 
(blue circles) and C1s (red circles) which form the complex. C1r and C1s possess the interaction and 
catalytic domains. (Image redrawn from [27]).  
1.2.3 Lectin pathway 
The lectin pathway (LP) is similar to the CP. It also activates C2 and C4 but does so 
when mannose binding lectin (MBL) or ficolins binds to carbohydrates found on the 
surface of pathogens that include viruses, bacteria, yeast and parasites [4, 28, 29]. In 
serum both MBL and ficolins are in complex with MBL-associated serine proteases 
(MASPs) which are closely related to C1r and C1s of the CP [30-32]. MASP-2 is 
able to cleave both C2 and C4 and therefore promotes formation of C4bC2a, as in 
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the CP. On the other hand, MASP-1 cleaves C2 but not C4 [33, 34]. The function of 
MASP-3 has not yet been established. 
1.2.4 Alternative pathway 
The alternative pathway (AP) is triggered by the spontaneous low-level hydrolysis 
(also termed “tick-over”) of the thioester bond buried in C3 (C3, C4 and C5 are all 
similar in structure and sequence but only C3 and C4 have thioester linkages) [35]. 
The hydrolyzed C3 forms C3(H2O) (Figure 1.4, A), which undergoes a major 
conformational change (very similar to that of C3 when cleaved to C3b) and 
becomes a binding site for factor B (FB) [36]. Factor B in the context of the 
C3(H2O)B complex is cleaved by factor D (FD) to generate the initiating C3 
convertase (C3(H2O)Bb). This (like C4b2a in the CP) cleaves C3 to form C3b and 
C3a [36]. 
As described in Section 1.2.1, cleavage of C3 by convertases into C3a and C3b 
exposes and activates a very reactive thioester group on C3b that allows it to 
covalently attach via an ester to a hydroxyl group on any nearby surface (in an 
analogous fashion to C4b that prefers amine nucleophiles). C3b (see Figure 1.2 (B)) 
is similar in structure to C3(H2O) and is also a binding site for FB, forming the C3bB 
“proconvertase” complex. As with C3(H2O)B, factor B in this complex is activated 
by FD to form the AP C3 convertase, C3bBb (Figure 1.4). This potentially surface-
bound proteolytically active complex generates additional molecules of C3b that 
attach to the surface in the immediate vicinity and seed the formation of additional 
convertase complexes. In this way, a positive-feedback amplification loop is 
established resulting in rapid deposition of multiple molecules of C3b (up to 10
8
 on 
one bacterial cell in ten minutes [37]). Some C3b molecules re-associate with C3bBb 
complexes resulting in formation of (C3b)2Bb and a switch of substrate to C5. Thus 
(C3b)2Bb is the C5 convertase of the AP (analogous to C4b2aC3b) while the 
resultant C5b is the starting point for assembly of the membrane-attack complex (see 
above). The C3b generated by the AP can also participate in forming the CP/lectin 
C5 convertase thus boosting all of the activation pathways. Importantly, the AP is 
very slightly activated (due to low-level C3 hydrolysis) at all times on every cell 
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exposed to serum, but amplification of C3b does not ensue due to the selective action 
of regulators. These are discussed in the next section. 
 
Figure 1.4 Activation of the AP. Shown in (A) is the spontaneous low level hydrolysis of C3 (via an 
initial reversible step that forms intermediate C3(H2O)*) that results in the formation of C3(H2O). The 
diagram in (B) shows the cleavage of C3 by C3 convertase and the attachment of C3b to the cell 
surface. The surface-tethered C3b then binds FB followed by cleavage by FD which results in the 
formation of a surface-attached C3 convertase. Some C3 convertases then bind a further C3b and 
form the C5 convertases, which nucleates the terminal events of the pathway resulting in the 
formation of the MAC. ((A) is re-drawn from [36] and (B) from [1]). 
1.3 Regulators of complement 
Complement regulation is vital to the wellbeing of the host organism.  A balance 
between activation and modulation must be struck such that pathogens or damaged 
host cells are cleared, yet the level of activation must be controlled to avoid 
damaging tissue. In order to maintain this balance, a family of proteins called the 
regulators of complement activation (RCA) is present, both in the fluid phase and 
bound to cell membranes. These down-regulate the central steps in all three 
pathways that involve conversion of C3 to its activated form, C3b. Well 
characterized RCAs found in the fluid phase are FH and C4b-binding protein 
(C4BP) while membrane-bound regulators include complement receptor type 1 
(CR1, also called CD35), membrane co-factor protein (MCP or CD46), decay 
acceleration factor (DAF also called CD55) (Table 1.2). Non-RCA members 
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including properdin, protectin (CD59) and C1-inhibitor are also important in 
complement regulation The fluid-phase RCAs have the important ability to act 
specifically to protect self surfaces (including ones not protected by a membrane) as 
opposed to bacterial and other foreign surfaces [38, 39]. 
The RCA proteins consist mainly of one type of domain; the complement control 
protein (CCP) module (also called a sushi domain or short consensus repeat). Factor 
H consists entirely of CCP modules. C4BP, MCP, and CR1 contain various numbers 
of CCPs along with: a linking chain (in C4BP that interlinks seven CCP-containing 
chains); transmembrane and intracellular domains (in CR1); a serine-threonine-
proline-rich domain plus transmembrane and intracellular domains (in MCP) or a 
serine-threonine-proline-rich domain and GPI-anchor (in DAF) [38]. Table 1.2 
summarizes the main proteins found in the RCA family. 
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1.4 Factor H 
Factor H (FH) was first identified in 1965 as β1H globulin by Nilsson and Mueller-
Eberhard [40]. The gene encoding FH is CFH which is part of the RCA gene cluster 
on chromosome 1q32 [41]. FH itself is a single polypeptide chain composed of 20 
CCP modules containing approximately 60 amino acid residues each; it has 1213 
residues and eight N-glycans with a total mass of about 155,000. It is found in 
plasma at a concentration between 116-562 µg/ml [42, 43] but recently estimates 
have been lowered to 150-300 µg/ml [44]. 
1.4.1 Structural properties of Factor H 
The 20 CCP modules (Figure 1.5) that form FH are attached to their neighbors via 
short linkers that seem to vary in flexibility. Since the N- and C-termini are at 
opposite poles of each of the spheroidal CCP module structures, modules within FH 
have been compared to “beads on a string”. No crystals of FH have been reported in 
the literature while the available electron microcopy [45], analytical 
ultracentrifugation and small angle x-ray scattering (SAXS) study [46] point to a 
flexible overall structure that is, nonetheless, more compact (about half as long), on 
average, than would be the case if the protein were fully extended. Upon binding to 
C3b, FH is hypothesized to form a bent-back conformation that allows the N-
terminus and C-terminus to interact with the same C3b molecule [47-49] but this is 
unproven. 
All CCP modules that have been studied to date share a similar globular structure 
(40 Å by 15 Å by 10 Å) that is stabilized by disulphide bonds formed between four 
consensus cysteine residues in the pattern, CysI- CysIII, CysII- CysIV  and a highly 
conserved set of hydrophobic residues – including a near-invariant Trp - that 




Figure 1.5 NMR derived structure of a CPP module. Cartoon diagram of CCP 16 of FH (PDB_ID 
1HCC, [50]). β-strands are shown as red arrows connected by loops of non-standard secondary 
structure (blue). The four invariant cysteine residues are represented as sticks (yellow). The structure 
was visualized using PyMOL (www.pymol.org). 
A multiple sequence alignment of all 20 FH CCPs (Figure 1.6) highlights highly 
conserved residues which include a proline residue at the third position after the first 
cysteine and tyrosines at a position two residues before (conserved in 14 out of 20 
CCPs) and four residues (conserved in 12 out of 20 CCPs) after the second cysteine 
residue. Other common residues include Glycine and Glutamic acid. 
 
Figure 1.6 Multiple sequence alignment of the 20 CCPs of FH. Single-letter code used throughout. 
The invariant cysteines are highlighted by the dark blue box and the near-invariant tryptophan by the 
blue box. The tyrosine residues are also indicated (pale blue). The alignment was created using 
Jalview version 2 [51].  
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Currently there are 3D structures available for 17 out of the 20 CCPs (9, 14 and 17 
are still unsolved) ,which have been determined by either X-ray crystallography or 
NMR spectroscopy using recombinantly expressed fragments containing between 
one and four CCP modules [50, 52, 53]. To date a full model for FH has yet to be 
determined but alongside the crystal and NMR models, techniques such as small 
angle X-ray scattering (SAXS), analytical ultracentrifugation and electron 
microscopy have helped to gain information regarding the overall shape of FH [54, 
55]. 
The NMR-derived structures for CCPs 1-2 and 2-3, when over-laid on the common 
module, indicated that the N-terminal CCPs (1-3) adopt a highly extended “rod-like” 
shape [56]. A crystal structure of CCPs 1-4 in complex with C3b confirmed the “rod-
like” shape of CCPs 1-3 but additionally revealed a kink between CCPs 3 and 4 
giving CCPs 1-4 an L-like shape [57]. Data obtained using both SAXS [58] and 
FRET [59] confirmed the “L” shape of FH 1-4 . NMR-derived structures of CCPs 5 
[60] and CCP 7 have been solved [61] whilst a crystal structure for CCPs 6-8 (in 
complex with sucrose octasulfate) showed an extended shape with a slight bend 
between CCPs 7-8 [62]. The central region of FH (CCPs 8-15) might act as a hinge 
or tether between the two termini of FH that are involved in binding to ligands (see 
Section 1.4.3) [63]. This central region contains CCPs that contain fewer residues 
(CCP 13 is the smallest at 51 residues) than average (60 residues) and these modules 
are joined by linkers that are longer in length when compared to the rest of FH (see 
figure 1.7). 
Figure 1.7 Linker lengths. The number of residues found in each linker is written below the CCP 
pairs. For each CCP the number of residues is written. Linker lengths and CCP residue data taken 
from (http://www.bionmr.chem.ed.ac.uk/bionmr/public_html/Residue_lengths.pdf). 
Structures determined by NMR are available for CCPs 10-11, 11-12 and 12-13 while 
SAXS data is available for CCPs 8-15, CCPs 10-12 and CCPs 10-15 [52, 55]. The 
NMR-derived solution structures for CCPs 10-11 and 11-12 have intermodular 
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bends of 118° and 90°, respectively, while 12-13 is also a “V-shape”, and features a 
bend of 80° (0° corresponds to a fully extended linear structure). Analysis of SAXS 
data using the ensemble optimization method (EOM) along with overlaid ensembles 
of solution structures for CCPs 10-12 suggests there is little flexibility between the 
modules. The lack of flexibility seen in CCPs 10-12 is also seen in the CCP pair 12-
13 as relaxation data (T1, T2 and heteronuclear NOEs) recorded for the pair implied a 
relatively rigid conformation [55]. When the study was extended to include CCPs 
10-13, a model based on the structure of the three pairs was created, showing that the 
modules formed an “out of plane zigzag structure” rather than the arc seen with 
CCPs 11-13. Analysis of the SAXS data for CCPs 10-15 with the model of CCPs 10-
13 fitted as a rigid body yielded a confirmation that suggested CCPs 14 and 15 
interacted very closely with CCP 13 resulting in a compact structure. The fitting of 
the NMR models to the SAXS data of CCPs 10-15 suggested that CCPs 13-14 form 
a near 180° bend allowing CCPs 14 and 15 to interact with CCP 13 and the 12-13 
linker which gives a compact conformation to the central region [52, 55].  
With regard to the C-terminus, both X-ray diffraction and NMR spectroscopy-
derived models are available for CCPs 19-20 and there are crystal structures for FH 
18-20 and for FH 19-20 in complex with C3d. The crystal structure [64, 65] and the 
NMR-derived structure [66] of CCPs 19-20 showed that a “rod like” shape was 
adopted. When the crystal model was extended to CCPs 18-20, a distinct “J” shaped 
was formed with an approximately 122° tilt between CCPs 18 and 19 [48]. This was 
not borne out, however by SAXS. Figure 1.8 shows all the NMR and crystal models 




Figure 1.8 NMR and crystal-derived structural information for FH. (A) shows the CCPs that 
have had their structures solved using NMR whilst (B) show those modules solved by X-ray 
crystallography. The NMR section labeled FH 1-3 is composed of both NMR models of CCP 1-2 and 
CCP 2-3 aligned over CCP 2. PDB models used for NMR: CCPs 1-2 (2RLP, [56]), CCPs 2-3 (2RLQ, 
[56]), CCP 7 (2JGX, [61]), CCPs 10-11 (4B2R, [52]), CCPs 11-12 (4B2S, [52]), CCPs 12-13 (2KMS, 
[55]), CCPs 15-16 (1HFH) and CCPs 19-20 (2G7I, [64]).CCP 5 was taken from the CCP module 
database (http://www.bionmr.chem.ed.ac.uk/bionmr/public_html/ccp-db.html). For the crystal 
structure: CCPs 1-4 with C3b (2WII, [57]), CCPs 6-8 (2UWN, [62]) and CCPs 18-20 (3SW0, [48]). 
1.4.2 Functional properties of Factor H 
Factor H is the main soluble regulator of the AP and it protects host cells from 
damage that could be caused by activation of the complement system [40, 43]. 
Regulation by FH occurs in three ways. It acts as a cofactor for cleavage (of the 
alpha chain) by the serine protease FI of C3b into an “inactive” form, iC3b (Figure 
1.9) with release of the small fragment C3f (this is known as cofactor activity). iC3b 
remains an opsonin but cannot bind factor B. Further cleavage by FI of iC3b α-chain 
(with other cofactors) generates C3c that is released and C3dg (that can be further 
degraded by other proteases to C3d), which remains bound to the cell surface by an 
ester linkage [36]. Factor H also blocks assembly of the AP C3 (and C5) convertases 
by competing with factor B for binding to C3b. Finally FH acts catalytically in 
accelerating the decay of any AP convertases that do manage to form, yielding C3b 
and Bb that cannot re-associate (this is called decay-acceleration activity) [36, 67]. 
Note that the convertases are already labile and prone to dissociate, with a half life of 
a few minutes, while FH reduces this to a few seconds. These regulatory functions of 
FH are contained within the four N-terminal CCPs such that a recombinant fragment 
consisting of FH CCPs 1-4 has both decay-accelerating activity and cofactor activity 
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in the fluid phase [68, 69]. Inactivation of C3b bound to a surface by FH (and 
FH/FI), however, is modulated by the chemical make-up of the surface to which it is 
bound. Discrimination by FH between self and non-self surfaces depends on CCP 
modules 5-20. 
 
Figure 1.9 Cofactor assay. C3b contains two chains referred to as α-chain and β-chain linked by 
disulphide bonds. After incubation with FI and FH, the α-chain undergoes cleavage which results in 
the formation of iC3b. The α-chain cleavage can be visualized using SDS-PAGE followed by 
Coomassie staining or Western Blot; an example of a Western Blot is shown. 
1.4.3 Binding sites of Factor H 
Structure-function analysis of FH has highlighted binding sites for C3b and for 
polyanionic compounds such as glycosaminoglycans (GAGs). 
C3b-binding sites 
The main binding sites for C3b are located at both the N terminus and C terminus of 
FH [69]. At the N terminus, CCPs 1-4 interact with C3b. The crystal structure of 
C3b in complex with FH 1-4 (Figure 1.10) [57] showed a large buried interface of 
4,500 Å
2
. The interface between C3b and FH features four contact points that span 
the entire length of FH 1-4. Firstly the lower half of CCP 1 and the linker between 
CCPs 1 and 2 interacts with the new (following convertase cleavage) α-chain N-
terminal residues (α’NT) and the MG7 domain through salt bridges and hydrophobic 
interactions. A second binding site is located on CCP 2 and is formed by an area of 
hydrophobic residues surrounded by hydrophilic residues which interact with the 
MG6 and CUB domains. The third site in CCP 3 makes contact with both the α- and 
β-chains as well as bridging the MG2 and CUB domains. Finally, CCP 4 bridges the 




Figure 1.10 Structure of FH 1-4 in complex with C3b. The structure (PDB_ID 2WII, [57]) shows 
FH 1-4 represented as a surface (CCP 1 is pink, CCP 2 is pale blue, CCP 3 is pale green and CCP 4 is 
wheat) and C3b presented as a ribbon. The structure was visualized using PyMOL (www.pymol.org). 
Binding to C3b at the C-terminus occurs through CCPs 19 and 20. As previously 
mentioned (section 1.2.1) the TED domain of C3b is “C3d-like” so the crystal 
structures of C3d in complex with FH 19-20 (Figure 1.11) [65, 70] can give useful 
information as to how the CCPs may interact with the TED domain of C3b. The 
complexes suggest that the main binding site for C3b is located in CCP 19 and the 
linker between CCPs 19 and 20 leaving CCP 20 free to interact with polyanions on 
the cell surface (see below) or, as suggested by Kajander et al. [70], bind a nearby 
C3d molecule on the cell surface. Interestingly recombinant FH 19-20 has been 
shown to discriminate between host and non-host cells and can inhibit full-length FH 
from binding to cell surface-bound C3b as well as inhibiting decay acceleration and 
cofactor activities on the cell surface. In fluid phase FH 19-20 has no effect on decay 




Figure 1.11 Structure of FH 19-20 in complex with C3d. The complex (PDB _ID 3OXU, [65]) 
highlights that most of the interactions occur between CCP 19 (orange) and the yellow section of C3d 
(teal). CCP 20 (blue) is free to interact with polyanions found on the cell surface. The structure was 
visualized using PyMOL (www.pymol.org).  
A weaker binding site has also been suggested in the region of CCPs 6-8 [63] or 
CCPs 6-10 [72]. 
Polyanion binding 
In order for FH to distinguish host cells from non-host it must be able to recognize 
molecular patterns on the cell surface. These patterns are mainly polyanionic 
markers (molecules that contain negatively charged patches) like 
glycosaminoglycans (GAGs) and sialic acid [73]. GAGs are linear polysaccharides 
of varying molecular weights that are found on the surface of all animal cells. They 
are usually linked to protein side chains. Sialic acid is a derivative of neuraminic 
acid and structurally contains a backbone of nine carbons. Figure 1.12 shows the 




Figure 1.12 Structures of Heparin and Sialic acid. A typical heparin disaccharide unit (upper 
structure) comprising of IdoA and GlcN. R=SO3
-
. or H, R'= SO3
-
. or Acetyl group. For sialic acid 
(lower structure) the α-anomer is shown as this is the form sialic acid takes when bound to glycans. 
Structures were created using ChemDraw Std 12.0. 
Sialic acids were first reported [74] to control the extent to which FH regulated 
amplification of surface-bound C3b. Studies have shown that FH could possibly 
contain three binding sites for heparin (which is used as a model for highly sulfated 
GAGs); CCP 7, CCP 20 and in the region containing CCPs 9-15 [63, 64, 66, 71, 75-
78]. The heparin binding sites located in CCPs 7 and 20 are now unanimously agreed 
upon but the region containing CCPs 9-15 is uncertain. A study by Pangburn et al. 
[75] suggested that a binding site was located in CCPs 12-15 as fragments containing 
CCPs 6-15 and 12-15 bound to heparin agarose. The study also suggested that CCP 
13 was the primary binding site based on cross linking, and consistent with CCP 13 
containing a large number of basic residues compared to CCPs 12, 14 and 15. Two 
studies have been carried out to investigate whether CCP 13 was a binding site for 
heparin. The results from Blackmore et al. [76] did not support CCP 13 as a binding 
site for heparin as Δ13 (FH with CCP 13 deleted) bound to heparin-agarose affinity 
columns to a similar level as full length FH. Subsequently, Schmidt et al. [63] 
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showed recombinant fragments containing CCPs 12-13, 13, 11-14 and 13-15 did not 
bind to heparin.  
In a separate study, another potential binding site was suggested for CCP 9. In 2006 
Ormsby et al. [78], based on results with various recombinant fragments 
corresponding to the  CCPs 8-15 region, suggested that either CCP 8 or 9 could 
potentially contain a binding site for heparin. That FH 8-9 and 9-11 both bound 
heparin suggesting that this site was in fact located in CCP 9. A later study by 
Schmidt et al. [63], however, found that recombinant FH 8-9 did not bind to a 
heparin-affinity column. These authors pointed out that the FH 8-9 construct 
expressed in the Ormsby et al. study had an N-terminal sequence artifact that 
contained two arginine residues and they showed that a peptide 
(EFTWPSRPSRIGTKT) that matched the non-native sequence of Ormsby’s FH 8-9 
(plus two native residues, K and T) had a weak affinity for heparin. In summary, no 
heparin binding site has been convincingly demonstrated to lie in the within the 
central region of FH corresponding to CCPs 8-15. Figure 1.13 summarizes the major 
binding sites for C3b and polyanions within FH. 
 
Figure 1.13 Major ligand-binding sites within FH. The N-terminal CCPs 1-4 and C-terminal CCPs 
19-20 contain the major binding sites for C3b (solid purple line) whilst CCPs 6-8 contain a weak C3b-
binding site (dashed purple line). The major polyanion-binding sites are located in CCPs 7 and 19-20 
(solid orange line). 
1.4.4 Factor H protein family 
The FH protein family consists of seven multi-domain proteins which are solely 
composed of CCP modules; FH, Factor H-like protein 1 (FHL-1) and five factor H-
related proteins (FHR-1, -2, -3, -4 and -5) [79]. FHL-1 is a splice variant of FH and 
is identical to the first seven CCPs of FH with an additional four amino acid 
extension at its C terminus (Ser-Phe-Thr-Leu). Due to the overlap with the first 
seven CCPs of FH, FHL-1 also shares cofactor and decay-accelerating activity as 
well as the ability to bind C3b and heparin [79, 80]. The FHR proteins (Figure 1.14) 
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are all encoded by their own genes which are located close to CFH. FHR-1 consists 
of five CCP modules with CCPs 1 and 2 being similar in sequence to CCPs 6 and 7 
of FH and CCPs 3-5 being almost identical to the C-terminal CCPs 18-20 of FH. In 
human plasma two glycosylated forms of FHR-1 exist differing by one carbohydrate 
attachment site [81]. The smallest FHR is FHR-2, formed from four CCPs with 
CCPs 1 and 2 being similar to CCPs 6 and 7 of FH whilst CCPs 3 and 4 are similar 
to the C-terminus of FH. Like FHR-1 two glycosylated forms of FHR-2 exist - a 
single glycan and a 2-glycan form [82]. FHR-3 is composed of five CCP modules 
with CCPs 1-3 having high identity to CCPs 6-8 and CCPs 4 and 5 sharing similarity 
with CCPs 19 and 20 of FH [83]. The FHR-4B protein contains five CCPs with the 
first three being similar to FH CCPs 6, 8 and 9 while CCPs 4 and 5 of FH4B are 
similar (64% and 39% respectively) to 19 and 20 of the FH C-terminus [84]. The 
largest protein in the family is FHR-5 consisting of nine CCP modules with high 
identity to FH CCPs 6-7, 10-14 and 19-20 [85] (Figure 1.14). Functionally, all FHR 
proteins have been shown to bind C3b and polyanions but in general they lack 
detectable cofactor or decay-accelerating activity [79, 83, 86, 87]. The exception is 
FHR-5 which has been reported to display cofactor and decay-accelerating activity, 
although this is weak compared to FH [88]. Though they have neither cofactor nor 
decay-accelerating activity of their own, both FHR-3 and FHR-4B have been shown 
to enhance the ability of FH to perform these activities which was seen by the 
increase in cleavage of the α-chain of C3b into 68 and 41/43 kDa fragments visible 




Figure 1.14 FH protein family members. The members of the FH protein family are composed 
entirely of CCP modules. The alignment is shown according to the highest percentage (%) of 
homology to FH. CCPs highlighted in red indicate cofactor and decay accelerating activity, green is 
for heparin binding and blue for C3b and polyanion binding. FHR4A is not shown. Image adapted 
from [79, 89, 90]. 
1.4.5 Factor H and disease 
Polymorphisms, deletions and mutations found within the CFH gene cluster are 
associated with human diseases including the kidney diseases atypical haemolytic 
uraemic syndrome (aHUS) and membranoproliferative glomerulonephritis type II 
(MPGN II, also called dense deposit disease (DDD)), and the retinal disease, age-
related macular degeneration (AMD) [43]. There are also links between FH sequence 
variations and susceptibility to bacterial infections [91]; moreover, since FH is one 
of the main regulators of complement, it is exploited by many pathogenic organisms 
as a means to avoid diminish complement attack [92]. 
Atypical hemolytic uremic syndrome 
Atypical HUS is a rare but severe kidney disease that is characterized by thrombotic 
microangiopathy, haemolytic anaemia and acute renal failure [90]. There are two 
forms of aHUS, familial and sporadic. The majority of mutations linked to aHUS are 
heterozygous mis-sense mutations that are mainly found in the C-terminal region 
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with CCP 20 containing the most mutations (see Figure 1.15). At the N-terminus the 
highest number of mutations are located within CCP 1, including R53H [93] and 
R78G, which was found in a patient with sporadic HUS [94]. The SNP I62V also 
found in CCP 1 is linked to aHUS as well as being protective for AMD and DDD 
[95]. 
 
Figure 1.15 Number of aHUS mutations/SNPs located within the CCPs of FH. 
In many cases, the mutant form of the protein is able to control complement 
activation in the fluid phase but unable to do so on self surfaces [65, 96, 97]. 
Nonetheless, in the familial form of aHUS, approximately 50% of individuals that 
carry an aHUS-linked mutation in FH will not developed the disease. Other triggers 
for developing aHUS may be required, such as an infection or pregnancy [98]. 
Alternatively, an additional genetic variant might contribute to the risk of developing 
the disease; this could be a mutation in one of the other complement proteins and it 
is now recognized that approximately 20% of patients will have mutations in more 
than one gene [99].  
Membraneoproliferative glomerulonephritis type II 
Another kidney disease associated with FH is MPGN II. The disease which is rare is 
commonly found in children and is characterized by the formation of complement-
containing deposits in the glomerular basement membrane (GBM) that cause the 
kidney to become inflamed. In some cases deposits similar in structure and character 
are also found in the Bruch’s membrane located below the retinal pigment 
epithelium (RPE) in the eye [100]. Unlike aHUS the mutations located in FH that are 
linked to MPGN II are not located in the C-terminal modules but are found 
throughout the protein. For example, a homozygous mutation located in CCP 4, 
ΔK224, was identified in siblings (sisters aged 10 and 5). The mutation is located on 
a surface exposed loop. It disrupts regulation of complement because the deletion of 
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this single amino acid causes C3b binding to be weaker, and both cofactor and decay 
acceleration activity are reduced. The deletion has no effect on binding to C3d or cell 
surface indicating the C-terminus of the protein is still fully functional [101].  
Age-related macular degeneration 
Age-related macular degeneration (AMD) is a degenerative disease of the macula 
which is one of the leading causes of vision loss, in the developed world, for 
individuals aged over 60. AMD can be classed in two forms; wet and dry. Wet AMD 
(also called neovascular AMD) results in loss of vision through the growth of fragile 
blood vessels that, if broken, allow blood and fluid to fill the void between the retina 
and RPE, resulting in damage to surrounding tissue. The dry form of AMD is 
characterized by atrophy of the RPE along with the development of deposits called 
drusen that form between the RPE and Bruch’s membrane [102, 103] (Figure 1.16). 
Several studies have shown associations between AMD and the FH SNPs Y402H 
and I62V [95, 104-106]. The Y402 SNP located in CCP 7 can cause a six-fold 
increase in the risk of developing AMD in homozygous individuals whilst 
heterozygous individuals are 2.5 times more likely to develop the disease [107]. As 
CCP 7 contains one of the main binding sites for GAGs in FH the change from 
tyrosine to histidine may modify the ability of FH to bind to GAGs found on the cell 
surface [108]. In the case of I62V, which is found in CCP 1, the I62 variant is 
protective against AMD [95]. A quantitative study found that that when identical 
amounts of V62 FH or I62 FH were immobilized on a CM5 sensor chip within a 
surface-plasmon resonance instrument, and increasing concentrations of C3b was 
flowed across the chip, the I62 variant bound C3b more tightly (KD = 1.04 µM ± 
0.14 µM) than the V62 variant (KD = 1.33 µM ± 0.12 µM) [95]. In fluid-phase 
cofactor assays, I62 FH was calculated to be 20% more active than V62 (using 
densitometry to quantify cleavage products) and in a surface-bound cofactor assay it 
was shown that an approximately twofold increase in V62 compared to I62 was 




Figure 1.16 Age-related macular degeneration. Wet AMD is characterized by the formation of 
fragile blood vessels around the macular. Dry AMD is characterized by the formation of drusen 
deposits. Image adapted from http://www.beltina.org/health-dictionary/age-related-macular-
degeneration-armd-symptoms-treatment.html  
Capture of FH by pathogens 
In order for pathogens to survive in the blood stream they must be able to avoid 
attacks from the immune system. The ability of pathogens to evade the complement 
system has been intensively studied over recent years [92, 109]. Three mechanisms 
of action have been identified: recruitment of complement regulators, inactivation of 
complement proteins caused by enzymatic degradation and inhibiting complement 
proteins by interacting with them directly [92]. A wide range of pathogens exploits 
FH by sequestering this regulatory protein on their surfaces. Examples of pathogens 
that capture FH are Streptococcus pneumoniae (Gram-positive), Neisseria 
meningitides (Gram-negative), Candida albicans (fungus) as well as Echinococcus 
granulosus (parasites) and Human immunodeficiency virus [92, 110].  
Pneumococcus and pneumococcal surface protein C (PspC) 
S. pneumoniae (Pneumococcus) is a bacterium found naturally in the upper 
respiratory tract and at low levels is considered a normal part of the upper respiratory 
tract flora (Javra). When the levels of bacteria are high it can lead to upper and lower 
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respiratory infections as well as causing serious infections like meningitis [111]. In 
order for pneumococcal diseases to progress several virulence factors are known to 
be involved, one of which is pneumococcal surface protein C (PspC, also referred to 
as choline-binding protein A (CbpA)) [112, 113]. 
Currently there are 11 different subtypes of PspC proteins and these can be divided 
into a further two groups based on how they anchor to the bacterial cell wall. 
Subtypes 1-6 are known as the classical PspC proteins and form binding group 1. 
The proteins employ a C-terminal choline binding domain that anchors them to the 
cell wall through a noncovalent interaction with the phosphorylcholine groups on the 
bacterial surface. Classical PspC proteins show similar structure and organization 
within the N-terminal regions, they all have a leader peptide and an N-terminal 
domain which is followed by one or two repeating domains then a proline-rich 
region (Figure 1.17). The second group is formed by subtypes 7-11 and uses an 
LPXTG motif which interacts covalently with peptidoglycans on the cell wall via a 
sortase-catalyzed transpeptidation reaction [114-116]. 
 
Figure 1.17 Illustartion of the domain organization of classical PspC proteins. The blue cylinders 
represent the N-terminal regions, R1 and R2 cylinders represent the repeating domains, the P square 
the proline-rich domain and the orange CBD rectangle the choline binding domanin. 
PspC is able to bind FH which results in FH becoming attached to the pathogens 
surface, restraining complement activation and thus stopping complement mediated 
attack. Once bound to PspC, FH has been shown to remain functional. The 
interaction sites been the two proteins have been located to a 121 amino acid 
sequence found in N-terminal region of PspC and within CCPs 8-11 and 19-20 of 
FH [117, 118]. 
1.5 Investigating the structure of Factor H  
In order to fully understand how FH carries out its functional roles we need to 
investigate it at a structural level. The main challenges associated with studying the 
structure of FH are its large size – 1215 residues – extended nature and flexibility. 
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High-resolution NMR and X-ray crystallographic methods have been used to 
obtained detailed structural models of several short segments of FH. Unfortunately 
both techniques have their drawbacks; NMR – even using high fields and taking 
advantage of isotopic labeling - is size-limited to three or four CCP modules, while 
crystallography requires well-ordered three-dimensional arrays (crystals) of the 
protein, which are less likely to form in the case of extended and flexible molecules. 
An additional technique that can be used alongside NMR and crystals is electron 
paramagnetic resonance (EPR) spectroscopy. This can provide useful information on 
structure and dynamics [119] for larger proteins and complexes that would be 
difficult or impossible to obtain using the more established high-resolution 
techniques. 
EPR is particularly insightful when used in combination with site-directed spin 
labeling (more details in Section 1.5.3). This allows short and long-range distance 
measurements to be inferred. These distances can then be used as restraints when 
generating 3D models that have been built up from other information – such as 
models for the structures of FH and the C3:FH complex that are based on structures 
of fragments. The theory of EPR is similar to that of NMR. The major difference is 
that EPR makes use of the magnetic moment from unpaired electrons rather than 
nuclei [120].  
1.5.1 Basic principles of EPR 
Classically, electromagnetic radiation is thought of as magnetic (B1) and electric (E1) 
fields that are perpendicular to the direction of propagation. Electromagnetic 
radiation can also be represented by a stream of photons. The energy of a photon is 




) and v is frequency. 
When a photon has been either emitted or absorbed by an electron, atom or 
molecule, the energy of the total system must be conserved. 
Every electron has a spin number (s = 
1
/2) and a magnetic moment. Upon placing an 
unpaired electron in a magnetic field two spin states are created, anti-parallel (ms = 
+
1
/2) or parallel (ms = -
1
/2), and each alignment has a specific energy (due to the 
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Zeeman effect). The simplest energy level diagram for a particle containing a spin 
1
/2 
in a magnetic field is shown in Figure 1.18. 
 
Figure 1.18 Energy level diagram. The energy levels are labeled ms = +
1
/2 and ms = -
1
/2 and by 
adjusting the magnetic field (B0) the separation of the energy levels will change. When the frequency 
is adjusted so that the energy change (Δ ) = h , where   is the frequency of the source, resonant 
absorption will occur. The second equation for ΔE in Figure 1.18 uses the electron g-factor (g), Bohr 
magneton (µB) and magnetic field B0 [120].   
1.5.2 Distance measurement theory 
In all EPR methods, distance measurements depend on the magnetic dipole-dipole 




 of the two spins, A and B. 
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Where R is the distance between A and B. The energy equation can be transformed 
to the quantum mechanical spin Hamiltonian using the relationship between the 
electron magnetic moment and the electron spin operator ( S

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where the gyromagnetic ratio of the free electron is e , and  is Planck constant 
divided by 2π. When the dipolar coupling is small in comparison to the Zeeman 









      (3) 





for each rotation of the dipolar axis parallel (θ = 0°) and perpendicular (θ = 90°) with 
respect to the external magnetic field (BO). The average value of the dipolar 
interaction is zero for molecules with random orientation that are rotating fast in 
comparison to the inverse coupling strength. In PELDOR and DEER experiments, 
the sample is generally frozen so the spectra are a superposition of randomly 
oriented bi-radicals and each consists of two lines split by dipolar coupling. The 
spectrum from a sample containing molecules orientated randomly is called a Pake 
pattern (Figure 1.19). Distance between the two edges of the Pake pattern relate to 
the dipolar splitting from molecules where θ = 0°. The distance between the two 
peaks relates to the dipolar splitting for molecules where θ = 90° [121]. 
 




1.5.3 Site-Directed Spin Labeling 
Site-directed spin labeling (SDSL) combined with EPR has become a powerful tool 
for the investigation of protein structure and dynamics [122, 123]. A commonly used 
method for SDSL involves the introduction of a nitroxide side chain at a selected site 
which has been typically inserted using site directed-mutagenesis. Typically, 
cysteine-substitution mutagenesis is used (while any native cysteines are replaced by 
alanines or serines), followed by modification via a covalent interaction, of the 
sulfhydryl group with a specific nitroxide reagent, [122, 124] (more details in next 
section).  
An alternative method is to incorporate an unnatural amino acid (e.g. p-
acetylphenylalanine) into the protein sequence, using amber-codon suppression, 
which allows site-specific labeling [125]. In this approach, a stop codon is inserted 
into the DNA at the sequence position of interest. A “suppressor” tRNA which 
recognizes the stop codon and competes with release factor is then prepared and 
acylated with the unnatural amino acid; then together with the mutated DNA this is 
added to the appropriate translation system [126].  
Additionally, enzymatic post-translational modification of proteins can be used to 
achieve site-specific labeling. The method works by inserting a short recognition 
sequence, typically at the N or C terminus of the protein, for a suitable enzyme. Sato 
et al. showed that the use of a transglutaminase enzyme and a short recognition 
sequence at the N-terminus (see Section 1.5.5) allowed a single fluorophore to be 
attached to a glutamine residue within the recognition sequence [127]. An advantage 
to this method is that it can be performed under mild conditions.  
1.5.4 Modification of Cysteine 
A thiol or sulfhydryl group is one of the strongest nucleophiles in a protein and is 
therefore available for selective modification with an assortment of spin-labeled 
reagents (Figure 1.20 using MTSSL as an example). Maleimide and iodoactamide 
derivatives that contain a nitroxide ring are suitable, but the most commonly used 
spin label is 1-oxyl-2,2,5,5–tetramethylpyrrol–3-yl-methyl methanethiosulfonate 
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(MTSSL). The modification of sulfhydryl groups in proteins is generally achieved at 
a pH between 7 and 9 and the thiolate ion is thought to be the reactive species [128]. 
 
Figure 1.20 Reaction between cysteine and MTSSL. The cysteine is shown with the proton 
dissociated from the sulfhydryl group to form the thiolate ion, the reactive species. 
1.5.5 Transglutaminase catalyzed labeling of proteins 
One of the challenges of studying FH by EPR is that insertion of additional cysteines 
may disrupt the formation of the native disulphide bonds; enzymatic labeling 
circumvents this potential problem. Members of the transglutaminase (TGases) 
family catalyze the calcium (Ca
2+
)-dependent acyl transfer reaction between the γ-
carboxyamide of a glutamine residue (acceptor) and a primary amine donor (Figure 
1.21) [129].  
 
Figure 1.21 Transglutaminase reaction. The protein can be labeled at the glutamine residues when 
the R group is part of a primary amine in the calcium-dependent reaction.  
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The primary amine of lysine residues can act as a substrate, resulting in the 
generation of intra- or intermolecular cross links [130]. The actual requirements that 
allow a glutamine residue to be a substrate for TGase are not yet fully understood but 
TGases extracted from tissue display strict structural and sequence requirements 
[131]; to participate in acyl transfer, a glutamine residue needs to be accessible in a 
solvent-exposed position that is located in a flexible segment of polypeptide [132]. 
The specificity for the amine donor is less strict in that natural primary amines and 
non-biological substrates are recognized [131]. A study by Taki et al. compared the 
fluorescent labeling of glutathione S-transferase (GST) via chemical labeling 
techniques, with the TGase-catalyzed labeling approach. This study showed that 
TGase-catalyzed labeling was preferred as this procedure avoided the non-specific 
labeling of glutamine residues that occurred with the chemical labeling method. 
Moreover, TGase-labeled proteins were more likely to retain activity while the 
labeling reaction could, if necessary, be carried out at a temperature as low as 4° C, 
suitable for less thermally stable proteins like FH [133].  
1.5.6 EPR in biological studies 
EPR has been used to study structure and structural changes in proteins [134-138]. 
The development of pulsed EPR methods such as PELDOR (pulse electron-electron 
double resonance) and DEER (double electron-electron resonance) have allowed 
long-range distance measurements (up to 60 Å) to be made between two nitroxide 
labels or between a single nitroxide label and a paramagnetic centre. A collection of 
multiple distance measurements (based on multiple samples of individually site-
specifically labeled proteins) allows triangulation and hence yields valuable 
structural information. For example it can shed light on the three-dimensional 
arrangements of proteins, subunits or protein domains within a large protein or 
complex. Such measurements also allow any structural changes upon binding with a 
ligand to be monitored [121, 139].  
1.6 Aims of this work 
Our working hypothesis is that the central region of FH, containing the smallest CCP 
(CCP 13) and the longest inter-modular linkers of seven and eight amino acid 
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residues, acts as a hinge which promotes a stable conformation in which the N and C 
termini engage simultaneously with C3b. Structural studies [52, 55] of the central 
segment of FH have suggested that CCPs 10-15 do indeed adopt a compact structure 
with little intermodular flexibility. Functionally, this region contains no known 
major binding sites for C3b or GAGs, consistent with a purely structural or 
architectural role [63]. Three theories have been advanced to explain the interaction 
of FH with C3b; (i) FH engages, 1:1, with a single C3b molecule located on the cell 
surface [65]; (ii) FH molecule is bound, 1:2, to two neighboring C3b molecules;  (iii) 
FH can bind (1:1:1) to a C3b and a separate C3d molecule on the cell surface [70]. 
These theories are not mutually incompatible.  
The first aim is concerned with the link between FH mutations and disease outlined 
earlier. As discussed, the N-terminus is necessary for both cofactor and decay 
accelerating activity. Two mutations that are linked to the kidney disease aHUS are 
located in CCP 1 and previous work has shown that these mutations reduce the 
ability of FH to bind to C3b or cause loss of cofactor or decay-accelerating activities. 
As most aHUS-linked mutations are heterozygous the work will aim to try and 
understand how the mutant protein disrupts the wild type protein thus resulting in the 
susceptibility to aHUS. 
 Initial work will focus on the two mutations in CCP 1 (in the context of FH 
1-4) and the development of a fluid phase cofactor assay which would allow 
both homozygous and heterozygous to be functionally compared. 
 This will lay the groundwork for experiments in the context of full-length 
FH which will take into account the architecture of the intact protein.  
As mentioned previously, full-length FH is too large and, probably, flexible for 
NMR or crystallography and hence a new approach is needed. SAXS has been 
successfully applied to FH as well as to fragments of FH but it does not allow 
domain arrangements to be reliably inferred in the absence of complementary data. 
The second aim of the work was to lay the foundations for deploying EPR as a 
means of testing hypotheses regarding the “bent back” structure of FH and its 
engagement with C3 degradation products. In order to achieve this: 
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 Modified versions of FH 12-13 were produced in recombinant form at a high 
level to develop labeling strategies and record initial distance measurements. 
 Apply this approach to longer fragments (such as FH 10-15), and to use the 
resultant distance measurements as possible restraints in NMR and SAXS-
based models. 
The overall goal of this strand of the project was to establish proof-of-principle by 
showing that EPR-derived distance measurements can be obtained for FH. 
Eventually – if all of the hurdles could be overcome - EPR could be immensely 
valuable in defining the overall architecture of full-length FH, free and bound to C3b 
The third aim of the project also involved studies of FH 12-13. The uncommonly 
long linker (of eight amino acids) between these central CCPs forms a “mini-
domain” between them that imposes a rigid V-shape. According to our hypothesis, 
this architectural feature at the centre of FH must be important for cooperation 
between the N- and C-terminal binding sites for C3b/GAGs. Thus the intention was 
to test this hypothesis by: 
 Mutating the linker in such a way as to change the flexibility between 
domains, and to assess the functional and structural consequences. 
 Quantify the effects of such mutations on flexibility (and module integrity) 
by working on the easy-to-study FH 12-13 module pair. 
 Examine at a lower resolution (with SAXS) the structural effect of 12-13 
linker mutations in the setting of FH 8-15 and FH 10-15 fragments. 
 Study the functional outcome of these mutations by making them in the 







Chapter 2 Methods and Materials 
For compositions of buffers and media, and for vector maps and sequencing primers, 
please see Appendices. 
2.1 Amplification, cloning, screening and mutagenesis of DNA 
2.1.1 Polymerase chain reaction (PCR). 
PCR was used for the amplification of DNA sequences, and in the screening of 
colonies and sequencing of clones. Site-directed mutagenesis was also performed 
using PCR. All primers used in this study were either ordered from Sigma Genosys 
or Invitrogen and were shipped de-protected, and de-salted. 
2.1.1.1 Amplification of codon-optimized factor H fragments. 
A plasmid containing factor H-encoding DNA that had been codon optimized (by 
GeneArt) for expression in Pichia pastoris, was available in the group [140]. This 
served as the template DNA from which most of the fragments used in this study 
were generated. Two sets of oligonucleotide primers were designed. The first set 
allowed the amplification of the desired DNA sequence; the second set added the 
restriction enzyme sites (5’ PstI and 3’ XbaI) as well as codons for any additional 
cysteine or tag sequence required for labelling experiments. Table 2.1 shows the 
sequences of all primers used in this study. 
Table 2.1 Sequences of oligonucleotide primers. 







AGAGAGTGCGAGTTGCCAAAGATC 68.7 None 
CCP12 SNUG 
FOR 





GGAACAGTTAACTTCAGGGTCCCA 67.9 None 
CCP10 PST1 
FOR 




























































Restriction enzyme sites are shown in italics. Codons for additional cysteine or tag sequences, which 
will be used in labelling experiments, are underlined. Tm is the melting temperature for each primer 
calculated using the DNA calculator from Sigma (http://www.sigma-
genosys.com/calc/DNACalc.asp), FOR stands for forward and REV for reverse. 
To generate the required coding sequences, a reaction was prepared containing 2 µl 
of template DNA (50-100 ng), 1 µl each of forward and reverse primers (25 µM 
stock), 1 µl deoxynucleoside triphosphates (dNTPs) (2.5 mM mix, Invitrogen), 1.5 
µl dimethyl sulfoxide (DMSO), 5 µl of 10x Cloned Pfu buffer (Stratagene), 1 µl Pfu 
Turbo (DNA polymerase) (Stratagene) with the final volume being made up to 50 µl 
with double-distilled water. The thermal cycling parameters are shown in Table 2.2 
and were implemented on an Eppendorf Mastercycler personal (Eppendorf, 
Germany) in 0.25 ml thin-wall PCR tubes. 
Table 2.2 Amplification PCR program. 
Step Temperature (°C) Time (min) Cycles 
Initialization 95 5 1 
Denaturation 95 0.5 
30 Annealing Tm - 5°C 0.5 
Elongation 72 1 
Final elongation 72 10 1 
Hold 4 - - 
The annealing temperature was set according to the lowest melting temperature (Tm) of the primer 
pair with 5 °C subtracted.  
2.1.1.2 Screening of transformation colonies 
Screening was performed on between eight and 20 colonies. The colonies were 
firstly re-streaked onto a freshly prepared low-salt LB agar plate containing Zeocin 
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(25 µg/ml final concentration) (Invitrogen) and left at 37 °C overnight. A small 
amount of the re-streaked colonies was then added to 20 µl “EB buffer” (10 mM 
Tris, pH 8.5) and heated to 95 °C for five minutes to cause the bacteria to lyse and to 
solubilize the plasmid DNA. After this, 2 µl of each lysate was transferred to a 
0.25ml PCR tube containing 5 µl PCR master mix (Promega) and 2 µl of each 
primer. The primers used are shown in (Appendix B) and the thermal cycling 
parameters are summarized in Table 2.3. 
Table 2.3 Program used for thermal cycling 
Step Temperature (°C) Time (min) Cycles 
Initialization 95 1 1 
Denaturation 95 0.5 
39 Annealing 60 0.5 
Elongation 72 2 
Final elongation 72 4 1 
Hold 4 - - 
 
2.1.1.3 Sequencing PCR. 
Sequencing by PCR was performed using the same primers as used for screening by 
PCR (Appendix B). The reaction contained 250-300 ng of template DNA, 1 µl of 
either forward or reverse primer (10 µM stock) and 4 µl of ABI prism BigDye 
terminator v3.1 (Applied Bioscience), made up to 20 µl with double-distilled water. 
The thermal cycling program used for the sequencing PCR is shown in Table 2.4. 
The resulting PCR products were submitted to the Genepool automated sequencing 
service (University of Edinburgh) and the output was analyzed using BioEdit version 





Table 2.4 Sequencing PCR program 
Step Temperature (°C) Time (min) Cycles 
Initialization 95 1 1 
Denaturation 96 0.5 
30 Annealing 50 0.5 
Elongation 60 1 
Hold 4 - - 
 
2.1.1.4 Site-directed mutagenesis 
Clones expressing the desired DNA sequences (for FH 10-11, FH 11-14 and FH 12-
13) were already available in the group. To perform in vitro site-directed 
mutagenesis the QuikChange II Site Directed Mutagenesis Kit (Stratagene) was 
used. Primers were designed according to the guidelines in the manual, which 
suggested they should be between 25 and 45 base pairs in length with 10-15 bases on 
either side of the mutation site, have a melting temperature greater than 78 °C and 
have more than 40% GC content with the ends being either a G or C. All primer 
sequences used are shown in Table 2.5. The PCR reaction contained 1 µl of template 
DNA (100 ng), 1.3 µl of forward and reverse primers (10 µM stock), 1.5 µl DMSO, 
1 µl dNTPs (2.5 mM mix, Invitrogen), 5 µl of 10x Cloned Pfu buffer (Stratagene), 1 
µl Pfu Turbo DNA polymerase and double-distilled water to make up to 50 µl. Table 
2.6 shows the thermal cycling parameters used. 
Table 2.5 Mutagenesis primer sequences. 




fH_10_15_CYS_5’ AGAGAGGCTGAAGCTTGTGGAGAATGCGAACTTCCT 79.8 50 
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fH_10_15_CYS_3’ AGGAAGTTCGCATTCTCCACAAGCTTCAGCCTCTCT 79.8 50 
11-14_CYS 5’ GAGAGGCTGAAGCTTGTCAATCATGTGGTCCACC 80.3 52.9 
11-14_CYS 3’ GGTGGACCACATGATTGACAAGCTTCAGCCTCTC 80.3 52.9 
10-15_TTag_1+2 5’ TCTCCACCTCAGTGTGAACCAAAGTAGTCTAGAAC 72.8 45.7 
10-15_TTag_1+2 3’ GTTCTAGACTACTTTGGTTCACACTGAGGTGGAGA 72.8 45.7 
10-15_TTag_3+4 5’ CCTCAGTGTGAACCAAAGCCACAATAGTCTAGAAC 74.1 45.7 
10-15_TTag_3+4 3’ GTTCTAGACTATTGTGGCTTTGGTTCACACTGAGG 74.1 45.7 
10-15_TTag_5+6 5’ CAGTGTGAACCAAAGCCACAACAATTTTAGTCTAGAAC 74.4 39.4 
10-15_TTag_5+6 3’ GTTCTAGACTAAAATTGTTGTGGCTTTGGTTCACACTG 74.4 39.4 
10-15_TTag_7 5’ GAACCAAAGCCACAACAATTTATGTAGTCTAGAC 69.6 38.2 
10-15_TTag_7 3’ GTCTAGACTACATAAATTGTTGTGGCTTTGGTTC 69.6 38.2 
11-14_TTag_AA+1 5’ CAGTCAATACCACTCTGTGTTGAACCATAGTCTAGAAC 72.3 42.1 
11-14_TTag_AA+1 3’ GTTCTAGACTATGGTTCAACACAGAGTGGTATTGACTG 72.3 42.1 
11-14_TTag_2+3 5’ CAATACCACTCTGTGTTGAACCAAAGCCATAGTCTAG 74.1 43.2 
11-14_TTag_2+3 3’ CTAGACTATGGCTTTGGTTCAACACAGAGTGGTATTG 74.1 43.2 
11-14_TTag_4+5 5’ CTGTGTTGAACCAAAGCCACAACAATAGTCTAGAAC 73.7 41.6 
11-14_TTag_4+5 3’ GTTCTAGACTATTGTTGTGGCTTTGGTTCAACACAG 73.7 41.6 
11-14_TTag_6+7 5’ CCAAAGCCACAACAATTTATGTAGTCTAGAAC 68.2 37.5 
11-14_TTag_6+7 3’ GTTCTAGACTACATAAATTGTTGTGGCTTTGG 68.2 37.5 
12-13 3xGLY FOR CAGTGTGTTGCTGGTGACGGTGGTAAGAAGTGTAAATC 78.4 47.4 
12-13 3xGLY REV GATTTACACTTCTTACCACCGTCACCAGCAACACACTG 78.4 47.4 
The bases highlighted in italics show the mutation part of the primer. 
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Table 2.6 Mutagenesis PCR program. 
Step Temperature (°C) Time (min) Cycles 
Initialization 95 2 1 
Denaturation 95 1 
18 Annealing 55 1 
Elongation 68 10 
Hold 4 - - 
 
The QuikChange PCR product was then digested with 1.5 µl DpnI (New England 
Biolabs – 20000 units/ml) for between two and four hours at 37 °C to allow the 
methylated template DNA to be digested before being transformed into chemically 
competent E. coli cells. 
2.1.2 Restriction-enzyme digestion 
All restriction enzymes were purchased from New England Biolabs and were used 
with the appropriate buffer and, if required, purified bovine serum albumin (BSA) 
that was supplied with the enzyme.  
All the amplified DNA products and the pPICZαB vector were digested with PstI 
and XbaI to generate overlapping ends. The digest mixture included amplified DNA 
or vector (50 µl), 1x New England Biolabs (NEB) buffer 3 (6 µl of 10x stock), PstI 
and XbaI (1.5 µl of each 20,000 units/ml), 1x BSA (0.5 µl of 100x stock). NEB 
buffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2 and 1 mM DTT pH 7.9) 
was used as recommended by the NEB Double digest finder tool 
(http://www.neb.com/nebecomm/DoubleDigestCalculator.asp) The digests were 
carried out at 37 °C for three hours (amplified DNA) or overnight (pPICZαB). After 




In preparation for the transformation of the FH-encoding constructs into P. pastoris, 
the DNA was linearized using SacI which cuts only in the pPICZαB vector (209 bp) 
and not the FH-coding insert. Each digest contained 440 µl of plasmid DNA, 6 µl 
SacI (20,000 units/ml) 50 µl NEB buffer 1 (10x stock), 5 µl BSA (100x stock). NEB 
buffer 1 contains (10 mM Bis-Tris-Propane-HCl, 10 mM MgCl2 and 1 mM DTT pH 
7.0) Following incubation at 37 °C for six hours, the mixture was phenol-chloroform 
extracted to remove any remaining enzyme. 
2.1.3 Dephosphorylation of digested vector 
To prevent the re-ligation of the digested vector the 5’ phosphate groups were 
removed. An aliquot of 50 µl of the digested vector was incubated with 1 µl (10 
units) of calf intestinal alkaline phosphatase (CIP, New England Biolabs) and 5 µl of 
NEB buffer 3 for three hours at 37 °C, followed by gel extraction. 
2.1.4 Ligations 
All ligations were carried out using the T4 DNA Ligase (NEB) or the Rapid DNA 
Ligation Kit (Roche). 
The following protocol was adopted when using the NEB kit that included the 
requisite buffer. Approximately 50 ng of digested pPICZαB vector was mixed with 
approximately 150 - 200 ng of the DNA insert and 2 µl of 10x “T4 DNA-ligase 
reaction buffer”, made up to 19 µl with double-distilled water. After brief vortexing 
and centrifugation, the mixture was allowed to stand for ten minutes at room 
temperature. The T4 DNA ligase was then added (1 µl, 400 units/µl) and, following 
another brief vortexing and centrifugation, left to incubate overnight at room 
temperature. On the following day, 10 µl of the ligation mix was used to transform 
50 µl of chemically competent XL1 Blue E. coli cells. 
The following protocol was employed in the case of the Rapid DNA Ligation Kit. 
Insert DNA at a concentration of either 150 ng or 250 ng per µl was added to 50 ng 
of digested pPICZαB vector along with 1 µl of 5x “DNA-dilution buffer” and 5 µl of 
2x “T4 DNA-ligation buffer” in a final volume of 10 µl. The reaction was then 
vortexed and allowed to stand for ten minutes at room temperature followed by the 
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addition of 1 µl T4 DNA ligase (5 units/µl). The reaction was then vortexed and left 
to incubate overnight at room temperature. On the next day, 4 µl of the ligation mix 
was used to transform 50 µl of chemically competent XL1 Blue E. coli cells. 
2.1.5 Purification of plasmid DNA 
To prepare plasmid DNA from bacterial cultures, a QIAprep Spin MiniPrep kit was 
used for small-scale amounts or a HiSpeed Plasmid Maxi kit for large-scale amounts 
(both from Qiagen). The QIAquick Gel extraction kit (Qiagen) was used to recover 
DNA from agarose gels and the QIAquick PCR Cleanup kit (Qiagen) was used to 
purify and concentrate any PCR products that were to be used as template DNA in 
other PCR reactions. All kits were used out according to the protocols supplied and 
the resulting DNA was stored at -20 °C. 
2.1.6 Phenol-chloroform extractions. 
To remove any remaining enzymes from the DNA prior to transformation into P. 
pastoris, phenol-chloroform extractions were used. The volume of DNA was 
measured and to this an equal volume of phenol:chloroform:isoamyl alcohol mixture 
(25:24:1, saturated with 10 mM Tris, pH 8.0, 1 mM EDTA) was added. An emulsion 
was formed by inverting the tube several times, which was then centrifuged for 60 s 
in a bench-top micro-centrifuge (Eppendorf) at full speed (13,200 rpm). The 
resulting aqueous phase (top layer) was transferred to a fresh tube and the process 
was repeated. Finally, the aqueous layer was washed with an equal volume of 
chloroform, an emulsion was created and this was centrifuged as before. The DNA 
was recovered from the aqueous layer by ethanol precipitation. 
2.1.7 Ethanol precipitations 
Based on the volume of DNA recovered after phenol-chloroform extractions, 3 M 
sodium acetate solution, pH 5.2 (stock), was added to arrive at a final concentration 
of 0.3 M. Between 2 and 2.5 volume of cold ethanol was then added, followed by 
mixing, after which the sample was kept at -20 °C for at least an hour or overnight. 
The mixture was then centrifuged (Eppendorf centrifuge 5415R) for 30 minutes at 
13,200 rpm, at 4 °C and the supernatant discarded. The pellet was washed with 400 
µl 70% (v/v) cold ethanol and centrifuged for ten minutes at 13,200 rpm at 4 °C. The 
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supernatant was again discarded, and the pellet allowed to air dry to eliminate any 
remaining ethanol. Finally the pellet was re-suspended in 10 µl of doubled-distilled 
water and stored at -20 °C. 
2.1.8 Quantification of DNA 
The concentrations of DNA were estimated by spectrophotometry using a 
Biospectrometer (Eppendorf) to measure absorbance at a wavelength of 260 nm. The 
purity of the DNA was approximated by measuring the ratios of A260 nm/ A 280 nm and 
A260 nm/ A 320 nm. 
2.1.9.1 Preparation of chemically competent E. coli cells 
Chemically competent XL-1 Blue cells were prepared according to the Qiagen 
method. 
A starter culture was prepared containing 10 ml LB broth with 12.5 µg tetracycline 
and a small scrape of stock XL-1 Blue cells. These were cultured overnight at 37 °C, 
in a shaking incubator (200-250 rpm). The buffers were prepared as follows, and 
stored overnight at 4 °C. Buffer 1 contained 100 mM rubidium chloride, 50 mM 
manganese chloride:4H2O, 30 mM potassium acetate, 10 mM calcium chloride and 
15% glycerol, pH 5.8. Buffer 2 contained 10 mM MOPS, 10 mM rubidium chloride, 
75 mM calcium chloride and 15% glycerol, pH adjusted to 6.8 with 1 M potassium 
hydroxide. After everything had dissolved both buffers were filter sterilized. 
Next morning, 1 ml of the starter culture was added to 100 ml of pre-warmed LB 
broth containing 12.5 µg tetracycline in a 500ml baffled flask and cultured in the 
shaking incubator at 37 °C, 250 rpm, until the OD600 reached 0.5. The culture was 
then cooled on ice for five minutes and transferred to a centrifuge bottle. Cells were 
then collected by centrifugation at 4000 xg, 4 °C, for five minutes. The supernatant 
was discarded and cells re-suspended in 30 ml of cold buffer 1 and incubated on ice 
for 90 minutes. Cells were again collected by centrifugation (4000 xg, 4 °C, five 
minutes). The supernatant was again discarded and the cells re-suspended in 4 ml of 
buffer 2. Aliquots containing 50 or 200 µl were prepared in pre-chilled 1.5 ml tubes 
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which were then snap-frozen in liquid nitrogen and transferred quickly to the -80 °C 
freezer for storage. 
2.1.9.2 Transformation into chemically competent E. coli cells 
All transformations were carried out using 50 µl of XL-1 Blue super competent cells 
(Stratagene) or lab-made XL-1 Blue cells. The cells were mixed with either 1 µl of 
plasmid DNA, or 4-10 µl of ligation products and then incubated on ice for 30 
minutes. Subsequently, cultures were heat-shocked by placing in a 42 °C water bath 
for 45 seconds then quickly transferred back to ice for two minutes. After heat shock, 
250 µl of pre-warmed SOC medium (2% (w/v) tryptone, 0.5% (w/v) yeast extract, 
10 mM sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 
10 mM magnesium sulphate and 20 mM glucose per litre, Invitrogen) was added and 
the cells were incubated at 37 °C (250 rpm) for one hour to recover. The cells were 
plated onto low-salt LB agar containing 25 µg/ml Zeocin (Invitrogen) and incubated 
overnight at 37 °C. 
2.1.10 DNA agarose gel electrophoresis 
To prepare the gel, a mixture containing agarose and 1x Tris-acetate-EDTA (TAE) 
buffer was heated in a microwave oven until the agarose had completely dissolved. 
After addition of 5 µl SYBR Safe (Invitrogen) the mixture was poured into a tray 
containing a comb for the desired number of wells. Once the gel had set, a 100-bp or 
1-Kb DNA size-ladder (New England Biolabs) was loaded alongside the DNA 
samples. The gel was run until the resolution of bands in the size-ladder was clear. 
Visualization of the gel was carried out using UV light on a transilluminator, and 
pictures were taken using a digital camera fitted with a UV filter. 
2.2 Protein production in Pichia pastoris 
2.2.1 Overview 
Pichia pastoris was the eukaryotic expression host used in this work. It can perform 
the key post-translational modifications needed for production of factor H, namely 
disulphide bond formation. A mixed blessing is that it adds high-mannose glycans at 
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N-glycosylation sites [141, 142] that aid solubility but do not resemble the smaller 
and simpler sialylated glycans found on human factor H. P. pastoris is 
methylotrophic meaning it can exploit methanol as a sole source of both carbon and 
energy [142]. The first step in methanol metabolism is oxidation to formaldehyde 
and hydrogen peroxide catalyzed by the enzyme alcohol oxidase (AOX) in the 
peroxisome. The hydrogen peroxide is degraded to water and oxygen by catalase 
whilst a quantity of the formaldehyde leaves the peroxisome and is oxidised further 
to formate and carbon dioxide by two cytoplasmic dehydrogenases, with this 
reaction providing the energy for cell growth. Remaining formaldehyde is used to 
form cellular constituents by a cyclic pathway [142]. 
Two genes, AOX1 and AOX2, encode alcohol oxidase in P. pastoris with the two 
enzymes being 97% identical and sharing similar specificity [143, 144]. The 
majority of the alcohol oxidase activity is carried out by AOX1, which metabolizes 
methanol at a higher rate than AOX2. The strains used for protein production can be 
categorized based on which of the two alcohol oxidase genes has been deleted. The 
wild-type strain is Mut
+ 
(methanol-utilization plus phenotype). Strains lacking the 
AOX1 enzyme are termed Mut
S
 (methanol-utilization slow phenotype) and include 
the KM71H strain (Invitrogen) used in this work [141, 145].  
P. pastoris can express foreign proteins intracellularly or can secrete them into the 
expression medium. Secretion of the foreign protein requires a secretion signal in 
order for the protein to be directed to the secretion pathway. The advantage of the 
foreign protein being secreted is that the first step of purification is easier as P. 
pastoris does not secrete high levels of native proteins [142]. 
2.2.2 Preparation of electrocompetent cells 
A 5 ml starter culture containing a single colony of the P. pastoris strain KM71H 
and yeast-peptone-dextrose (YPD) medium was prepared in a 50 ml
 
tube and placed 
in a shaking incubator for 24 hours at 30 °C, 200 rpm. Three 100 ml cultures 
containing fresh YPD medium were inoculated with 30-500 µl of this overnight 
culture, and were subsequently grown (overnight) and until the OD600 reached 1.3-
1.5. The culture that had reached the required OD600 was then centrifuged at 1500 
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xg, 4 °C for five minutes and the resulting pellet was re-suspended in 100 ml ice-
cold sterile water; this procedure was then repeated. Finally cells were centrifuged 
and re-suspended in 4 ml ice-cold 1 M sorbitol. A final centrifugation step was 
performed and the cells re-suspended in 200 µl of ice-cold 1 M sorbitol, then stored 
on ice until required. Cells were only used on the day that they had been prepared. 
2.2.3 Transformation of Pichia pastoris by electroporation 
Once the linearised DNA had thawed, 80 µl of the electrocompetent KM71H cells 
were added with agitation, and the mixture was transferred to a 0.2-cm ice-cold 
electroporation cuvette (Gene Pulser I, BioRad) and incubated on ice for five 
minutes. After incubation the cells were pulsed for 6 s at 1.5 kV and immediately 
afterwards, 1 ml of ice-cold 1 M sorbitol or yeast-peptone-dextrose-sorbitol (YPDS) 
broth was added to the cuvette. The contents were then transferred to a 15 ml tube 
and incubated at 30 °C, without shaking, for 2-3 hours. In the meantime, YPDS 
plates were poured containing either 100 µg/ml, 200 µg/ml or 300 µg/ml Zeocin 
(Invitrogen). After incubation, aliquots from the tube of 50 µl and 250 µl were 
spread out on the 100-µg/ml Zeocin YPDS agar plates, while the remaining volume 
was split equally between the 200-µg/ml and 300-µg/ml plates. Finally, the plates 
were incubated (30 °C for three to five days) until colonies were visible.  
2.2.4 Small-scale flask expression tests 
In order to see if the transformation into P. pastoris had resulted in detectable levels 
of protein production, small-scale trial expressions were carried out using the 
following protocol. 
The transformed colonies were re-streaked onto a fresh YPDS agar plate, containing 
the same concentration of Zeocin as the original plate, then left for three days at 30 
°C. 
A 5 ml starter culture containing buffered glycerol-complex medium (BMGY) in a 
50 ml tube was inoculated with a small amount of the re-streaked colony and 
incubated with shaking for 24-48 hours at 30 °C, 250 rpm. The 5 ml culture was then 
added to 100 ml of fresh BMGY medium in a 500 ml baffled flask and cultured for a 
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further 24-48 hours at 30 °C, 250 rpm. Finally, the cells were harvested by 
centrifugation at 3000 xg, 4 °C, for ten minutes and re-suspended in 25 ml buffered 
methanol-complex (BMMY) medium. The suspension was returned to the 500 ml 
baffled flask and incubated, with shaking (250 rpm), at room temperature. At 24-
hour intervals, methanol was added, to a final volume of 0.5-1% (v/v) to induce 
protein expression for a total of three days. On the fourth day, supernatant was 
recovered by spinning at 3000 xg, 30 minutes and the cell pellet discarded. The 
supernatant was then filtered using a 0.22-µm sterile filter and brought to a final 
concentration of 5 mM ethylenediaminetetraacetic acid (EDTA) and 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF) by addition of stock solutions. Protein 
expression was then checked using sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
2.2.5 Large-scale flask expression 
Those colonies that had shown the best levels of protein production in the small-
scale expression trials were then used in larger-scale expression attempts.  
A single colony was added to 10 ml BMGY medium in a 50 ml tube and incubated 
at 30 °C, with shaking (250 rpm) for 24-48 hours. The 10 ml culture was then added 
to 100 ml of fresh BMGY in a 500 ml baffled flask and returned to the incubator for 
another 24-48 hours before being added to 400 ml of BMGY medium in a 2 L 
baffled flask. After a further 24-48 hours at 30 °C, shaking at 200 rpm, the cells were 
harvested by spinning at 3000 xg, 4 °C, for 15 minutes; the supernatant was 
discarded and the cell pellet re-suspended in 125 ml BMMY medium to induce 
expression. The temperature of the incubator was reduced to 20 °C and the agitation 
to 200 rpm. After initial induction the cells were fed methanol to 0.5% (v/v) final 
concentration every 24 hours for two days and then on the third day were fed twice. 
Finally, the cells were pelleted at 4000 xg, 4 °C for 30 minutes, and the supernatant 
filtered using a 0.22-µm sterile filter. As quickly as possible after harvest, EDTA (to 
5 mM) (pH 8.2) and PMSF (to 0.5 mM) were added to reduce protease activity. The 
supernatant was stored either at 4 °C for immediate purification or -80 °C for long-
term storage before purification. 
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2.2.6 Fermentation for 
15
N enrichment 
A fermentor was used when a recombinant protein were required be to be expressed 
in 
15
N-enriched media for NMR studies. Fermentation, conducted on a Bioflow 3000 
(New Brunswick Scientific), allowed the temperature, pH, agitation and air flow to 
be monitored and adjusted as required to increase the yield. All fermentations were 
performed in one-litre cylindrical fermentation vessels, using the following protocol. 
A YPDS agar plate containing 100 µg/ml Zeocin was streaked with the desired P. 
pastoris clone and left at 30 °C for between three and five days until colonies were 
about 3 mm in diameter. Two 10 ml starter cultures were prepared by inoculating 
BMG medium with a single colony, and incubated at 30 °C for two days. The 10 ml 
cultures were then added to 130 ml BMG and incubated at 30 °C for a further two 
days. 
While the cultures were growing, the fermentor vessel was prepared. The media (see 
Table 2.7) were prepared and poured into the vessel after all the probes were 
attached, then the entire unit was autoclaved. 
Table 2.7 Basal salts and initial medium for 1-L fermentation 
CaSO4 0.75 g 
MgSO4.7H2O 12 g 
K2SO4 8 g 
Glycerol 20 ml 
1 M Potassium phosphate pH 6.0 60 ml 
Double-distilled H2O Make up to 600 ml 
 
After autoclaving all the probes were connected to the fermentor and the dissolved 
oxygen (DO) probe was charged overnight by setting the agitation to 200 rpm (and 
temperature to 30 °C) and the air flow to “on” so that the medium became saturated 
49 
 
with oxygen. Next morning the DO probe was calibrated, the base feed-line 
supplying 2 M potassium hydroxide was attached and the agitation/DO cascade set 
up. To make the media 
15
N-rich for labeling, 7 g 
15
N-ammonium sulfate (dissolved 
in 20 ml double-distilled H2O) and 3.5 ml PTM1 salts (Amresco) were filtered (0.2 
µm) into the media and 0.5 ml of autoclaved Antifoam 204 (Sigma Aldrich) was also 
added. The cells were then harvested and re-suspended in approximately 20 ml of 20 
mM potassium phosphate, pH 6.0. To increase the density of the cells, they were 
grown in the presence of glycerol as a carbon source for one to two days prior to the 
addition of methanol. Before induction with methanol, the temperature was reduced 
to 15 °C and (for labeling) 1 g of 
15
N-ammonium sulfate dissolved in 2 or 3 ml of 
double-distilled H2O was filtered into the culture. Four hours later, gene transcription 
was induced by addition of methanol to a final concentration of 0.5% (v/v), and 
PTM1 salts were added. Once all of this initial addition of methanol had been 
consumed, further feeds of methanol – to 1% (v/v) - were given for three to four 
days; the timing of these feeds was based on the agitation rate and the amount of 
dissolved oxygen so as to avoid overfeeding or poisoning the cells. 
Centrifuging the culture at 4000 xg for 30 minutes removed the bulk of the cell mass 
from the supernatant that was then transferred to fresh bottles for a second 
centrifugation step of 30 minutes at 4000 xg. After this the supernatant was carefully 
decanted and filtered (0.2 µm). Finally, stock solutions of EDTA and PMSF, to final 
concentrations of 5 mM and 0.5 mM respectively, were added in preparation for 
protein purification. 
2.2.7 Ten-Litre Fermentation 
All large-scale (ten-litre) fermentations were performed by Dr. John White. A 1-L 
BMGY (2 x 500 ml) culture grown for 48 hours at 30 °C, 200 rpm was used to 
inoculate the fermentor. To induce gene transcription 0.5 % (v/v) methanol and 
PTM1 salts were added. After all of the initial methanol had been consumed, further 
feeds of methanol – to 1.5% (v/v) - and 1% tryptone (w/v)  were given for three 
days; the timing of these feeds was based on the agitation rate and the amount of 
dissolved oxygen as before. 
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Initial removal of the cell mass was performed by centrifuging the culture at 4000 
rpm, 4 °C for 30 minutes. The supernatant was then transferred to clean bottles and 
re-centrifuged for 45 minutes at 7000 rpm, 4 °C. After this the supernatant was 
carefully decanted and stock solutions of EDTA and PMSF, were added, as above, in 
preparation for protein purification. 
2.3. Protein Purification 
All pre-packed columns or resins were purchased from GE Healthcare. An ÄKTA 
FPLC system (GE Healthcare) was used to perform all chromatography steps.  
2.3.1 Ion-exchange chromatography 
As an initial purification step, an XK 26/20 column packed with 30 ml of either SP 
Sepharose fast flow (FF) resin (cation-exchange) or Q Sepharose FF resin (anion-
exchange) was used. Crude supernatant from either flask or fermentor expression 
was diluted with double-distilled water and the pH adjusted to allow binding prior to 
being loaded onto the column which had been equilibrated with 20 mM sodium 
acetate (for cation-exchange) or 20 mM Tris-HCl (for anion-exchange) at the same 
pH as the cell culture supernatant (typically between pH 4 and 5 for cation-exchange 
chromatography and pH 8 or 8.5 for anion-exchange chromatography). In order to 
choose the best pH, the calculated pI (http://web.expasy.org/protparam) of each 
protein and the pH-range of the resin were taken into account. The column was 
eluted in two steps by first washing with binding buffer (same buffer used to 
equilibrate the column) for about five column volumes, and second applying a 
gradient from 100% binding buffer to 100% elution buffer over three column 
volumes, at a flow rate of 3.5 ml/min. The elution buffer was the same as the binding 
buffer but contained 1 M sodium chloride.  
A Tricorn Mono Q 4.6/100 (1.7 ml column volume) was used to perform a higher-
resolution anion-exchange step. This column was eluted at a flow rate of 2 ml/min 
with a two-step gradient consisting of 0–50% elution buffer over 20 column volumes 
followed by 50-100% elution buffer over three column volumes.  The binding buffer 
was 20 mM glycine, pH 9.75, or 20 mM sodium carbonate pH 9.0; the 
corresponding elution buffer also contained 1 M NaCl. 
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2.3.2 Affinity Chromatography 
In order to purify recombinant proteins containing a hexa-histidine tag, Ni
2+
- affinity 
chromatography was performed. The columns used were either 1 ml HisTrap 
columns (GE Healthcare) or an XK 16/20 column packed with 25 ml IMAC 
Sepharose 6 fast flow (FF) resin (GE Healthcare). All columns were charged with 
NiSO4.  The buffers used for Ni
2+
- affinity chromatography are shown in Table 2.8. 
Table 2.8 Ni
2+
- affinity chromatography buffers. 
Buffer Composition 
Binding 20 mM potassium phosphate, pH 7.0 
0.5 M sodium chloride 
Wash 20 mM potassium phosphate, pH 7.0 
0.5 M sodium chloride 
20 mM imidazole 
Elution 20 mM potassium phosphate, pH 7.0 
0.5 M sodium chloride 
500 mM imidazole 
The wash buffer was only used when manually eluting the 1 ml HisTrap columns. 
The elution of the 25 ml 16/20 IMAC column was performed at a flow rate of 3 
ml/min, using a three-step imidazole gradient as follows: step 1, 0-8% imidazole 
over four column volumes; step 2, 8% imidazole for six column volumes; step 3, 8-
100% imidazole in four column volumes. When HisTrap columns were used, 
samples were eluted manually. 
2.3.3 Size-exclusion chromatography 
Size-exclusion chromatography was performed on either a HiLoad 16/60 Superdex 
75 prep-grade column at a flow rate of 1 ml/min, a Superdex 75 HR 10/30 column at 
a flow rate of 0.5 ml/min, or a Superdex 200 HR 10/30 column at 0.5 ml/min. For 
the HiLoad 16/60 Superdex 75 prep-grade column and Superdex 75 HR 10/30 
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columns the buffer was PBS (pH 7.4). The buffer used for the Superdex 200 HR 
10/30 column was 20 mM potassium phosphate containing 500 mM NaCl, pH 7.4. 
2.3.4 Concentration and buffer-exchange of protein samples. 
After each step of purification the protein sample was concentrated using either a 6 
ml or 20 ml Vivaspin (Sartorius or GE Healthcare) concentrator with a molecular 
weight cut off of 5,000, 10,000 or 30,000 Da as appropriate. The Vivaspin 
concentrators were also used to buffer-exchange the sample by spinning the sample 
to 0.5 ml then filling the concentrator with the new buffer, and repeating this process 
multiple times. Centrifugation steps were carried out at 3000 xg and 4 °C for varying 
amounts of time. 
Mini-dialysis units (Thermo Scientific) (with a MW cut off = 3.5 kDa) furnished an 
alternative method for buffer-exchanging small volumes of protein sample. The 
protein was initially dialyzed into the required buffer for a period of a few hours 
before the buffer was renewed and the sample left to dialyze overnight. All steps 
were carried out at 4 °C with continuous stirring. 
2.3.5 Estimation of protein concentration 
The concentrations of protein were estimated using a Biospectrometer (Eppendorf) 
by measuring absorbance at 280 nm. The online Protparam tool from ExPASy 
(http://web.expasy.org/protparam) was used to calculate the extinction coefficient for 
each construct. The application of Beer-Lamberts law allowed the concentration of 
the sample to be calculated. Purity of the protein was approximated by the ratios of 
A280 nm/ A 260 nm and A280 nm/ A 320 nm. 
2.3.6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
For SDS-PAGE, either 12% agarose or 4-12 % agarose gradient gels from the 
NuPAGE Bis-Tris range (Invitrogen) were prepared according to manufacturer’s 
instructions. Samples were prepared by mixing the protein with 4x NuPAGE LDS 
sample buffer (106 mM Tris HCl, 141 mM Tris Base, 2% lithium dodecyl sulfate, 
10% glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue G250, 0.175 mM phenol 
red, pH 8.5, Invitrogen) and, if reduced samples were required, 10x NuPAGE 
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sample-reducing agent (Invitrogen, 500 mM dithiothreitol) was added to a final 
concentration of 1x. Then the sample was heated at 95 – 100 °C for between two and 
five minutes. The sample was run out on the gel alongside the Precision-Plus protein 
ladder (10 – 250 kDa range) at 180 V until good separation of the ladder was 
achieved (approximately 50 minutes). Prior to staining, the gel was washed in water 
followed by heating, using a microwave oven, for 30 seconds; this was repeated 
three times to remove the SDS from the gel. Staining was performed using either 
Bio-safe Coomassie stain (Bio-Rad), which was left for one hour at room 
temperature, or lab-made Coomassie stain which was heated again in the microwave 
for ten seconds. To remove any excess stain the gel was washed in water for a few 
hours, with the water changed at least three times before being scanned. 
2.3.7 Western blot 
A western blot was used to confirm expression of full-length factor H. Firstly, the 
proteins were resolved as described in section 2.3.6 but the staining step was omitted 
and the gel was instead soaked in 1x transfer buffer (10x stock, Invitrogen). The gel 
was then transferred to a nitrocellulose membrane (BioRad) using an XCell II™ 
.Blot Module (Invitrogen) at 30 V for 1 hour in 1x transfer buffer. Pre-stained 
molecular weight markers allowed for the transfer to be monitored. After transfer the 
membrane was transferred to a 50 ml tube and blocked using 40 ml of blocking 
buffer (1x PBS with 5% milk) for four hours at 4 °C on a roller (Stuart scientific). 
After blocking the membrane was treated as follows: 
1) Washed with 10 ml PBS for 10 minutes. 
2)  Given four washes (10 minutes each) with 10 ml PBS containing 0.05% 
TWEEN 20. 
3)  Given a final wash with 10 ml of PBS for 10 minutes.  
The membrane was then incubated overnight at 4 °C on a roller with 10 ml of the 
primary antibody - i.e. Shp pAB to factor H, (Abcam) - in a 1:200 dilution in 5 ml of 
blocking buffer. After incubation the membrane was again rinsed as described 
above, the membrane was then incubated with the secondary antibody (Rb pAB to 
Shp IgG (HRP)) at a 1:20000 dilution in 5 ml of blocking buffer for 2 hours at 4°C 
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on a roller. The membrane was rinsed again as previously described. Development of 
the membrane was achieved using the SIGMAFAST
™
 3,3′-diaminobenzidine tablets. 
2.3.8 N-linked deglycosylation 
Proteins that were suspected to contain N-linked glycosylation sites were 
deglycosylated either at the end of the test (small-scale) expressions or after the first 
purification step for large-scale expression. For test expressions, the protein sample 
was treated with 1 µl of a 1:3 dilution of Endo HF (1,000,000 units/ml New England 
Biolabs) for one hour at 37 °C. The protein from the large-scale preparations (i.e. 
~50 – 100 ml) was first adjusted to pH 5.5. This is the optimal pH for Endo HF, and 
was only chosen providing the protein was stable at this pH. Alternatively, pH 6.0 
was used, then the protein was incubated at 37 °C for six hours with 15 µl Endo HF 
added along with protease inhibitors. 
2.4 Protein Characterization 
2.4.1 Mass spectrometry 
2.4.1.1 Accurate mass 
Samples were submitted to the Scottish Instrumentation and Resource Centre for 
Advanced Mass Spectrometry (SIRCAMS) at the University of Edinburgh for high-
resolution liquid chromatography (LC) – MS, with the aim of acquiring an 
approximate mass. The samples were supplied in 2–5 µM concentrations in 20 µl of 
either 20 mM potassium phosphate, pH 6, or PBS. Data was collected by passage 
through an LC-MS U300HPLC 500 µM PSDVB monolyth column (Dionex) 
followed by Fourier-transform ion-cyclotron resonance (FT–ICR) mass spectrometry 
(Bruker Daltonics 12T SolariX Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometer). 
2.4.1.2 In – gel trypsin digest 
Prior to performing the trypsin digest the protein samples were run on a 4 – 12% 
agarose gradient SDS-PAGE gel, which was subsequently washed thrice with 100 
ml of H2O. Staining was carried out for 30 minutes on a shaking platform (~ 50 rpm) 
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with InstantBlue protein stain (Expedeon) followed by three 10-minute washes to 
remove excess stain. The band to be analysed was then cut from the gel along with 
the smallest possible amount of polyacrylamide and placed in a 1.5 ml Eppendorf 
tube for same-day digestion, or storage (-20 °C). 
Once the segment of gel had been excised it was washed with 300 µl of 200 mM 
ammonium bicarbonate (ABC) in 50% (v/v) acetonitrile (ACN) at room temperature 
for 30 minutes, and this was repeated three times to remove SDS and stain. The gel 
segment was then incubated in 20 mM dithiothreitol (DTT), 200 mM ABC in 50% 
ACN for one hour at room temperature to reduce the protein. Subsequently, the gel 
segment was washed three times with 300 µl of 200 mM ABC in 50% (v/v) ACN 
followed by incubation in 100 µl of 50 mM iodoacetamide, 200 mM ABC in 50% 
(v/v) ACN for 20 minutes at room temperature to alkylate the cysteines. The excised 
gel segment was then washed three times with 500 µl of 20 mM ABC in 50% ACN 
before being covered with 100% ACN. Once the gel segment had turned white, 
acetonitrile was removed and the gel segment allowed to dry (e.g. 10 minutes at 37 
°C). The gel segment was then swollen in 29 µl of 50 mM ABC containing 2 µl of 
trypsin at 4 °C for up to one hour (or until swelling was evident); note that at 4 °C, 
auto-digestion of trypsin is avoided. Tubes were then sealed with Parafilm and 
incubated at 32 °C overnight (16 – 24 hours). The tube was then placed in a 
sonicating water bath for ten minutes to extract the digested protein. Finally, data 
was collected by SIRCAMS using electrospray ionization-mass spectrometry. 
2.4.2 NMR 
Protein samples for NMR analysis were concentrated and buffer-exchanged into 20 
mM potassium phosphate, pH 6.6. The sample then had D2O (Sigma Aldrich) added 
to a final volume of 10% of the sample volume to act as a frequency lock. Spectra 




N HSQC [146]) were recorded on an AVANCE™ 18.8 
Tesla (800 MHz) spectrometer (Bruker) fitted with a 5-mm triple-resonance TCI 






Spectra (T1, T2, and NOE) were recorded on an AVANCE™ 600 MHz spectrometer 
(Bruker) by Jurja Bella. 
Processing and analysis of the data was performed by Dr Mateusz Maciejewski. Raw 
spectra were processed using the NMRPipe software [147]. All T1, T2, and NOE 
spectra were analysed using the CCPNmr Analysis software v. 2.2.2 [148]. The 
NMR assignments of the wild type protein (WT), as well as the short linker (SL), 
and the three-Gly-insert (3xGLY) mutants were carried over from the assignments 
associated with the PDB entry 2KMS. T1 and T2 values were extracted from the 
spectra by non-linear least square fitting the decaying intensities observed in the 
spectra, as implemented in CCPNmr Analysis [148]. In house C programs were used 
to calculate the diffusion tensors for the considered proteins, and to calculate their 
model free (MF) [149] and extended model free (EMF) [150] parameters. In these 
programs, the parameters were determined by conducting a coarse grid search in the 
parameter space of a given tensor model, followed by a Powell minimization [6] of 
the error function E. In all preliminary diffusion tensor determinations E was based 
on a sum of squares of differences (normalized to the experimental error) between 
the experimentally measured T1/T2 ratios and the T1/T2 ratios calculated for each 
residue n using the model being tested. In tensor refinements the differences in T1, 
T2, and NOE relaxation values were used in the same fashion to calculate E. Finally, 
the MF and EMF parameters were calculated for each residue separately on the basis 
of T1-, T2-, and NOE-based error functions. 
2.4.3 Cofactor assay 
Fluid-phase cofactor assays were used to measure the cofactor activity of FI-
mediated cleavage of C3b to iC3b. Two assays were used; a concentration-dependent 
assay [151] and a fluorescence assay [152]. The stock proteins for both FI and C3b 





Concentration-dependent co-factor assay  
The concentration-dependent co-factor assay was performed in a final reaction 
volume of 20 µl in a micro-centrifuge tube (Eppendorf). In each reaction, 3 µg (850 
nM in 20 µl (3 µl of stock in 20 µl reaction)) of C3b and 0.05 µg (25.5 nM, 5 µl of 
1:10 dilution of stock in 20 µl reaction) of FI were mixed and then FH 1 - 4 at final 
concentrations of between 0 and 300 nM (see chapter 3, section 3.2 for specific 
details) was added. The FH samples were prepared from 1 µM stocks. The final 
reaction volume of 20 µl was reached by adding PBS. The negative control 
contained the same amounts of C3b and FI but lacked FH. The reactants were mixed 
and incubated in a circulating water bath at 37 °C (see chapter 3, section 3.2 for 
specific details). The addition of FH to the reaction was used as the starting point of 
the reaction. Addition of SDS buffer containing reducing agent (5 µl 4x NuPAGE 
LDS sample buffer and 2 µL 10x NuPAGE sample-reducing agent), and heating the 
reaction tube at 95 °C for two minutes, terminated the reaction prior to analysis by 
SDS-PAGE. 
Fluorescence co-factor assay  
The fluorescence assay employed in this study for the measurement of fluid-phase 
FH co-factor activity monitored, in real time, the loss of 8-anilino-1-
naphthalenesulfonic acid (ANS) (Sigma Aldrich) fluorescence as C3b was converted 
to iC3b by FI and FH [152]. Data was collected using a SpectraMax M5 multimode 
plate reader (Molecular Devices). Excitation was set at 386 nm with emission 
recorded at 472 nm with a 420 nm cutoff. Stock solutions were pre-warmed to 37 °C. 
The assay was performed at 37 °C and in PBS, within the wells of a 96-well black 
polystyrene microplate (Greiner Bio-One) using a reaction volume of 50 µl. Each 
reaction contained final concentrations of 1.5 µM C3b and 0.05 µM FI to which was 
added FH to give a concentration of between 0.0125 µM and 8 µM. The reaction 
was then mixed after the addition of FI and the loss of ANS fluorescence recorded 




2.4.4 Dynamic light scattering 
Dynamic light scattering measurements were performed on a Zetasizer Auto Plate 
Sampler (Malvern). Protein concentrations were in the range of 0.5-1.0 mg/ml. 
Samples were filtered (0.2 µm Millipore) prior to use and then 100 µl was loaded 
into each well of a 384-well plate (Thermo Scientific). 
2.4.5 SAXS data collection and analysis 
Synchrotron radiation X-ray scattering data were collected at the SAXS/WAXS 
beam line of the Australian Synchrotron using a 1M PILATUS pixel detector 
(Dectris, Switzerland). Samples (50 µl) were flowed through a temperature 
controlled capillary (1.5 mm i.d.) and ~ 10 frames of 2-s exposure time collected. 
Samples were analysed at 20°C, using protein concentrations of 0.4 – 1.8 mg/ml. 
The sample-to-detector distance was 1.6 m, covering a range of momentum transfer 
0.01 ≤ q ≥ 0.5 A
-1
 (where q = 4πsin(θ)/λ , with 2θ being the scattering angle and 
λ=1.13 A the X-ray wavelength). Based on comparison of successive 2-s frames, 
frames in which radiation damage was detected as an increase in low-q scattering 
intensity were excluded from averaging. 
Data from the detectors were placed on an absolute scale (referenced to the known 
scattering of pure water, 0.016 cm-1), normalized to the transmitted beam intensity, 
averaged, and the scattering of buffer solutions subtracted. The difference curves 
were scaled for solute concentration. Data manipulations were performed using the 
ATSAS software package utilizing the recently developed DATTOOL library for 
averaging, merging and extrapolation to infinite dilution from concentration series. 
The forward scattering I(0) and radius of gyration, Rg were determined from Guinier 
analysis, assuming that at very small angles (s ≤ 1.3/Rg ) the intensity is represented 
as I(s)=I(0)exp((sRg)2/3). These parameters were also estimated from the full 
scattering curves using the indirect Fourier transform method implemented in the 
program GNOM, along with the distance distribution function p(r) and the 
maximum particle dimensions Dmax. Molecular masses (MMs) of solutes were 
estimated from SAXS data by comparing the extrapolated forward scattering with 
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that of the water reference. The data was collected and analyzed by Dr Haydyn 
Mertens.   
2.5 Labelling of proteins for EPR 
2.5.1 Synthesis of 4-(6-amino-hexaneamido)-2,2,6,6-tetramethyl-
piperidyl-1-oxyl for enzymatic labelling 
First Step: preparation of 6-(Fmoc-amino) hexanoic acid 
 
A solution of sodium carbonate (1.695 g, 16 equivalents) and 6-aminohexanoic acid 
(1.048 g) in H2O (11 ml) and dioxane (7 ml) at 0 °C was stirred for one hour. 
Fluroenylmethyloxycarbonyl (Fmoc) chloride (2.069 g, 8 mM) was dissolved in 10 
ml dioxane and added drop-wise to the mixture and stirred at 0 °C for one hour then 
at room temperature for 18 hours. The reaction mixture (reddish brown solution) was 
then poured into 100 ml cold H2O, mixed and extracted with diethyl ether (3x 50 
ml). The aqueous phase was adjusted to pH 2 - 3 and separated with ethyl acetate (3x 
50 ml). The organic layer was then dried (magnesium sulfate) to remove water, 
filtered to remove solid and then dried under rotary evaporation to give a reddish 
brown solid (2.2 g). 
Rf (50% EtOAc in DCM) = 0.50; mp 108-109 °C; IR (KBr) (cm
-1
) paper = 3310, 
2920, 2850, 1700 sample = 3344, 2942, 1686. m/z expected 353.16 (100%), 354.17 
(23.1%), 355.17 (3.4%) found 376.1 which is the product plus 1 sodium molecule; 
1
H NMR δ (360 MHz, CDC13) 7.70-7.19 (11H ddtts ArH), 4.72 (s, OH), 4.39-4.42 
(2H, q, J = 6.8 and 7.5 Hz), 4.06 (1H, s, ), 3.63-2.98 (2H, qs, J = 6.5 and 6.4 Hz, 
CHCH3), 2.30-2.26 (2H, t, J = 7.3 Hz  ), 1.62-1.54 (2H, q, J = 7.2, 7.5, 7.4 and 7.2 
Hz), 1.42-1.41 (2H, q, J = 6.7 Hz,) 1.31-1.29 (2H, t, J = 6.7 Hz), 1.21-1.17 (2H, q, J 
= 1.4, 5.7, 7.1 Hz ); 
13
C NMR δ (90.5 MHz, CDC13) 178.56 (C), 156.34 (C), 143.86 
(2 x C), 141.21 (2 x C), 127.54 (CH), 126.91 (2 × CH), 124.90 (CH), 119.84 (2 × 
CH), 47.17 (CH), 40.66 (CH), 33.61 (CH), 29.47 (CH), 25.98 (CH), 24.12 (CH).  
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Second step: preparation of 6-(Fmoc-amino-hexaneamido)-2,2,6,6-tetramethyl-
piperidyl-1-oxyl 
 
The 6-(Fmoc-amino) hexanoic acid was dissolved in 10 ml tetrahydrofuran (THF) 
and left to stir in an ice bath. Dry triethanolamine (TEA) (1 ml, 1.1 mM) was added 
and stirred for 30 minutes at 0 °C. 4-Amino-2,2,6,6-tetramethylpiperidinyloxy (4-
amino TEMPO) (1.066 g, 1 mM) was dissolved in 8 ml THF and added to the 
FMOC solution and stirred at room temperature for one hour. To remove the THF 
the reaction was boiled under reflux for 20 minutes at 70 °C, then the remaining 
solvents were removed by rotary evaporation to give a reddish brown solid. The 
compound was dissolved in dichloromethane (DCM) and washed with 0.1 M HCl (2 
x 50 ml) and then saturated sodium bicarbonate (1 x 50 ml). Water was again 
removed using magnesium sulfate and the DCM was removed using rotary 
evaporation to give a reddish brown semi-solid. 
The semi-solid was then chromatographed on Silica gel 60 and eluted using ethyl 
acetate. The fractions from the brown band were combined and rotary evaporated to 
remove solvent. Residue was again dissolved in DCM and applied to the fresh silica 
gel 60 (Sigma Aldrich) column. Once solvent had been removed the result was a 
reddish brown semi-solid of approximately 2 g. 
Rf (50% EtOAc in DCM) = 0.33; mp not collected due to product being semi solid; 
IR (KBr) (cm
-1
) paper = 3320, 3050, 2925, 2850, 1690, 1640, 1600 sample = 2936, 
1699, 1652. m/z expected 506 (100%), 507.31 (33.1%), 508.31 (6.1%), 507.30 
(1.1%) found 507.2; 
1
H NMR δ and
13






Third step: preparation of 4-(6-amino-hexaneamido)-2,2,6,6-tetramethyl-piperidyl-1-
oxyl 
 
To remove the FMOC protecting group, the residue was first dissolved in DCM and 
then 20% (w/v) piperidine in dimethylformamide (DMF) was added and left to stir at 
room temperature for approximately one hour. The solution was then 
chromatographed on silica gel 60 and eluted with 10% (v/v) methanol in DCM. 
Fractions containing the product were combined and then rotary evaporated to give a 
reddish brown semi-solid of 320 mg. 
Rf (20% methanol in DCM) = 0.15; mp not collected due to product being semi 
solid; IR (KBr) (cm
-1
) paper = 3400, 3280, 2920, 2850, 1650, 1530 sample = 2940, 
1652, 1541. m/z expected 284.23 (100%), 28.24 (16.6%), 286.24 (1.7%), 285.23 
(1.1%) found 285.2; 
1
H NMR δ and
13
C NMR δ not collected due to free radical in 
product. 
2.5.2 Labeling of free cysteine 
Labeling of proteins which contained a free cysteine was carried out by incubating 
the proteins with excess MTSSL spin label (10-20 fold excess) for 4 hours at room 
temperature in the dark. Un-reacted spin label was removed by excessive dialysis 
into 20 mM Tris-HCl, pH 7.5. 
2.5.3 Labeling of Transglutaminase tag 
Enzymatic labeling of the transglutaminase tag was achieved by incubating the 
proteins (in 20 mM Tris-HCl, pH 7.5) with a 20-fold excess of the synthesized spin 
label in the presence of 10 mM CaCl2 and 2 µM guinea-pig liver transglutaminase 
(from lyophilized powder, Sigma Aldrich) at room temperature overnight in the dark. 
Removal of the un-reacted spin label and transglutaminase from the samples was 
achieved by size-exclusion chromatography using a Superdex 75 HR 10/30 column 
in 20 mM Tris-HCl, pH 7.5. 
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2.5.4 EPR data collection 
Samples were dialyzed into deuterated 20 mM Tris-HCl, pH 7.5 and deuterated 
glycerol was added to each to a final concentration of 50% prior to data collection. 
Data was recorded at the University of St Andrews using a Bruker E580 EPR 
machine running pulsed X-band EPR set at 50 K. Analysis of the data was 
performed using the DeerAnalysis2011 software. Data was collected and analyzed 
by Dr David Norman, University of Dundee. 
2.6 Surface Plasmon Resonance  
2.6.1 Binding affinity of FH linker mutants to the bacterial protein 
PspCN 
The binding affinity of the FH linker mutants to PspCN was monitored using surface 
plasmon resonance (SPR) on a BIAcore T200 sensitivity-enhanced instrument (GE 
Healthcare). All experiments were carried out at 25 °C using HBSP
+
 (10 mM 
HEPES, 150 mM NaCl and 0.05% surfactant P20) supplemented with 50 µM EDTA. 
The surface of the NTA chip (matrix: carboxymethylated dextran pre-immobilized 
with nitrilotriacetic acid (NTA), Series S Sensor Chip NTA from GE Healthcare) 
was prepared by first coating the surface with nickel chloride at 5 µl/min for 25 
seconds until ~40-60 RUs were observed. Second, 15 nM hexaHis-tagged SUMO-
PspCN (prepared by Dr Andrew Herbert) was flowed over at 30 µl/min for 25 
seconds until ~120 RUs was achieved. The reference surface was prepared by only 
coating it with nickel chloride until the desired amount of RUs was achieved.  
The proteins were injected at a flow rate of 100 µl/min for 180 seconds (contact 
time) followed by a dissociation time of 1500 seconds. For the FH 8-15 linker 
mutants, single injections were performed for concentration 0, 1, 2, 4, 8, 16 and 32 
nM with a double injection performed for 64 nM. For the full-length FH constructs 
single injections were performed for 0, 0.25, 0.5, 1, 2 and 4 nM with a double 
injection for 8 nM. 
After each injection the chip was stripped (because of the very slow off-rates for 
FH:PspCN) using 375 nM EDTA with 1 M NaCl followed by 50 mM NaOH and 
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finally 0.5% (w/v) SDS. All stripping steps were carried out at 30 µl/min for 30 
seconds.  
Dissociation constants were calculated by fitting kinetic parameters to a one:one 
Langmuir binding model. 
2.6.2 Interaction of full length FH variants with C3b, C3c and C3d 
Analysis of the interaction between the full-length FH linker constructs and C3b, 
C3c and C3d (Complement Technology, Texas) was also performed using the 
BIAcore T200 instrument. The surfaces of a C1 chip (Series S Sensor Chip C1 with 
a matrix free carboxymethylated surface, GE Healthcare) were prepared by 
immobilizing 272 RUs of C3b, 166 RUs of C3c and 69 RUs of C3d using standard 




For FH (wild-type) and for the FH (3xGLY) mutant, concentrations of 0, 0.0313, 
0.625, 0.125, 0.25, 0.5 and 1 µM were injected singularly whilst a double injection 
was performed for 2 µM. For the FH (short-linker) mutants (due to sample 
availability) only single injections were performed for the concentration range 0, 
0.0313, 0.625, 0.125, 0.25, 0.5 and 1 µM. A contact time of 90 seconds was used 
with a dissociation time of 400 seconds at a flow rate of 30 µl/min. Between sample 
injections the chip was regenerated using two injections of 1 M NaCl for 30 seconds 
at a flow rate of 30 µl/min. 
These experiments were then repeated with the only difference being that the wild-
type and mutant versions of FH were pre-incubated with a two-fold molar excess of 
PspCN. An excess of PspCN was used in an effort to ensure that nearly all the FH 
had engaged in forming the complex. PspCN had previously been shown not to bind 
to C3b or its fragments. The concentrations used in these experiments were identical 
to those used for studying wild-type and mutants versions of FH alone. 
2.6.3 Decay-acceleration assay of full-length FH mutants 
Analysis of the ability of full-length FH mutants to accelerate the decay of the C3 
convertase (C3bBb) was also performed using the BIAcore T200 instrument and a 
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running buffer of HBSP
+
 supplemented with 1 mM MgCl2. Using standard amine 
coupling (see above), 500 RUs of a freshly thawed C3b solution were coupled to a 
C1 chip. A mixture of 0.5 µM FB and 50 nM FD was then flown over the surface, at 
a flow rate of 10 µL/min for 120 seconds, to form the C3 convertase (monitored by 
RUs, achieved was 150 RUs) Subsequently, natural decay of the convertase was 
allowed to occur for 200 seconds followed by injections of the FH variants for 120 
seconds at 10 µL/min. Concentrations of wild-type FH and FH mutants used were 
2.5, 5 and 10 nM. The surface was regenerated between injections with 30 sec of 0.1 
µM FH+0.2 µM PspCN at 10 µl/min followed by 30 sec 1M NaCl at 10 µl/min. 
The experiment was repeated except that (as before) FH was pre-incubated with 
PspCN (2:1 ratio of PspCN:FH) . The concentrations used in these experiments were 














Chapter 3: Study of disease-associated sequence 
variations in CCP 1 of FH 
Various mutations and polymorphisms found within the genes encoding some 
proteins (CR1, MCP, FI, FB, C3 and FH) of the complement system have been 
linked with aHUS, DDD and AMD. The main pathogenic feature of these three 
diseases is dysregulation and/or excessive activation of the AP [153-155]. As 
described in more detail in the Introduction, FH has at least two common SNPs that 
are linked to the risk of developing both AMD and DDD: Y402H is part of a 
haplotype that increases risk (six-fold for homozygous individuals and 2.5 times for 
heterozygous individuals) [107] while I62V is part of another common haplotype 
that is protective for DDD and AMD [95].  
Background information for study. 
As also described in the Introduction, the majority of mutations linked to aHUS and 
found in FH are heterozygous single-point mis-sense mutations found towards the C-
terminus and especially in CCPs 19 and 20 [156, 157]. It has been hypothesized that 
these mutations may lead to a dominant-negative effect. A study by Heinen et al 
[158] showed that the FH mutant E1172STOP (CCP 20 deletion) purified from a 
heterozygous patient’s plasma showed defective binding to C3b, C3d, heparin and 
the surface of endothelial cells. When regulatory activities were compared, the 
mutant protein was as active as wild-type FH in fluid phase but on the cell surface 
activity was reduced. The patient’s plasma was shown to contain both wild type and 
the mutant protein at almost equal levels and when compared to wild-type FH (from 
a healthy control) the heterozygous mixture displayed reduced binding (six-fold 
reduction in mean fluorescence detected) to human umbilical vein endothelial cells. 
The reduction in the cell-binding suggests an interaction between the mutant and 
wild-type protein, which results in the wild-type protein function being affected. 
This reduction in activity for wild type FH could indicate the operation of a 
dominant negative effect. 
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When in solution FH is believed to exist as 95% monomer [159] but on the cell 
surface FH may well behave differently. It has been suggested that FH forms 
oligomers through its C-terminus [64] and the oligomers can bind to the cell surface 
either through GAGs [160] or C3d [161]. The Heinen study showed that, after 
treating both proteins with the cross linker DMA and analysis using western blot, 
both wild-type FH and mutant FH could form dimers but the wild-type protein 
seemed to form a dimer more readily with itself. 
As discussed in the Introduction, the N-terminal region containing the first four 
CCPs of FH has three important roles; it competes with FB for binding to C3b; it 
acts as a vital cofactor for the FI-mediated cleavage of fluid-phase C3b to iC3b; and 
it accelerates the decay of C3b.Bb, the C3 convertase complex that cleaves C3 to 
C3a and C3b. Interestingly the N-terminal module (CCP 1) contains two mutations 
linked to aHUS, namely R53H and R78G, as well as the AMD/DDD-protective SNP 
I62V [93, 94] mentioned above. Work performed on R53H and R78G showed that 
both disrupt the cofactor function of FH but do so by different mechanisms [53]; the 
former blocks interactions with FI while the latter blocks interactions with C3b. Both 
also disrupt decay-accelerating activity, which proceeds via an unknown mechanism.  
The work in this chapter aimed to investigate one possible mechanism of a putative 
dominant-negative effect for the two aHUS-linked CCP 1 mutants (and the I62V 
SNP) by assessing the extent to which the mutant proteins interfered with the 
cofactor activity of the wild-type protein.  Mutations were made in the context of the 
recombinant, four-CCP module, N-terminal truncation fragment FH 1-4. These 
proteins were produced and purified from P. pastoris. Fluid-phase cofactor assays 
were developed that allowed both “homozygous” (either wild-type or mutant 
proteins, alone) and “heterozygous” (a mixture of wild-type and mutant FH 1-4) 
conditions to be compared. 
3.1 Production and purification of FH 1-4 proteins. 
A clone containing the DNA for each of three FH 1-4 constructs - R53H (on a V62 
background), I62V and R78G (on a V62 background) - in the pPICZαB expression 
vector had been prepared previously [53]. Each of the constructs contained an N-
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terminal Myc tag (EQKLISEEDL) and a C-terminal hexa-His tag to aid purification 
and reduce handling time, and because FH 1-4 without tags was found to be 
susceptible to proteolysis. A sample of FH 1-4 V62 had been prepared previously by 
Dr Christoph Schmidt in the lab. 
3.1.1. Small-scale tests of protein production 
After each vector containing the DNA encoding the FH 1-4 variants had been 
transformed successfully into the KM71H strain of P. pastoris, between two and 
four colonies were chosen for small-scale tests of protein production (see Methods 
Section 2.2.4). The supernatant from each culture was applied manually to a 1 ml 
HisTrap chromatography column and eluted using an increasing gradient of 
imidazole (to 500 mM, see Methods Section 2.3.2). The results of these test 
productions were assessed using gradient SDS-PAGE (Figure 3.1).  
 
Figure 3.1 Small-scale protein production trials for disease-associated sequence variants of FH 
1-4. In (A) the gel (run under non-reducing conditions) shows, for each of two colonies, the 
supernatant from I62V-production trials before application to the HisTrap column (SN); the flow 
through (FT); and fractions (W1 and W2) collected from two sequential wash-steps applied before 
commencing the imidazole gradient. The gel in (B) (run under non-reducing conditions) shows, for 
each I62V colony, the five elution fractions (E1-E5) from a HisTrap column as in A; protein of the 
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expected mass was detected exclusively in fraction E2. Production trials for R53H are shown in (C) 
and for R78G in (D). For these gels, the lane numbers indicate the colony number; only the second 
elution fraction was run on the gel in each case. Samples for (C) and (D) were run under both 
reducing and non-reducing conditions as indicated above each gel. The black arrows indicate the 
expected migration position, under non-reducing and reducing conditions. 
These protein-production trials showed that both I62V colonies produced a species 
that migrated in the position expected for non-reduced FH 1-4 (at about 25 kDa). In 
the case of R53H, colonies 1, 2 and 4 all produced correctly sized protein as did all 
four R78G colonies; but the bands were weak compared to those obtained for I62V 
while for R53H in particular, substantial degradation was apparent under reducing 
conditions. The next stage was to perform a larger-scale protein production trial, in 2 
L shaking flasks, for the three variants and it was decided to use colony 2 for 
inoculation in each case.  In these trials, as described in Methods, both the BMG and 
BMM media were enriched with 10% (w/v) cas-amino acids - these media will 
henceforth be referred to as BMG-CA and BMM-CA. 
3.1.2 Larger-scale production trials of FH 1-4 R53H in shaking flasks 
An initial volume of 5 L BMG-CA was used for cell culture as described in Methods 
Section 2.2.5. Cells were subsequently spun down and re-suspended in 1.25 L of 
BMM-CA in ten 2 L baffled flasks (i.e. 125 ml per flask) for induction (see section 
2.2.5). After harvesting, the supernatant was adjusted to pH 7.5, filtered (0.22 µm) 





The elution was performed using a three-step imidazole gradient 
(to 1 M, see Methods Section 2.3.2). The resulting chromatogram is shown in Figure 




Figure 3.2 R53H eluted from Ni
2+
-affinity resin. (A) Shows the chromatogram (OD
 280 nm
, blue line; 
black line shows imidazole gradient) for R53H following Ni
2+
-affinity chromatography.  Four main 
peaks are present.  In (B) are the results of gradient SDS-PAGE for the fractions shown in A, run 
under both reducing and non-reducing conditions as indicated. Proteins migrating to the expected 
positions on the gel (indicated by black arrows) were found in fractions 81-83. 
The elution profile from the Ni
2+
-affinity column contained four main peaks. SDS-
PAGE analysis of the fractions showed that despite the detection of material 
absorbing at 278 nm, no or very little protein was present in fractions 18, 93 or 104. 
In fractions 81 and 83, on the other hand, three bands were detected under non-
reducing conditions; the dominant band migrating just above the 25-kD marker is 
likely to be R53H FH 1-4 and is accompanied by a smeary band above, and a very 
faint band below. While the lower band is most likely a degradation product of 
R53H FH 1-4, the origin of the higher smear is unknown. Since an N-glycosylation 
site is present in CCP 4 it was initially hypothesized that this had become 
glycosylated, but following treatment with an endoglycosidase enzyme the smear did 
not improve (not shown). Under reducing conditions, two main bands are detected, 
with the lower band likely corresponding to FH 1-4 that had been proteolytically 
clipped (but remains intact until the disulfides have been reduced). The upper band 
under reducing conditions – running a little more slowly than the same material 
under non-reducing conditions – is almost certainly the FH 1-4 mutant. The next 
purification step was performed after concentration and buffer-exchange into PBS. 
This consisted of size-exclusion chromatography using a Superdex 75 HiLoad 16/60 




Figure 3.3 Size-exclusion chromatography of R53H FH 1-4. The size-exclusion chromatogram 
shown in (A) is from the second injection. For the gradient SDS-PAGE gels in (B) the lane numbers 
indicate the fractions numbers (also indicated in (A)) for both injections; black arrows indicate the 
expected migration positions for FH 1-4 under non-reducing and reducing conditions. 
The size-exclusion chromatogram for injection 2 contained one main protein peak 
eluting at 60 ml. SDS-PAGE showed that the smear is still present in this peak, and 
under reducing conditions there appears to still be some clipped protein. Across the 
peak there is some resolution of these species, so it was decided in the interest of 
yield to pool (separately) protein fractions 43, 44 and 45 from the two injections. 
These were run on an SDS-PAGE gel in non-reducing and reducing conditions 
(Figure 3.4), and on this bases, fractions from 43 and 44 were judged to be the most 





Figure 3.4 Final quality check for R53H FH 1-4. The gradient SDS-PAGE gel shows fractions 43 – 
45 (pooled from two runs) under non-reducing (NR) and reducing (R) conditions. 
The concentration of each fraction in a final volume of 1.5 ml is shown in Table 3.1 
Table 3.1 Concentrations of R53H fractions. 











The fractions from run 1 were combined and gave a concentration of 43.7 µM (1.2 
mg/ml) in a final volume of 1 ml (from 1.25 L of BMM-CA final concentration was 
~ 1.3 mg/L). 
3.1.3 Larger-scale production trials of FH 1-4 I62V in shaking flasks  
Using the same method as employed for R53H FH 1-4, a starting volume of 5 L 
BMG-CA media was used and then cells transferred for induction to 1.25 L BMM-
CA media. As before, the supernatant was adjusted to pH 7.5, filtered and applied to 
the 25 ml XK 16/20 IMAC column charged with Ni
2+






-affinity chromatography and SDS-PAGE gel for I62V FH 1-4. The Ni
2+
-affinity 
elution profile for I62V (A) shows multiple peaks. The constant blue line shows absorbance at 280 
nm and the dark green line shows the imidazole gradient. In (B) the flow-through (FT) was run to 
check for protein that did not adhere to the column, while the numbered lanes correspond to the 
fraction number analyzed. The black arrows in (B) indicate the expected position of FH 1-4 in non-
reducing and reducing conditions. 
Analysis by SDS-PAGE shows that a species likely corresponding to I62V FH 1-4 
was present in fractions 32 and 38 (elution at 200-225 ml). There was no detectable 
protein in the lane corresponding to the flow-through (FT). As was seen in the case 
of R53H FH 1-4, a higher-molecular weight smear is present which did not disappear 
after endoglycosidase treatment. Size-exclusion chromatography was performed on 
I62V FH 1-4-containing fractions as before (Figure 3.6). 
 
Figure 3.6 I62V FH 1-4 size-exclusion chromatogram and SDS-PAGE. The elution profiles (red 
and blue) for duplicate injections of I62V FH 11-4 (eluted from the Ni
2+
-affinity column) are overlaid 
in (A). In (B) are the results of gradient SDS-PAGE showing fractions 34 – 40 from injection 1 run 
under both reducing and non-reducing conditions. The expected migration position of FH 1-4 is 
shown by the black arrows. 
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Both the higher-molecular weight smear and the clipped material (visible on the gel 
under reducing conditions) are partially resolved from the target material. Injection 2 
showed a similar result, so fractions 39 and 40 were kept from both injections for 
cofactor analysis. After being combined and concentrated the final sample for I62V 
was 30 µM (0.8 mg/ml) in 2 ml (from 1.25 L of BMM-CA final concentration was ~ 
0.6 mg/L).  
3.1.4 Larger-scale production trials of FH 1-4 R78G in shaking flasks 
In this case 4 L of BMG-CA media was used initially followed by 1 L of BMM-CA 
media. As for the other FH 1-4 sequence variants, a XK 16/20 IMAC column 
charged with Ni
2
 was used for the first step. The elution was performed using a 




-affinity elution chromatogram and SDS-PAGE of R78G FH 1-4. The Ni
2+
-affinity 
elution profile (blue) is shown in (A) with the dark green line indicating the imidazole gradient. The 
corresponding SDS-PAGE is shown in (B).  
Fractions corresponding to the main peak (elution at 250 ml) of the Ni
2+
-affinity 
chromatogram contain species that migrate as expected for the target protein, along 
with the familiar higher-molecular weight smear. A small amount of dimer (running 
at just above 50 kDa) may be present in the non-reduced fractions from the middle of 
the peak. As before fractions 56-68 were pooled and subjected to size-exclusion 




Figure 3.8 Size-exclusion chromatogram of R78G FH 1-4. The elution profile is shown in (A). The 
fractions indicated in (A) were then run in reducing conditions on SDS-PAGE (B) alongside fraction 
41 run under non-reducing conditions. Arrows indicate the expected position on the gel of the target 
protein. 
Analysis by SDS-PAGE shows that the smear reduces towards the end of the peak 
with very little present in fraction 45. Fractions 38 - 43 were combined, concentrated 
and exchanged into 20 mM glycine with 70 mM NaCl buffer, pH 9.75, as a prelude 
to high-resolution anion-exchange chromatography. A gradient to 500 mM salt was 
run over 20 column volumes, then three column volumes were used to reach 1 M 
NaCl (Figure 3.9).  
 
Figure 3.9 Anion-exchange chromatography of R78G. (A) Anion-exchange elution profile (blue), 
with green line showing NaCl gradient to 1 M final concentration. The SDS-PAGE in (B) shows 
fractions taken from across the peak in both non-reducing (NR) and reducing (R) conditions. The last 
four lanes on the gel are fractions 45 and 46 from the size-exclusion step. 
Anion-exchange chromatography of R78G resulted in two incompletely resolved 
peaks and analysis by SDS-PAGE showed that the smear was still present at the 
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same level as in the size-exclusion fractions. Fractions 30-42 were stored but unused 
due to the smear. Size exclusion fractions 45 and 46 were run in the last four lanes of 
the SDS-PAGE under non-reducing and reducing conditions to check the purity and 
were stored for cofactor analysis. The final concentration when the fractions were 
combined was 18 µM (0.5 mg/ml) in a volume of 1 ml (from 1 L of BMM-CA final 
concentration was ~0.5 mg/L). 




SDS-PAGE cofactor assay 
A standard fluid-phase cofactor assay [151] – based on the use of SDS-PAGE to 
detect the cleaved alpha chain into 67-kDa and 43-kDa fragments - was adapted and 
optimized in an attempt to test hypotheses regarding the dominant-negative effects of 
FH sequence variants. It was important to ensure that the assay would be responsive 
(i.e. the outcome would be roughly proportional) to the amount of functional FH 
present.  This would ensure the outcome would be sensitive to the possibility of the 
(inactive) mutant FH interacting with wild-type FH in such a way as to reduce the 
latter’s activity. With this in mind, a concentration series of FH 1-4 was investigated 
in the SDS-PAGE-monitored assay as described below.  
The concentration range of FH 1-4 used in a previously reported cofactor activity 
was 3-700 nM [162]. On this basis a dilution series was performed starting with 300 
nM FH (stock was 1 µM). The concentration of C3b were kept at 0.85 µM (stock 
was 7 µM), and the concentration of factor I (FI) at 28.4 nM (stock was 14 µM), in a 
final volume of 20 µl with an incubation time of 10 minutes at 37 °C. A threefold 
dilution series was used and thus the final concentrations of FH were; 300 nM, 100 
nM, 33 nM, 11 nM and 3 nM. An additional two concentrations of 75 nM and 25 nM 
were also included in an attempt to detect smaller differences between the mutants 
                                                 
1
 The data from the concentration assay was published in 53 Pechtl IC, Kavanagh D, McIntosh N, 
Harris CL, Barlow PN. Disease-associated N-terminal Complement Factor H Mutations Perturb 
Cofactor and Decay-accelerating Activities. Journal of Biological Chemistry 2011, 286: 11082-11090 
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(Figure 3.10). The FH 1-4 V62 protein used in all these experiments was prepared by 
Dr Christoph Schmidt. 
 
Figure 3.10 Factor H 1-4 concentration-dependent cofactor assay. The concentrations of FH 1-4 
used to perform this assay were 300 nM, 100 nM, 75 nM, 33 nM, 25 nM, 11 nM and 3 nM. All four 
proteins have cofactor ability at 300 nM but R78G is the weakest. At 100 nM, a very clear difference 
is visible with a decrease in R78G activity, which is no longer detectable at 75 nM. R53H has 
detectable cofactor activity at 75 nM but not at 33 nM. At the lower concentrations a difference is 
observed between V62 and I62V in that for 25 nM I62V a 43-KDa band is detected but this is not the 
case for V62. 
This experiment (Figure 3.10) showed that R78G is the least active variant followed 
by R53H. The comparison between V62 and I62V reveals that I62V has slightly 
more cofactor ability than V62 (on the basis that more iC3b is present at 25 nM for 
I62V than V62); this was also seen in the study by Tortajada et al [95] where the 
I62V FH variant (purified from homozygous plasma) was ~20% more active than the 
V62 variant (also from homozygous plasma) in a fluid-phase C3b assay. At the 
lowest concentration of 3 nM none of the four proteins had detectable activity over 
the 10-minute incubation period. 
Based on this concentration series, conditions for the test of the dominant-negative 
hypothesis (see section 3.2.3 for results) were selected. It was desirable to use a 1:1 
ratio of wild-type:mutant (on the assumption that heterozygous individuals have an 
equal amount of each protein) and a concentration of V62 for which activity (i.e. the 
iC3b 43-kDa band) should be detectable in this assay along with a concentration of 
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R53H or R78G for which no cofactor activity could be detected. Based on this 
reasoning, 40 nM of each protein was selected. 
Fluorescence cofactor assay 
To monitor the cofactor ability of the mutants in real time a fluorescence assay was 
used [152] where the conversion of C3b to iC3b results in a reduction of 
fluorescence in the presence of a fluorophore, ANS, that binds less well to iC3b [14]. 
The assay was adapted from the original protocol to use significantly smaller 
volumes in 96-well plates (see Methods). The main reason for this was to conserve 
proteins, and in particular C3b. But the use of smaller volumes did increase the risk 
of errors in consistency and accuracy. Another challenge was to keep the 96-well 
plate at a constant 37 °C; to ameliorate this problem all proteins as well as the buffer 
were incubated at 37 °C throughout the experiments. Timing issues were also 
challenging; after the addition of FI to the ANS:C3b:FH complex there was a delay 
in recording data due to a mixing step of 5 seconds performed by the plate reader. 
This assay had not been performed previously in the lab. In order to test it, both 
plasma-purified FH (5 µM stock, Complement Technologies) and a recombinant 
version of full-length FH containing the aHUS-linked mutation, D1119G (6.4 µM 
stock, prepared by Dr Heather Kerr, Edinburgh) were used. A two-fold dilution 
series was used with the final concentrations of FH being 200 nM, 100 nM, 50 nM, 
25 nM and 12.5 nM. All experiments were performed in duplicate and each reaction 
mixture contained 1.5 µM C3b 50 nM FI and 100 µM ANS in a final volume of 50 
µl PBS; all experiments were performed at 37 °C.   
The results for plasma-purified FH (Figure 3.11 (A)) showed a decrease over time in 
relative fluorescence units (RFU), consistent with C3b being cleaved to iC3b. The 
initial rate of iC3b production/C3b loss increased with higher concentrations of FH 
(Figure 3.11 (B)) although the relationship between rate and FH concentration (this 
will depend on the affinity of FH for C3b and the Km of the C3b:FH complex for FI) 
in this set of test assays was unclear. Note that to emulate physiological conditions of 




Figure 3.11 Fluorescence-based cofactor assay for plasma-purified FH. (A) Loss of fluorescence 
over time reflecting conversion of C3b to iC3b. (B) Rate of iC3b production as a function of FH 
concentration. 
When FH containing the D1119G mutation was tested (Figure 3.12 (A)), a plot of 
ΔRFU/s against FH concentration (Figure 3.12 (B)) showed a linear relationship, 
which is more in line with expectation, although rate was not proportional to FH 
concentration. The differences in shape between Figures 3.11(B) and 3.12(B) are 
probably not significant and likely reflect technical issues of temperature control, 
timing, and the errors associated with small differences in fluorescence for the lower 
FH concentrations. It is potentially interesting that the plasma-purified FH appears to 
be three times more active than the recombinant D119G mutant but this was not 




Figure 3.12 Fluorescence cofactor assay for FH containing D1119G mutation. As in Figure 3.11. 
Results from these trials with full-length FH were encouraging, so the assay was 
repeated using identical concentrations of V62 FH 1-4. Little to no conversion was 
observed so it was concluded that FH 1-4 is not, in this assay, as active as full-length 
FH in terms of cofactor activity. Subsequently, 400 nM plasma-purified and 
recombinant FH (D1119G) were compared to 4 µM V62 FH 1-4 (Figure 3.13 (A)). 
This suggested that the full-length proteins were about ten times more active than FH 
1-4.  This was an unexpected result – given that the dogma states that CCPs 1-4 are 
necessary and sufficient for the fluid-phase cofactor activity of FH – but it was not 
pursued further in this work. While (Figure 3.13 (B)) the full-length D1119G mutant 
protein appeared less active in this comparison than the plasma-purified protein (as 
above), this was also not investigated further although again it suggests a role for C-
terminal modules in fluid-phase complement regulation.  
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Based on the above results it was decided to use a two-fold dilution series of V62 FH 
1-4 and the variants, with final concentrations of 0.5 µM, 1.0 µM, 2.0 µM, 4 µM and 
8 µM.  
 
Figure 3.13 Fluorescence cofactor activity assay: full-length FH vs. FH 1-4 V62. The conversion 
of C3b to iC3b over time for each protein monitored by loss of fluorescence. 
The results for fluorescence concentration series (Figure 3.14) were noisy and 
difficult to interpret. At the highest concentrations of FH 1-4 used (4 and 8 µM), all 
three proteins exhibit very roughly comparable cofactor activity even though this 
was well below the KD reported for R78G (KD > 35 µM). At the lowest concentration 
(0.5 µM), none of the FH 1-4 proteins yielded much activity (although the initial 
reading was very low for V62 so an initial fall in fluorescence may have been missed 
for technical reasons). The reaction mixtures containing 1 and 2 µM FH 1-4 afforded 
the best comparisons. In these cases, FH V62 was more active than R78G with 
R53H being the least active. 
Thus the SDS-PAGE and real-time fluorescence assays suggest differing conclusions 
with regards to the relative activities of the two mutants, but both support the 
hypothesis that these disease-related mutants are deficient in cofactor activity 




Figure 3.14 Fluorescence cofactor assay – concentration series. Each graph shows the conversion 
of C3b to iC3b over time for each concentration (0.5, 1, 2, 4 and 8 µM). 
3.2.2 Inhibition Assay 
The intention was to test if the FH 1-4 fragment containing a disease-linked mutation 
could inhibit the cofactor activity of the wild-type protein (in this study V62 FH 1-4) 
by performing SDS-PAGE-based assays on mixtures of the two proteins. While the 
ratio of wild-type FH to mutant FH may be one-to-one in the plasma of a 
heterozygote, it was decided for the purposes of this test, to maintain a total 
concentration of 40 nM FH but to vary the ratio of wild-type and mutant proteins, 
starting with “40 nM wild-type plus no mutant” and progressing to “no wild-type 
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plus 40 nM mutant”. The concentration of FI was 25.5 nM while C3b was kept at 
860 nM (as determined in section 3.2.1 SDS-PAGE assay). To avoid confusion, 
sample conditions were named using a system based on the concentration of each 
protein present, i.e. 40:0 means 40 nM V62 and 0 nM of the mutants, while 30:10 
means 30 nM V62 and 10 nM of the mutants. Each of the experiments was 
performed in duplicate. 
A trial assay was performed using PBS instead of the mutant proteins (over the 0-40 
nM wild-type (V62) FH 1-4 range). Inspection of the resulting SDS-PAGE (Figures 
3.15 and 3.16) showed no differences in the amount of iC3b produced (judged from 
densitometry of the bands attributed to the 43-kDa and 67-kDa fragments of the 
alpha-chain) for FH concentrations between 40 nM and 15 nM FH. Below 15 nM 
FH, there was an approximately linear relationship between cofactor and iC3b 
production. Although it might have been preferable to have included (in the 
subsequent experiments) more FH concentrations that lay within this linear range, 
the effects of co-incubation with mutants could not be predicted, so it was decided to 
stick with the 40 nM total concentration of wild-type and mutant. 
In the case of R53H, SDS-PAGE (Figures 3.15 and 3.16) showed that there was little 
difference in iC3b production between 40 nM FH and 15 nM FH + 25 nM mutant 
FH. The previous study had shown that 25 nM R53H produced no detectable iC3b so 
nearly all of the iC3b produced in the 15:25 sample must be due to the 15 nM V62 
FH 1-4. That the quantity of iC3b produced matches what would be expected from 
this concentration of V62 FH 1-4 in the absence of any inhibitor implies that the 
presence of R53H FH 1-4 had an insignificant effect on wild-type (V62) FH 1-4 
cofactor activity. At concentrations of V62 FH below 15 nM (and of R53H above 25 
nM), cofactor activity drops off in a very similar manner to the trial experiment (no 
R53H). This reinforces the conclusion that the mutant does not inhibit the “wild 
type”. 
A broadly similar result was obtained for R78G (Figure 3.15 and 3.16). As before, 
iC3b production was essentially constant over the 15-40 nM V62 FH 1-4 (25-0 nM 
R78G) range but fell off below 15 nM in way that was independent of the presence 
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or absence of R78G. In conclusion, these experiments demonstrate the absence of an 
interaction between wild-type (V62) FH 1-4 and either of the mutants under 
investigation. 
 
Figure 3.15 Inhibition assay for R53H and R78G. The SDS-PAGE shown are for the PBS trial gel, 
V62 against R53H and V62 against R78G.  
 
Figure 3.16 Quantification charts for inhibition assay. The left chart shows the average result for 
the quantification of the iC3b 67 kDa bands and the right chart is for the iC3b 43 kDa bands. The PBS 
trial is the blue line, red line is for V62 against R53H and the green line is V62 against R78G. 
Both plots from the previous experiment showed a dip in iC3b production at the 1:1 
ratio of wild-type FH 1-4: mutant FH 1-4. But since these were not part of an overall 
trend, these results were regarded with suspicion (loading error, staining time etc. 
could also explain the dip). Nonetheless, this was investigated further as it may 
reflect the physiological situation in the plasma of a heterozygote for the mutation. In 
84 
 
the next study, C3b and FI (as in the previous experiment) were incubated with 40 
nM, 30 nM, 20 nM and 10 nM total concentrations of FH 1-4 consisting of 0:1 or 1:0 
(controls) and 1:1 mixtures of wild-type (V62) and mutant. In this case, the assay 
time was extended to four hours to increase the strength of the bands and thereby 
allow for more accurate density measurements. 
Inspection of the resultant SDS-PAGE (Figure 3.17) and the densitometry readings 
(Figure 3.18) indicated that over the 24-fold extended assay period, there was 
detectable iC3b produced for both mutants (no wild-type FH 1-4 present) at 10 nM. 
Nonetheless, the mutants (alone) were, as expected, much less active than the V62 
(wild type) FH 1-4. At 30 nM and 40 nM, the mixed samples (1:1 R53H:V62 and 
1:1 R78G:V62) were equal in cofactor activity to the pure V62 samples. At 10 nM 
(total) the 1:1 mixtures exhibited less cofactor activity than pure V62 FH 1-4 but this 
is unremarkable since the mixtures contain only 5 nM V62 FH 1-4 and these 
concentrations of cofactor lie in the linear range (versus activity) according to the 
previous experiment (0-15 nM). The 20 nM mixtures exhibited an almost identical 
activity to 10 nM pure V62, in line with expectations. Therefore the dips in the plots 
shown on Figure 3.15 are likely to be anomalous and of no significance.
 
Figure 3.17 Homozygous vs. Heterozygous assay. The left SDS-PAGE shows the results for the 40 




Figure 3.18 Quantification results for Homozygous vs. Heterozygous assay. The bar chart on the 
left shows the average result for the iC3b 67 kDa bands and the right hand chart the average result for 
the iC3b 43 kDa bands. 
The fluorescence-based assay was also used to investigate differences in cofactor 
activity between pure and mixed samples at a total concentration of 4 µM FH 1-4. 
Thus the “heterozygous samples” contained 2 µM of V62 FH 1-4 plus 2 µM mutant. 
Concentrations of C3b and FI were 1.5 µM and 50 nM, respectively, in a final 
volume of 50 µl that also contained 100 µM ANS.  
The outcome of these experiments (Figure 3.19) was similar to that of the SDS-
PAGE assay (Figure 3.16). Unlike in the fluorescence assays shown in Figure 3.14, 
R78G is less active than R53H. But more importantly, the mixed samples showed no 
indication that the mutant FH 1-4 interferes with the wild-type FH 1-4. Taken 
together these results and combining with the SDS-PAGE results it seems that in 
these assays there is no destructive interference between mutant and wild-type 




Figure 3.19 Fluorescence cofactor assay of Homozygous vs. Heterozygous. (A) Decrease in 
fluorescence as C3b becomes iC3b; (B) comparison of the initial rates of iC3b production. 
3.3 Discussion 
Our work showed that recombinant R53H FH 1-4 and R78G FH 1-4 (produced in P. 
pastoris), corresponding to aHUS-linked mutations in the N-terminal CCP of FH, 
have decreased cofactor activity and hence ability to regulate C3b amplification (and 
thereby control the AP) compared to FH 1-4 with the wild-type (V62) sequence, in 
the fluid phase. The ability of the mutants to bind C3b was investigated [53] and it 
was shown that R78G binds immobilized C3b poorly (KD > 35 µM) whilst R53H can 
bind with a similar affinity as that seen for WT FH 1-4 (R53H KD was ~ 12 µM 
compared to WT KD of 10 µM)  
The rare mutant R78G FH has been linked to aHUS [93] even though it occurs 
alongside wild-type FH in heterozygous patients. It is very likely that aHUS-linked 
R53H FH will also occur in heterozygous individuals, although this has not been 
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confirmed [93]. This suggested a dominant-negative effect in which the normal 
unaffected protein is prevented from working to some extent by the presence of the 
mutated protein [163, 164]. The work in this chapter was performed to investigate 
this suggestion using fluid-phase cofactor assays.  
Two fluid-phase cofactor assays were used in the study, an end-time SDS-PAGE-
based assay and a continuous fluorescence-based one. The SDS-PAGE assay is more 
commonly used [53, 140] as the results are easy to interpret visually in a qualitative 
sense. In trying to use this assay in a quantitative fashion during this study, a few 
challenges became apparent like the importance of minimizing any differences in gel 
staining and de-staining times and variations between batches of stain that were more 
difficult to control. The fluorescence assay was adapted from the original protocol 
[152] to use significantly smaller reaction volumes. Although the assay allowed the 
conversion of C3b to iC3b to be monitored in real time it too presented technical 
challenges. Using small volumes increased the risk of errors during pipetting. 
Controlling the temperature of the reaction was also an issue as the plastic 96-well 
plates was prone to cooling very quickly when removed from the plate reader for the 
purposes of adding solutions to the wells; to ameliorate this problem, all the proteins 
and the buffer were incubated at 37 °C. But the biggest challenge for the 
fluorescence assay was timing; The FI was added last but then the reaction mixture 
required agitation. During this mixing step (5 seconds) FI begins to act so that initial 
rate is hard to measure. 
A series of incubations were set up for the SDS-PAGE based cofactor assay, with 
FH, FI and C3b, where the total concentration of FH was kept constant but the ratio 
of wild-type protein (V62 FH 1-4) to mutant protein (R53H FH 1-4 or R78G FH 1-4) 
was incremented over the range 1:0 to 0:1. This would have revealed any inhibitory 
effects of the mutant on the cofactor activity of the wild-type (V62) FH 1-4 since 
R53H and R78G are both very significantly poorer as cofactors than the wild-type 
material. The presence of the mutant proteins in the reaction mixture had no 
significant effects on the activity of V62 FH 1-4 in these assays. Similarly, in a 
fluorescence-based assay that affords the opportunity to observe C3b cleavage in real 
time, the mutants appeared to have no effect on the activity of the V62 FH 1-4. 
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In order to appreciate why both R53H and R78G are poor co-factors, the position of 
the mutations within the three-dimensional structure of CCP 1 must be considered 
(Figure 3.20 (A) and (B)). Arg 78 of R78G is within the binding interface for C3b. 
Substitution of the Arg side chain, which is polar and charged, to the non-polar 
neutral side chain of Gly could certainly explain the lower binding to C3b seen 
previously and the associated loss of cofactor activity [53]. Interestingly, in their 
subsequent crystal structure of the FH 1-4:C3b complex, Wu et al. reported the 
presence of a salt bridge between the guanidinium group of R78 and D732 of the 
α’NT domain in C3b (Figure 3.20 (C)) [57]. 
 
Figure 3.20 Location of R78G within the C3b-FH 1-4 complex structure solved by 
crystallography. (A) Complex of C3b and FH 1-4 (PDB_ID 2WII) with the position of R78G 
indicated by red spheres. (B) A zoomed-in view of the region of the complex in the vicinity of R78. 
(C) Salt bridge between FH 1-4 G78 (red sticks) and C3b D732 (green sticks). Images visualized with 
PyMOL. 
In the case of R53H FH, the mutated residue is located on the opposite side of CCP 
1, i.e. away from the C3b-binding interface. Petchl et al hypothesized that this could 
explain why R53H FH 1-4 has a similar C3b-binding affinity to V62 FH 1-4 [53]. 
89 
 
Hence affinity for C3b is not the source of this mutant’s lowered cofactor activity. 
Recently, Roversi et al [155] proposed a model of the C3b:FH 1-4:FI ternary 
complex based on the FI crystal structure [155]. This implied (Figure 3.21) a 
possible interaction between Arg53 and the FIMAC domain from the heavy chain of 
FI. Hence these findings suggest that R53H has a decreased cofactor activity due to 
the inability of the C3b:FH 1-4 (R53H) complex to bind to FI.  
 
Figure 3.21 Location of R53H on the ternary complex of C3b, FH 1-4 and FI. In (A) is the model 
of the C3b-FH-FI complex with FI shown as a cartoon and C3b and FH shown as cartoons with 
semitransparent surfaces. (B) shows a zoomed in view of the interaction between FI and R53H (cyan). 
Figure (A) from [155] and (B) adapted from [155]. 
Taken together, all these structural and functional observations suggested that R53H 
FH (but not R78G) should destructively interfere with the function of wild-type FH 
since the two proteins will compete for C3b binding but only the complex of wild-
type FH and C3b will be a substrate for FI. According to this hypothesis, R53H FH 
1-4 should inhibit the cofactor activity of V62 FH 1-4, but this is not what we 
observed. This is despite the fact that the concentration of C3b:CFH 1-4 (wt) 
complex should (by design) have been limiting, since C3b was present in excess and 
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we were working at FH 1-4 concentrations that were below the Kd (10 µM) for 
C3b:FH 1-4, and were in a linear range with regard to the rate of iC3b production. 
Nonetheless, we have not fully disproved the “negative dominant hypothesis” due to 
limitations of the current study. First, these studies were carried out in fluid phase 
whereas the key actions of FH occur on surfaces bearing specific molecular markers 
that activate FH. Second, we were using just the N-terminal region of FH that does 




















Chapter 4 Study of intramolecular distances within FH 
using EPR 
The most powerful techniques for determining the structures of proteins are X-ray 
diffraction and NMR spectroscopy but neither of these is ideally suited to the study 
of FH. Although crystal structures have been published for portions or segments of 
FH [48, 57, 62], no successful attempts at crystallizing FH either alone or in the 
presence of C3b have been reported to date. With NMR the challenge is the high 
molecular weight and extended shape of FH; currently, due to broad lines and 
spectral complexity, pairs or triplets of CCPs [52, 55] represent the upper limit for 
structure determination. 
Recently a very promising integrative approach has been developed to combine 
high-resolution structures derived from crystals and NMR with low-resolution 
techniques such as EM and SAXS [52, 165]. This allows the smaller high-resolution 
models to be fitted into shape envelopes generated form larger fragments of the 
protein.  Further structural restraints – such as from chemical cross-linking, EPR or 
FRET – can also be included to improve the reliability and accuracy of the modeling 
process [59, 166]. In the current work, the use of EPR-derived distance restraints as 
part of an integrative structure determination of FH was investigated.  
Early efforts were focused on the central region of FH since this is hypothesized (see 
section 1.6) to be critical for promoting a conformation of FH in which N-terminal 
and C-terminal C3b-binding sites are brought into proximity. The double module FH 
12-13 was used initially for a “proof of concept” study since its NMR-derived 
structure had previously been determined, and SAXS data collected. The plan was to 
incorporate a paramagnetic group into each module and compare the EPR-derived 
distance measurement to the one predicted from the solution structure. It was 
anticipated that a major challenge to be overcome would be the one of site-specific 
labeling. Subsequently, if successful, this approach would be applied to longer 
fragments such as FH 10-13, FH 10-15 and FH 11-14 for which combined 




4.1 Preparation of the DNA required for site-directed spin 
labeling of recombinant FH fragments. 
With the need for attachment of paramagnetic groups in mind, mutagenesis (see 
Methods, section 2.1.1.4) was used to place either an additional cysteine residue or a 
transglutaminase tag (PKPQQFM) at either the C terminus or the N terminus of each 
recombinant FH fragment or segment.  
A note on the naming convention for FH fragments used hereafter: the first letter 
after the FH module numbers within the recombinant segment corresponds to the 
addition of a residue or residues at the N terminus and the second letter to the C 
terminal addition; e.g. FH 11-14 CT has an additional cysteine at its N terminus and 
a transglutaminase tag inserted at its C terminus, while TT or CC would indicate 
transglutaminase tags or cysteine residues, respectively, at both termini.  WT 
signifies “wild type” proteins or, strictly speaking, native-sequence fragments. The 
mutated DNA constructs were ligated into the desired E. coli vector (see Methods, 
section 2.1.4) and sequenced prior to transformation into P. pastoris (see Methods, 
section 2.1.1.3).  
4.2 Production and purification of proteins 
4.2.1 Small-scale test expressions. 
Twelve DNA constructs (see Table 4.1) coding for the modified FH segments were 
transformed successfully into P. pastoris (see Methods section 2.2.3) and cells 
grown on agar plates containing Zeocin. For each construct, between two and four 
colonies were subsequently screened for protein production by inoculating 100 ml 
cultures (see Methods section 2.2.4) that were grown up in a shaking incubator. 
Protein production was assessed by SDS-PAGE (Figure 4.1) after enzymatic 






Table 4.1 Details of modified FH fragments for EPR. 
FH fragment No of CCPs N-terminus tag C-terminus tag 
12-13 WT 2 - - 
12-13 CC 2 Cys Cys 
12-13 TT 2 TTag TTag 
12-13 CT 2 Cys TTag 
12-13 TC 2 TTag Cys 
10-13 WT 4 - - 
10-13 CC 4 Cys Cys 
10-13 TT 4 TTag TTag 
10-13 CT 4 Cys TTag 
10-13 TC 4 TTag Cys 
11-14 CT 4 Cys TTag 
10-15 CT 6 Cys TTag 






Figure 4.1 Test expressions for all EPR constructs. SDS-PAGE was used to assess protein 
production by two to four colonies of each protein in 100 ml cultures. The bands visable at 75 kDa, in 
all gels, is Endo Hf while the arrows indicate the bands of interest. 12-13 SL is discussed in Chapter 5.  
Test expressions for a set of FH 12-13 constructs showed production, by all the 
colonies, of a protein that migrated at the expected positions of ~15 kDa under 
reducing conditions.  
On the other hand, mixed results were obtained for the four-CCP FH 10-13 
constructs. Candidate bands for native-sequence FH 10-13 (WT) were detected on 
polyacrylamide gels following electrophoresis under reducing and non-reducing 
conditions. But only one of the FH 10-13 CC colonies appeared, on this basis, to 
produce protein and yield was extremely poor. The FH 10-13 CT colonies also failed 
to produce any candidates that migrate as would be expected for a protein of the 
expected size during SDS-PAGE. To further investigate these colonies, the growth 
medium (after spinning out cells) from colony 1 was fractionated using size-
exclusion chromatography for analysis by mass spectrometry. This suggested that 
the main protein product of FH 10-13CT was between 5 and 6 kDa smaller than 
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expected.  In the cases of both FH 10-13 TC and FH 10-13 TT, protein production 
was achieved but at low levels compared to FH 10-13 WT.  
In the cases of FH 10-15 CT and FH 11-14 CT all four colonies produced protein of 
the expected size.  
As none of the FH 10-13 proteins designed for labeling had been produced 
successfully they were not subjected to any further investigation. Likewise, with 
regard to the FH 12-13 proteins, only FH 12-13 CC and FH 12-13 TT were taken 
forward for further study. Table 4.2 summarizes the results of the test expressions.  
Table 4.2 Summary of results from test productions. 
Construct Estimated MWt (Da) Outcome 
11-14 CT 29000 Good yield, used for large scale protein production 
10-15CT 42000 Good yield, used for large scale protein production 
10-13 WT 28000 Low yield, not used in further experiments 
10-13 CC 28000 Poor yield, not used in further experiments 
10-13 TT 29000 Poor yield, not used in further experiments 
10-13 CT 29000 MWt incorrect; to be investigated further 
10-13 TC 29000 Poor yield, not used  in further experiments 
12-13 WT 14000 Good yield, but not needed for further experiments 
12-13 CC 14000 Good yield used for large scale protein production 
12-13 TT 15000 Good yield used for large scale protein production 
12-13 CT 15000 Good yield, but not used for further experiments 
12-13 TC 15000 Good yield, but not used for further experiments 
Molecular weights (MWt) listed in Table 4.2 have been estimated based on the 
calculated result from Protparam. The reason for this is for unexplained reasons the 
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proteins (with the exception of FH 12-13 CC) failed to ionize during the recording of 
mass spectrometry experiments. 
4.2.2 Production and purification of FH 12-13 CC 
Production of FH 12-13 CC was carried out in shaker flasks (see Methods section 
2.2.5) with an initial volume of 4 L of BMGY media (500 ml per 2 L flask) which 
was reduced to 1 L of BMMY media (125 ml per 2 L flask). After removal of cells 
by centrifugation, the supernatant was adjusted to pH 4.0 and diluted fivefold prior 
to application to a 30 ml SP Sepharose chromatography column (containing cation-
exchange resin, see Methods section 2.3.1). The bound protein was then eluted from 
the column using a 1 M NaCl gradient, and 2 ml fractions were collected and 
analyzed by SDS-PAGE (Figure 4.2) based on 20 L aliquots (each was treated with 
Endo HF prior to preparation for loading on to the gel).  
 
Figure 4.2 Purification of FH 12-13 CC on SP Sepharose column. (A) The elution profile (blue 
line) using a 1 M NaCl gradient (green line). (B) SDS-PAGE for the fractions run under both non-
reducing and reducing conditions. Arrows indicate the FH 12-13 CC bands; the band visible at 75 
kDa is Endo Hf. 
A single broad peak with a very high OD reading was eluted between 200 and 275 
ml and SDS-PAGE confirmed the protein was present within fractions 46 to 53. 
Under reducing conditions a strong single band was present at the expected size for 
monomeric protein, but suspected dimer (26-kDa band) was present under non-
reducing conditions. Fractions 42-53 were pooled (giving a final volume of ~ 50 ml), 
then a 20 ml aliquot of this pool was concentrated to 2.0 ml, and buffer-exchanged 
into PBS for application to a size-exclusion column. The remaining 30 ml was stored 
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at -80 °C. Two injections onto the size-exclusion chromatography column of 1 ml 
were performed. 
 
Figure 4.3 Size-exclusion chromatography of FH 12-13 CC using HiLoad 16/60 Superdex 75, 
first of two 1.0 ml applications. (A) Elution profile for injection; (B) the gradient SDS-PAGE with 
the lane numbers corresponding to the fractions indicated on (A). The-75 kDa band is Endo Hf. 
Following each of the 1 ml injections, two poorly resolved peaks were present in the 
chromatogram, eluting between about 60 ml and 75 ml (see Figure 4.3 (A), only the 
result of the first injection is shown). Fraction 42 contains a high proportion of a 
putative dimer of FH 12-13 CC (that becomes monomeric under reducing 
conditions). Fractions 46-54 covered the 75 ml peak and reflected the incomplete 
resolution of monomer and dimer, while there was also evidence of “clipping” i.e. 
proteolytic cleavage products that become evident under reducing conditions. These 
have probably become more prominent over the course of the purification procedure 
due to the continuing action of proteases in the stored incompletely purified samples. 
Finally, fractions 46-54 from both SEC injections were pooled (final volume of ~ 20 
ml) and then treated with Endo HF before concentration to 1.0 ml, and reapplication 
to the size-exclusion chromatography column.  
The elution profile following this second pass through a size-exclusion column was 
dominated by three poorly resolved peaks, with the main one at 75 ml, as before 
(Figure 4.4 (A)). Analysis of the fractions by SDS-PAGE (Figure 4.4 (B) and (C)) 
suggested that the first peak contains trimeric FH 12-13 CC, the second peak 
contains a dimeric form and the third peak contained monomeric FH 12-13 CC 
(under both reducing and non-reducing conditions) although the “clipped” fragments 
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remain evident under reducing conditions. On this evidence, fractions 50-56 were 
pooled (fraction 49 was excluded due to a small amount of dimer being present) and 
concentrated to 1.0 ml, yielding a concentration of 200 µM (2.8 mg/ml), before 
being stored at – 20 °C. From 1 L of BMMY the approximate yield is 50 mg/L. 
 
Figure 4.4 Size-exclusion chromatography of FH 12-13 CC using HiLoad 16/60 Superdex 75, 
second application. (A) The elution profile; (B) The gradient SDS-PAGE for the fractions indicated 
on (A) under non-reducing conditions; (C) Fractions subjected to SDS-PAGE under reducing 
conditions. Arrows indicate the bands of interest. 
4.2.3 Purification of FH 12-13 TT 
Expression and initial purification of FH 12-13 TT, and analysis of the results by 
SDS-PAGE, was carried out in an identical manner to that of FH 12-13 CC. 
The elution profile form the SP-Sepharose column showed a very large and broad 
peak with some leading-edge shoulders (Figure 4.5). Analysis of the peaks by SDS-
PAGE (15 µl loaded) showed that fractions 12, 18 (first shoulder) and 24 (second 
shoulder) contained no protein. Fractions 30-42, corresponding to the main peak, 
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contained large amounts of protein at the expected sizes although under reducing 
conditions small amounts of clipped protein are visible. 
 
Figure 4.5 Ion-exchange chromatography of FH 12-13 TT on SP Sepharose. (A) The elution 
profile (blue line) using a 1 M NaCl gradient (green line). (B) Gradient SDS-PAGE for indicated 
fractions run under both non-reducing and reducing conditions. The putative FH 12-13 TT bands are 
indicated by arrows. The band visible at 75 kDa is Endo Hf. 
Fractions 28-42 were pooled (~ 60 ml) and then half was stored whilst the remaining 
half was treated with Endo Hf before being concentrated to 2 ml for size-exclusion 
chromatography; four injections of 0.5 ml were performed.  
 
Figure 4.6 Size-exclusion chromatography of FH 12-13 TT on Superdex 75 HR 10/30. (A) The 
four elution profiles are shown overlaid; (B) gradient SDS-PAGE for the first injection. The putative 
FH 12-13 TT bands are indicated by arrows. 
For all four injections a dominant peak was obtained with a leading-edge shoulder 
(Figure 4.6 (A)). The SDS-PAGE (Figure 4.6 (B)) for the shoulder (fraction 23) 
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showed protein that could correspond to FH 12-13 TT dimer although under 
reducing conditions there were two bands visible, the lower one probably being 
monomeric protein. Fractions 25-31, corresponding to the main peak, contained 
protein at the expected size with evidence of “clipped” material under reducing 
conditions. These fractions (25-31) were combined and concentrated to 300 µM (4.5 
mg/ml) in 1 ml and stored at -20 °C prior to being labeled. From 1 L of BMMY the 
approximate yield is 4.5 mg/L. 
4.2.4 Purification of FH 11-14 CT 
Protein production was, again, carried out in shaker flasks with an initial volume of 2 
L (4x 500 ml) of BMGY media, which was then reduced to 500 ml of BMMY 
media. As before the pH of the harvested supernatant was adjusted to 4.0 and diluted 
fivefold before being applied to a 30 ml SP Sepharose column. 
 
Figure 4.7 Ion-exchange chromatography of FH 11-14 CT on SP Sepharose. (A) Elution profile 
(blue line) using a 1 M NaCl gradient (green line). (B) Gradient SDS-PAGE of fractions (indicated in 
(A)) under both non-reducing and reducing conditions. The protein bands are indicated by arrows and 
the 75-kDa band visible is Endo Hf. 
The elution profile (Figure 4.7 (A)) showed a single peak eluting between 500 and 
900 mM NaCl. According to SDS-PAGE (Figure 4.7 (B)) fractions 47-62 contained 
protein of the appropriate size and there were combined for Endo Hf treatment then 
concentrated to 1.0 ml for size-exclusion chromatography using two 0.5 ml 
injections.  
Four peaks appeared in the elution profile from size-exclusion chromatography 
(Figure 4.8 (A), injection one only); the first peak contained no protein whilst the 
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second peak contained protein at the expected size for a dimer of FH 11-14 CT under 
non-reducing conditions (gel not shown). The third, most prominent, peak contained 
protein of the expected size for monomeric FH 11-14 CT (Figure 4.8 (B)). Under 
non-reducing conditions the protein gave a single band but under reducing 
conditions there was evidence that clipped versions of the protein were also present. 
 
Figure 4.8 Size-exclusion chromatography of 11-14 CT using HiLoad 16/60 Superdex 75. (A) 
The elution profile. (B) The fractions indicated in (A) were then run under non-reducing (NR) and 
reducing (R) conditions on gradient SDS-PAGE. 
In an attempt to remove the 75-kDa impurity from the sample both sets of fractions 
39-45 were combined and concentrated to 1.0 ml for re-application to the size-
exclusion column. The result was a broad peak with shoulders (Figure 4.9 (A)). 
Analysis of the fractions on SDS-PAGE (Figure 4.9 (B)) showed fractions 40 and 41 
still contained a small amount of the higher-molecular weight impurity so these were 
discarded; fractions 42-48 were combined and concentrated to a final volume of 1.0 
ml (concentration was 330 µM, 9.6 mg/ml ) and then stored at -20 °C. From 0.5 L of 





Figure 4.9 FH 11-14 CT: Second size-exclusion chromatography step performed on HiLoad 
16/60 Superdex
 
75. (A) Elution profile. (B) The fractions indicated in (A) were then run in reducing 
conditions on SDS-PAGE alongside fraction 42 and 43 run under non-reducing conditions. Arrows 
indicate the expected position on the gel of the target protein. 
4.2.5 Purification of FH 10-15 CT 
The production of FH 10-15 CT was carried in a similar manner to that of FH 12-13 
CC. The resulting supernatant was concentrated to 200 ml of which 20 ml was 
applied to HiLoad 16/60 Superdex 75 size-exclusion column (each injection 
contained 1 ml). Previous work (by Dr Christoph Schmidt, [167]) showed that FH 
10-15 WT eluted from an identical column at 60 ml so the peak eluting at 60 ml 
(Figure 4.10 (A)) was investigated by SDS-PAGE. A small amount of each fraction 
from the peak was treated with Endo Hf prior to being run on the gel  (Figure 4.10 
(B)), which confirmed that the eluted protein migrated as would be expected for FH 
10-15 CT (~40 kDa) although double bands were obtained (also seen by Schmidt). 
Pooled fractions (39-43) were combined for all 20 injections and (volume ~ 110 ml) 




Figure 4.10 First purification step for FH 10-15 CT using HiLoad 16/60 Superdex 75. (A) The 
elution profile for injection one. (B) Gradient SDS-PAGE analysis of the fractions indicated in (A). 
The putative FH 10-15 CT band is indicated by arrows; the 75-kDa band is Endo Hf. 
After deglycosylation the protein was concentrated to a final volume of 2.0 ml and 
two 1.0 ml injections were reapplied to the size-exclusion column. One major peak 
with a shoulder was obtained in the chromatogram (Figure 4.11 (A)). Analysis of 
fraction 36, which corresponded to the shoulder, showed it contained what is 
presumably dimeric protein under non-reducing conditions that became monomeric 
when reduced. Analysis of the remaining fractions (Figure 4.11 (B)) showed fraction 
38 contained both monomer and dimer protein under non-reducing conditions but 
fractions 40 and 42 contained only monomeric protein. Under reducing conditions 
fractions 40-46 contained a small amount of clipped protein. Nonetheless, fractions 
40-46 from both runs were combined and concentrated to a final concentration of 
200 µM (8.4 mg/ml) in 1 ml prior to being stored at - 20°C. From 1 L of BMMY the 





Figure 4.11 Second purification of FH 10-15 CT using HiLoad 16/60 Superdex 75. The size-
exclusion chromatogram is shown in (A). For SDS-PAGE in (B) the lane numbers indicate the 
fractions numbers (also indicated in (A)); arrows indicate the expected migration positions for FH 10-
15 CT under non-reducing and reducing conditions. 
The yields obtained for FH 12-13 CC, FH 12-13 TT, 11-14 CT and FH 10-15 CT are 
summarized in Table 4.3 
Table 4.3 Summary of final concentrations obtained from the large-scale production. 

















 from 1 L of BMMY (50 
mg/L, 4.5 mg/L and 8 mg/L respectively). 
C
 from 0.5 L of BMMY (10 mg/L) 
4.3 Distance measurements using DEER 
Labeling of FH 12-13 TT was carried out using a sample of 100 µl of protein at 100 
µM and 20x excess of the transglutaminase spin label overnight at room temperature. 
Excess spin label was removed using size exclusion chromatography on a Superdex 
75 10/30 column. 
As the “proof-of-concept” protein, the FH 12-13 TT sample (100 µl of 50 µM in 10 
mM Tris-HCl dissolved in 99.9 % D2O, pH 7.4 plus 50% deuterated glycerol) was 
studied in initial DEER experiments using a Bruker E580 EPR machine running 
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pulsed X-band EPR. Analysis of the data was performed by Dr David Norman, 
University of Dundee using DeerAnalysis2011 [168]. The original data is shown in 
Figure 4.12. 
 
Figure 4.12 Initial DEER experiment showing raw data for FH 12-13 TT. The black line 
represents FH 12-13 TT with the red line being the fit. Background is shown by the dark blue line. 
After background removal and applying Tikhonvo regularization to the data [169] 
(Figure 4.13), the process of extracting distances measurements could begin. 
Analysis of the data, however, highlighted a difficulty with the sample. The drop in 
the relative intensity of oscillation, from 1.0 to 0.92, is much smaller than the 
expected drop, which would typically be from 1.0 to around 0.6 (personal 
communication with Dr David Norman, University of Dundee). The main reason 




Figure 4.13 Background-corrected trace for FH 12-13 TT and Tikhonov fitting. Corrected time 
trace is shown in black and the Tikhonov fitting in red. 
Nonetheless, it was possible to extract inter-label distances from the data (Figure 
4.13). In the NMR-derived structure of FH 12-13 (PDB: 2KMS) the N-terminal and 
C-terminal residues - Thr690 and Ser804 - are ~ 5.2 nm apart (Figure 4.14). Allowing 
for the peptide tags to which the spin labels are attached, suggests a total distance in 
the vicinity of ~ 6 nm (measured between Gln686 and Gln808). 
 
Figure 4.14 Model of FH 12-13 with transglutaminase tags. The FH 12-13 model (PBD: 2KMS) is 
visualized as a cartoon and the transglutaminase tags as sticks. The distance was measured using 
PyMOL. 
This distance estimation does not take into account the flexibility of the tag sequence 
or of the spin label itself. A distance-distribution plot (Figure 4.15) was created for 
FH 12-13 TT after Tikhonov regularization. Multiple peaks were obtained 
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suggesting a possible distance of between 4.8 and 7 nm. An accurate distance cannot 
therefore be predicted, presumably due to the dynamic nature of the sample as well 
as the suspected low percentage of doubly labeled protein. Nonetheless, the DEER-
derived distances are compatible with the distance between N-terminal and C-
terminal residues measured in the NMR-derived structure. 
 
Figure 4.15 FH 12-13 TT DEER-derived distance distribution. The plot shows the range of 
possible distances obtained for FH 12-13 TT. The multiple peaks probably arise from the low 
percentage of doubly labeled protein as well as from the dynamic nature of the sample. 
For both FH 11-14 CT and FH 10-15 CT, the proteins (100 µM) were firstly labeled 
with 20x excess of MTSSL at room temperature for 4 hours and then dialyzed to 
remove the unused label. The protein was then labeled with the transglutaminase 
label (as for FH 12-13 TT) and removal of the excess label was performed using size 
exclusion. 
The DEER experiments performed on the labeled samples of FH 11-14 CT and FH 
10-15 CT were, unfortunately, unsuccessful. Figure 4.16 shows the original data for 
FH 11-14 CT and Figure 4.17 for FH 10-15 CT. Neither trace showed any drop in 
intensity. The most likely reason for this is that the proteins were not in fact doubly 
labeled. Another possible explanation was the low concentration of the proteins used 




Figure 4.16 Raw DEER data for FH 11-14 CT. Represented by the black line is FH 11-14 CT with 
the red line being the fit. Background is shown by the dark blue line. 
 
Figure 4.17 Raw DEER data for FH 10-15 CT. Blue line represents FH 10-15 CT with the red line 
being the fit. Background is shown by the green line. 
A further attempt to gather distance measurements was initiated using FH 12-13 CC. 
A sample containing 100 µM of FH 12-13 CC was incubated with a 20x excess of 
the MTSSL spin label for four hours at room temperature. The results of labeling of 
FH 12-13 CC after removal of the excess label was assessed using mass 
spectrometry (Figure 4.18). This showed that two species had originally been present 
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(before labeling), differing by a GlcNAc groups (200 Da). Only one of the cysteines 
had been successfully labeled in each of the two species. The simulated mass of two 
labels and either one or two GlcNac groups did not correspond to any of the majors 
peaks in the mass spectrum of the labeled protein. The labeled protein sample was 
submitted for DEER analysis but no distance measurement was achieved, consistent 
with the absence of a doubly-labeled sample. In order to confirm that both sulfhydral 
groups were available for labeling another sample was prepared but this time labeled 
with maleimide. The mass spectrometry data (Figure 4.19) showed that the majority 
of the protein remained unlabeled with a small amount showing the presence of a 
single label. A peak was obtained for double labeled protein but it is very small and 
could even be considered noise. Unfortunately labeling of both cysteines was never 
achieved despite further attempts (increase in incubation time as well as amount of 
reduction agent present) so no further work was continued with this protein  
 
Figure 4.18 LC-MS spectrum for FH 12-13 CC to check MTSSL labeling efficiency. The raw 




Figure 4.19 FH 12-13 CC labeled with maleimide. The spectrum shows the results of the use of 
maleimide to confirm if the sulfhydral groups are available for labeling. 
4.4 Conclusions 
The aim of the work presented in this chapter was to prove the principle that it will 
be possible to obtain EPR-derived distances measurements [121, 139] which will 
help to define the three-dimensional structure of the large complement regulatory 
protein, FH. A major challenge to this approach is the need for site-specific 
attachment of paramagnetic species. This is normally achieved [170, 171] through 
the insertion of cysteine residues using mutagenesis. While this is straightforward for 
proteins that do not contain disulfides bridges [172] it is more problematic in the 
case of a protein like FH that has 80 cysteines and 40 disulfides. This is because of 
the potential for disulfide scrambling as a result of the presence of extra non-native 
cysteines. Moreover, once the mutated protein is correctly folded the free cysteines 
can cause oligomerisation meaning that a careful selection of labeling conditions is 
required. As an alternative to the engineered-in cysteine route that avoids some of 
these potential pitfalls, the use of transglutaminase has its own problems since it 
involves the use of flexible N-terminal or C-terminal peptides and hence uncertainty 
in the precise position of the paramagnetic label with respect to the rest of the 
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protein. Given these challenges, it was decided to instigate EPR-based studies of FH 
by attempting to collect data on small recombinant segments from its central region 
that are known to form compact structures [55]. 
Twelve constructs were prepared which allowed for a combination of labeling 
techniques to be explored. The results for the various FH 12-13 constructs were very 
promising as all exhibited good levels of production during initial trials. To date, 
only FH 12-13 CC and FH 12-13 TT have been used for labeling experiments as it 
was decided to prioritize the proteins that could be labeled in a single step; there was 
insufficient time to attempt labeling of FH 12-13 CT and FH 12-13 TC but these 
samples have been stored for future experiments. The FH 12-13 CC results therefore 
demonstrated, for the first time, incorporation of cysteines (at both termini), without 
apparently disrupting disulphide bonds and this provides hope that such a feat could 
be repeated for larger segments and even intact FH in due course. 
For FH 12-13 TT, it proved possible to extract DEER-derived distances and compare 
them to what would be expected based on the NMR solution structure of FH 12-13 
WT. The result, however, should be treated with a degree of caution as the labeling 
of the sample was not very efficient. To try and improve this it is likely that more 
transglutaminase enzyme was required during the labeling process so any future 
experiments would involve finding the right amount of enzyme for each protein to 
achieve the highest percentage of labeling possible. 
Of the FH 10-13 constructs, only FH 10-13 WT produced a useful quantity of 
protein during trial growths. The reasons for lack of non-WT FH 10-13 production 
were not investigated due to lack of time and due to the availability of alternative 
constructs (shorter and longer) for proof-of-principle work. One possibility is that 
there is an upper limit on the number of cysteines that can be tolerated for this 
approach. Since none of the FH 10-13 constructs created for labeling were successful 
during the trials they were removed from the study.  
Of the two longer constructs, the production of both FH 11-14 CT and FH 10-15 CT 
was successful, but unfortunately neither was able to give distance measurements. 
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Possible reasons are, sample concentrations were too low or that the majority of the 
sample was only singly labeled but further investigation is required. 
EPR is now becoming a popular tool to aid structure determination of proteins [139] 
but is still relatively unused for the study of complement proteins with only DAF 
being studied so far [166]. After correcting all the issues identified by the current 
study, future work would move on to labeling larger fragments (e.g. FH 8-15) and 
then trying to measure various distance in the central region in order to gather more 
restraints for NMR and SAXS modeling. 
A method not used in the study but one which may aid future work is the insertion of 
unnatural (i.e. non-encoded) amino acids within the protein sequence. The insertion 
of the unnatural amino acid has two advantages over the techniques used in the 
study; first it removes the risk of disrupting the natural disulphides within the CCPs 
and second the flexibility within the transglutaminase tag is not an issue, reducing 
the errors in the distance measurements. 
An orthogonal labeling strategy might involve exploitation of the N-glycans present 
as post-transcriptional modifications in both recombinant and plasma-derived FH. 
These are mainly - but not exclusively - located in the central modules of FH and 
display sugars rings that contain diols. The diols could be used for tagging with a 
spin label that has been appropriately derivatised with a hydrazine group [173] [174]. 
Prior treatment with Endo Hf would result in a single GlcNAc attached to each N-
glycan site; the number and position of these could be varied by protein engineering 








Chapter 5 Investigating the architectural role of the 
central region of FH 
The segment of FH encompassing CCPs 8-18 appears to have no major binding sites 
for either C3b or GAGs [63]. The lack of binding sites in this region suggests that it 
plays a structural, or architectural, role in positioning the binding sites at either 
terminus so that they can cooperate in engaging ligands. It is noteworthy that 
intermodular linking sequences (linkers) within the CCPs 10-15 region are generally 
longer (5-8 residues) and CCPs generally smaller (e.g. CCP 13 is the smallest CCP 
at 51 amino acid residues) compared with N-terminal and C-terminal regions of FH. 
This could be consistent with a hinge-like role for these central CCPs. NMR-derived 
solution structures are available for double-module constructs consisting of CCPs 
10-11, 11-12 and 12-13 [52, 55]. All three adopt “V-shapes” (Figure 5.1). For 
example, FH 12-13 [55], which contains the smallest CCP as well as the longest 
linker (eight amino acid residues), exhibits an ~80° tilt between the modules 
(measured using a convention in which 0° would correspond to a fully extended 
conformation of the two modules). Six out of eight residues in the linker contain 
bulky side chains and four of these are buried in the interface between the two 
modules that “glues” them together and impedes motion between the modules. 
 
Figure 5.1 NMR-derived solution structures of module pairs from central region of FH. PDB 
models used: FH 10-11 (4B2R), FH 11-12 (4B2S) and FH 12-13 (2KMS). 
In the current study, a mutagenesis investigation was designed to assess the 
functional and structural roles of the long linker between CCPs 12 and 13 of FH. 
Initial work was aimed at studying the effects of linker mutations in the context of 
FH 12-13 since this would facilitate a detailed comparison by NMR of the structure 
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and dynamics of mutant and wild-type proteins [55]. Subsequently, the same 
mutations were introduced into FH 10-15 and FH 8-15 to allow assessment of the 
effects of a mutated linker, using low-resolution structural methods [52, 55], on 
longer segments of FH. The final goal was to mutate the CCPs 12-13 linker within 
full-length (20-CCP) FH.  
5.1 Design of the new linkers for FH 12-13 
The original linker between FH 12-13 contains eight residues: Val745 – Ala746 – Ile747 
– Asp748 – Lys749 – Leu750 – Lys751 – Lys752. The residues Val745, Ala746, Ile747 and 
Leu750 all have hydrophobic side chains that are buried in the interface between the 
modules. In designing a linker that would be expected to be less rigid, the residues 
Ile747, Lys749 and Leu750 were each mutated to glycine. While retaining the length of 
the linker, this should disrupt the interface between the two modules and hence 
promote significant intermodular flexibility. The name assigned to this linker was 
“three-glycine” (3xGLY). Another mutant was created in which Ala746, Ile747, Asp748, 
Lys749 and Leu750 were all deleted.  It was reasoned that the remaining three-residue 
linker would disrupt the V-shape of FH 12-13 but would be too short to allow much 
flexion between modules. This linker was referred to as “short-linker” (SL).  
5.2 Preparation of DNA encoding FH 12-13, FH 10-15, FH 8-
15 and full-length FH  
Polymerase chain reactions were successfully used to amplify DNA segments 
encoding native-sequence FH 12-13 (360 bp), FH 10-15 (1083 bp) and FH 8-15 
(1446 bp) from the full-length FH-coding synthetic DNA gene (designed by Dr 
Christoph, prepared by GeneArt) which had been codon/expression optimized for P. 
pastoris [140].  
The codon expression-optimized (for P. pastoris) DNA encoding full-length FH 
containing the short 12-13 linker (i.e. FH SL) was synthesised and cloned into 
pPICZαB by GeneArt (Life Technologies Ltd.). The DNA encoding FH 10-15 SL, 
FH 8-15 SL and FH 3xGLY was successfully generated in the current study from the 
codon-optimized full-length FH DNA from [140]using fusion PCR [175].  
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DNA encoding FH 12-13 SL was prepared using mutagenesis and cloned into 
pPICZαB by former lab member, Dr Mara Guariento.  
The PCR products were subject to restriction digestions and gel purification prior to 
ligation into pPICZαB. Colonies from the ligation reactions underwent PCR-based 
screening to ensure insertion of the product had occurred (as opposed to re-ligation 
of the empty vector). Successful ligation should yield bands at ~550 bp for FH 12-
13, ~1300 bp for FH 10-15, ~ 1600 bp for FH 8-15 and 3600 bp for full-length FH; 
empty pPICZαB should give a band of 330 bp. The results of both the amplification 
PCRs and screening PCRs are shown in Figure 5.2. Where bands of the expected 
size were obtained, the appropriate colonies were chosen for plasmid extraction and 
the resulting DNA was then sequenced. 
The DNA containing the 3xGLY linker in FH 12-13, FH 10-15 and FH 8-15 was 
achieved using site-directed mutagenesis (see methods section 2.1.1.4). To verify 





Figure 5.2 Amplification and screening PCR of various recombinant FH Segments. The agarose 
gels in (A) and (C) show the successful amplification of FH 12-13 WT (A, 360 bp), FH 10-15 WT (C, 
1083 bp) and FH 8-15 WT (C, 1446 bp) from codon-optimized DNA encoding full-length native 
sequence FH. In (B) is the screening result for FH 12-13 with lanes 1, 2, 4, 7, 9 and 10 corresponding 
to pPICZαB containing the FH 12-13 insert. Lanes 3, 5, 6, and 8 all contain empty pPICZαB. The 
screening results for FH 10-15 WT and FH 8-15 WT are shown in gel (D); all eight colonies screened 
for both constructs showed successful incorporation of the inserts with pPICZαB. In (E) and (G) is 
shown the amplification of the fragments need for fusion PCR to generate 8-15 SL, 10-15 SL and FH 
3xGLY. The screening results for 8-15 3xGLY and 10-15 3xGLY are shown in (F) with colonies 1-4 
being correct (6-8 not sequenced) for 8-15 3xGLY and 2, 4 and 6 being positive for 10-15 3xGLY. 
For FH 3xGLY all colonies screened were positive (H). 













DNA source PCR Site-directed 
mutagenesis 







YES Codon optimized DNA 
encoding for 12-13 WT 
- YES 
12-13 SL NO Non-codon optimized full 











YES Codon optimized DNA 
encoding for 10-15 WT 
- YES 
10-15 SL YES Codon optimized DNA 
encoding for 10-15 WT 
YES - 







YES Codon optimized DNA 
encoding for 8-15 WT 
- YES 
8-15 SL YES Codon optimized DNA 
encoding for 8-15 WT 
YES - 
FH WT YES Synthetic gene 
2
 - - 





FH SL YES Synthetic gene - - 
1
 was prepared by Dr Mara Guariento and 
2
 by Dr Christoph Schmidt. 
5.3 Expression and purification of proteins 
The DNA for all of the wild type, 3xGLY linker and SL linker constructs was 
successfully transformed into the KM71H strain of P. pastoris (methods section 
2.2.3). A small-scale protein production trial was carried out on between two and 
four colonies in the case of each construct (methods section 2.2.4). The resulting 





Figure 5.3 Small-scale protein production trials of all P. pastoris linker constructs. (A) Gradient 
SDS-PAGE; the band at 75 kDa detected in all gels is Endo Hf. Arrows indicate the bands of interest. 
NR means non-reducing, and R means reducing conditions. (B) Western blots; Lane “R” in each gel 
contains FH from Complement Technologies (used here as a positive control); in the FH 3xGLY gel, 
lanes 1-3 correspond to the colony number and are fivefold concentrated or are crude supernatant, as 




Prior to loading onto SDS-PAGE, all samples were treated with Endo Hf to 
deglycosylate them. The small-scale production attempts for all of the FH 12-13 
constructs were promising. Note that, as expected, the reduced samples tend to run 
slightly higher than equivalent size markers. Similarly, colonies  containing DNA for 
FH 8-15 wild type, FH 8-15 3xGLY and 8-15 SL all produced proteins that migrate 
according to expectations. The trial productions of both FH 10-15 wild type and FH 
10-15 3xGLY were also successful. For 10-15 SL only colonies 1, 3 and 4 produced 
protein successfully. The western blots for the full-length FH mutants were only run 
under non-reducing conditions, so a band was expected at ~100 kDa. All the 
colonies for FH 3xGLY as well as FH SL produced some protein that ran on the gel 





In order to record HSQC spectra of FH 12-13 wild type
2
, FH 12-13 3xGLY and FH 
12-13 SL, the first step was to produce isotopically labeled protein samples. The 
most efficient way to achieve this was with one-litre fermentations where the media 
was enriched with 
15
N-ammonium sulfate (see Methods section 2.2.6). Agitation 
rates, dissolved oxygen levels, pH and temperature were monitored over the time 
course for each of the fermentations. Figure 5.4 shows the logs obtained for FH 12-
13 WT and FH 12-13 SL (data for FH 12-13 3xGLY not shown due to software 
issues) which were as expected based on previous FH fermentation. After the 
addition of the cells (position A) a rapid increase in agitation occurs in order to 
maintain the oxygen level at 40% as the cells begin to consume the initial glycerol. 
Once the cells have consumed all the available glycerol, additional glycerol feeds are 
performed (position B). Before induction to methanol the temperature was reduced 
to 15°C to decrease proteolysis, once the temperature was reached the methanol was 
added (position C) where the agitation increased which indicated the cells were 
consuming the methanol. Additional methanol feeds were performed (position D) 
over 72 hours until the cells were harvested (position E). 




N fermentation and purification of FH 12-13 WT was carried out by Kate Fisher, MSc student 





Figure 5.4 Log for fermentations of 
15
N-labelled FH 12-13 wild type and FH 12-13 SL. The log 
for FH 12-13 wild type is shown above the log for FH 12-13 SL. In both are shown agitation (red), 
percentage of dissolved oxygen (DO2, blue), pH (green), temperature (30°C -15°C after induction to 
methanol, black) and potassium hydroxide feed (used to keep pH at 5, brown). The (A) position 
indicates the addition of cells (B) is for glycerol and PTM1 salts feed, (C) is induction to methanol 
(D) indicates methanol and PTM1 salts feeds and (E) is when the cells were harvested. 
5.3.2 Purification of FH 12-13 wild type 
After harvesting, the supernatant was diluted threefold and adjusted to pH 4.0 before 
application to a 30 ml SP-Sepharose (cation-exchange chromatography) column. The 
protein was eluted using a 1 M NaCl gradient and the peaks were analyzed by SDS-
PAGE (Figure 5.5). The chromatogram showed a major peak eluting at 700 mM 
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NaCl with a leading-edge shoulder. Analysis of the fractions by SDS-PAGE showed 
that fractions 51-78 from the main peak contained protein of the expected size. The 
higher band seen in fractions 69-78 could be dimer as it is not seen under reducing 
conditions; the lower bands seen in the reduced fractions are likely to be “clipped” 
species of FH 12-13 wild type. To conserve material, all of the fractions (numbers 
54-78) containing the protein were recovered, combined and treated with Endo Hf.  
 
Figure 5.5 FH 12-13 wild type eluted from SP-Sepharose. (A) The elution profile (blue line) using 
a 1 M NaCl gradient (green line). (B) Gradient SDS-PAGE of fractions in both non-reducing and 
reducing conditions. Arrows indicate expected position of FH 12-13. The band visible at 75 kDa is 
Endo Hf. 
After treatment with Endo Hf, the pooled fractions (50 ml) were concentrated to 1 ml 
then buffer exchanged into PBS to a final volume of 1 ml. The sample was then 
divided into two 0.5 ml samples for size-exclusion chromatography. Both of the 
size-exclusion profiles (Figure 5.6, (A)) show three peaks; a higher-molecular weight 
contaminant (ignored) followed by a small peak, then the main protein peak. The 
resulting SDS-PAGE gel from the first injection (Figure 5.6, (B)) confirmed that 
fractions 48-56 from the main peak contained FH 12-13. In the reduced samples the 
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lower-molecular weight clipped proteins were still present. The SDS-PAGE for 
injection 2 (Figure 5.6 (C)) gave the same result for the main peak fractions as 
injection 1. Samples containing fraction 44 were also run and showed that the 
smaller peak eluting ahead of the main peak was indeed dimer as the non-reduced 
sample had a size of ~ 30 kDa which when reduced ran at the expected size of 15 
kDa. 
 
Figure 5.6 Size-exclusion chromatography of 12-13 wild type using HiLoad 16/60 Superdex 75. 
(A) Elution profiles (blue and red lines) overlaid. Gradient SDS-PAGE shows fractions from injection 
1 (B) and injection 2 (C) in both reducing and non-reducing conditions. Bands of interest are 
indicated by arrows. The band visible at ~ 30 kDa in fraction 44 of (C) is probably dimeric FH 12-13. 
Fractions 48-57 from both injections were combined and concentrated to 1.0 ml (500 




N-HSQC so was 
dialyzed into 20 mM potassium phosphate, pH 6.6. The spectra (not shown) showed 
that the sample was not pure since it contained peaks that were consistent with 
degradation. In an attempt to improve its purity, the sample was subjected to a 
further size- exclusion chromatography step, using a Superdex 75 10/30 column. 
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An initial run on the Superdex 75 10/30 column contained 200  l of FH 12-13 and 
250 µM TCEP (included to try and remove some of the clipped protein from the 
sample; this concentration had been previously optimized by Dr Isabell Pechtl 
[162]). The elution profile (Figure 5.7, (A)) contained two peaks; a higher-molecular 
weight peak at around 67 kDa and a lower molecular weight peak at around 13.7 
kDa (correct for FH 12-13) based on a calibration profile. Analysis of the two peaks 
by SDS-PAGE (Figure 5.7, (B)) showed that the material in the 67-kDa peak gave a 
smear in non-reducing conditions but under reducing conditions returned back to the 
expected size for monomeric FH 12-13. Clipped protein was still present in the 13.7-
kDa peak. Fraction 9 was dialyzed back into 20 mM potassium phosphate. A sample 





N-HSQC spectra for comparison against the original FH 12-13 wild type 
spectra
3
 (see section 5.4). From a 1 L fermentation the approximate yield of 
15
N 
labeled 12-13 WT is 3 mg/L. 
 
Figure 5.7 Purification of FH 12-13 wild type by chromatography on a Superdex 75 HR 10/30 
size-exclusion column. The elution profile is shown in (A). In (B) is the gradient SDS-PAGE for the 
run, with the band suspected to correspond to FH 12-13 indicated by the arrow. 
5.3.3 Purification of FH 12-13 3xGLY 
The supernatant containing FH 12-13 3xGLY was diluted threefold and then 
adjusted to pH 5.0 prior to loading onto a 30 ml SP-Sepharose column. After loading 
the protein was eluted using a 1 M NaCl gradient. The elution profile (Figure 5.8) 
contained a single peak that was very small in comparison to FH 12-13 wild-type.  
                                                 
3
 Original spectra were recorded by Dr Christoph Schmidt as part of his PhD thesis. 
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This began to elute at approximately 300 mM NaCl. SDS-PAGE analysis of the peak 
in non-reducing conditions showed three weak bands: a high-molecular weight band 
of over 250 kDa, a band at approximately 25 kDa which might correspond to dimeric 
FH 12-13 3xGLY, and a band at 14 kDa which could be FH 12-13 3xGLY. In 
reducing condition the high-molecular weight band remains but the band thought to 
be a dimer is replaced by a band consistent with momomeric FH 12-13 3xGLY. As 
was seen in the expression of FH 12-13 wild type, the reduced sample for FH 12-13 
3xGLY also contain lower bands likely corresponding to clipped versions of the 
protein.  
 
Figure 5.8 Purification of FH 12-13 3xGLY on SP-Sepharose. (A) The elution profile using a 1 M 
NaCl gradient. The blue line shows the UV absorbance at 280 nm and the green line shows the NaCl 
gradient (0-100%). (B) Gradient SDS-PAGE of fractions indicated on the chromatogram in both non-
reducing and reducing conditions. The bands suspected to be FH 12-13 are indicated by arrows. The 
band visible at 75 kDa is Endo Hf. 
As before it was important to conserve protein so protein-containing fractions (28-
41) were combined to give a final volume of 30 ml. The fractions were treated with 
Endo Hf and then concentrated and buffer-exchanged into PBS to a final sample 
volume of 1.0 ml. 
A single size-exclusion chromatography step was then performed (Figure 5.9). The 
chromatogram contains a main peak with two small peaks or shoulders present on 
either side. The peak/shoulder to the left of the main peak appears to be FH 12-13 
3xGLY dimer as seen on the SDS-PAGE (fraction 44, non-reduced only) and the 
peak to the right was ignored. Analysis of the main peak by SDS-PAGE showed a 
single band in non-reducing conditions for fraction 52 but, under reducing 
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conditions, fractions 49-57 revealed the presence of a high proportion of clipped 
proteins in addition to some candidate FH 12-13 3xGLY. 
 
Figure 5.9 FH 12-13 3xGLY eluted from a HiLoad 16/60 Superdex 75 size exclusion 
chromatography column. (A) Elution profile. (B) The gradient SDS-PAGE gel shows analysis of 
the main protein-peak fractions.  
Fractions 49-57 were then concentrated to 1.0 ml for the final purification step using 
the Superdex 75 10/30 size-exclusion column. The resulting elution profile (Figure 
5.10 (A)) showed a single protein peak with a small leading-edge shoulder. Fractions 
26-30 from the main peak were analyzed by SDS-PAGE (Figure 5.10 (B)) and under 
reducing condition contained the main protein band at 15 kDa and clipped proteins 
which appear to have decreased in amount compared to the previous purification 
step. The non-reduced sample prepared from fraction 28 contains the FH 12-13 
3xGLY band at ~ 14 kDa but, in this heavily loaded sample, a slightly lower band is 
revealed that wasn’t visible previously. 
 
Figure 5.10 Purification of FH 12-13 3xGLY by Superdex 75 HR 10/30 size-exclusion 
chromatography. The chromatogram shown in (A) shows the main protein peak at 14 ml and the 
gradient SDS-PAGE for the fractions is shown in (B). The arrow indicates the protein bands. 
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The fractions were then combine and concentrated to give a final sample of 1.0 ml at 
approximately 100 µM, 1.4 mg/ml. An NMR sample was prepared by dialyzing 500 





spectra to be recorded for comparison with FH 12-13 wild type (see section 5.4). ). 
From a 1 L fermentation the approximate yield of 
15
N labeled 12-13 TT is1.4 mg/L. 
5.3.4 Purification of FH 12-13 SL 
After harvesting, the supernatant was treated and purified in the same way as the 
supernatant for FH 12-13 3xGLY. The elution profile showed one main peak (300 
mM NaCl) with a leading-edge shoulder (Figure 5.11 (A)). SDS-PAGE analysis 
(Figure 5.11 (B)) of the fractions in both non-reducing and reducing conditions 
showed that the main peak contained the target protein, and the tail was most likely 
impurities. As was seen for both FH 12-13 3xGLY and FH 12-13 wild type, the 
reduced samples for FH 12-13 SL also contain clipped versions of the protein.  
 
 
Figure 5.11 Purification of FH 12-13 SL on SP-Sepharose. (A) Elution profile (blue line). The 
green line is the NaCl gradient (0-100%). (B) The fractions indicated on the profile were analyzed by 
SDS-PAGE, which showed that protein of the expected size (arrow) was found only in the main peak.  
Fractions 22-27 were combined and then the sample was treated with Endo Hf prior 
to concentration and buffer-exchange into PBS. A final volume of 1.0 ml was 
achieved, which was then split into two 0.5 ml samples for size-exclusion 
chromatography (Figure 5.12). The separate injections both gave the same result of a 
single peak eluting at 80 ml. Analysis of the fractions from the peak by SDS-PAGE 
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showed that under non-reducing conditions there is a single band at the expected 
size, with the lower-molecular weight clipped contaminants still present. Fractions 
52-56 from both injections were combined and concentrated to a final volume of 1.0 
ml for a final purification step using the Superdex 75 10/30 size-exclusion 
chromatography column. 
 
Figure 5.12 Size-exclusion chromatography of 12-13 SL using HiLoad 16/60 Superdex 75. (A) 
Elution profiles (blue and red lines) containing the main protein peak for both injections overlaid. 
Gradient SDS-PAGE was performed for fractions from injection 1 (B) and injection 2 (C) in both 
reducing and non-reducing conditions. The bands of interest are indicated by arrows.  
Following size-exclusion chromatography on Superdex 75 10/30, the elution profile 
(Figure 5.13 (A)) contained a peak at 14 ml, corresponding to approximately 14 kDa 
(based on a previous calibration of the column). Analysis by SDS-PAGE (Figure 
5.13, (B)) (in reducing conditions only) showed only a trace of clipped proteins 





Figure 5.13 Purification of FH 12-13 SL by size-exclusion chromatography on Superdex 75 HR 
10/30. (A) Elution profile. (B) The gradient SDS-PAGE for the fractions, in reducing condition only. 
The lane labeled XX is FH 12-13 3xGLY, which was loaded in error. 
The fractions (26-39) were combined and concentrated to a final volume of 1.0 ml 
and concentration of ~200 µM, 2.8 mg/ml which was then dialyzed into 20 mM 




N-HSQC was recorded with 500 µl of the 
sample for comparison with FH 12-13 wild type (see section 5.4). ). From a 1 L 
fermentation the approximate yield of 
15
N labeled 12-13 SL is 3 mg/L. 
5.3.5 Purification of FH 8-15 wild type 
Production of FH 8-15 WT was carried out in shaker flasks (see Methods, section 
2.2.5). After removal of cells the resulting supernatant was diluted six-fold and 
adjusted to pH 8.5 for application to a 50 ml Q-Sepharose column. The protein was 
eluted using a 1 M NaCl gradient with the elution profile (figure 5.14 (A)) 
containing multiple overlapping peaks. Analysis by SDS-PAGE (figure 5.14 (B)) 
confirmed that a protein that had eluted between 100 and 200 mM NaCl ran at the 
expected size of ~50 kDa. The contaminants were thought to be proteins from P. 




Figure 5.14 Elution of FH 8-15 wild type from Q-Sepharose column. (A) Elution profile. The blue 
line is the UV absorbance at 280 nm and the green line indicates the NaCl gradient (0-50% over 6 
CV, 50% for 1 CV and 50-100% over 2 CV). Fractions indicated on (A) were then analyzed by SDS-
PAGE in non-reducing conditions (B) with the putative band of interest (judging by its apparent 
MWt) indicated by the arrow. The band visible at 75 kDa is Endo HF.  
Despite the very low yield obtained, the protein-containing fractions 42-49 were then 
pooled (approx 40 ml) and the pH was adjusted to 6.0 for de-glycosylation with 
Endo Hf. After treatment, the protein was concentrated to a final volume of 1.5 ml 
and buffer exchanged into 20 mM potassium phosphate with 500 mM NaCl, pH 7.4 
for application to a Superdex 200 10/300 GL size-exclusion chromatography 
column. Three separate injections of ~ 500 µl were performed and fractions from 




Figure 5.15 Size-exclusion chromatography of FH 8-15 WT, using a Superdex 200 HR 10/30 
column. (A) The three elution profiles are shown overlaid while the analysis by gradient SDS-PAGE 
of the fractions indicated for run 1 is shown in (B) and for run 2 is shown in (C). 
Analysis by SDS-PAGE showed that a protein of the expected size eluted between 
14 ml and 16 ml (fractions 24-29). In all fractions a band was visible at 75 kDa. This 
cannot be excess Endo Hf since after treating fraction 26 with Amylose resin the 
band was still present (not shown). It could be the AOX1 protein which is expressed 
alongside the protein of interest and when in monomer form has a molecular weight 
of 73.9 kDa [176]. In order to try to remove this larger protein from the FH 8-15 WT 
preparation, fractions 24-26 from all runs were concentrated and buffer-exchanged 
into 20 mM sodium carbonate buffer, pH 9.0, for application to a Tricorn Mono Q 
column. The bound proteins were then eluted over 20 column volumes to a final 
concentration of 500 mM NaCl followed by three column volumes to reach 1 M 




Figure 5.16 FH 8-15 WT Mono Q. (A) Elution profile and (B) gradient SDS-PAGE for the fractions 
highlighted on (A). In (A) the blue line is the UV absorbance at 280 nM and the green is the 
concentration of NaCl (0-50% over 20 CV and 50-100% over 3 CV). 
The elution profile showed five peaks eluting between 200 and 400 mM NaCl and 
analysis of the peaks showed that the 75-kDa protein was eluted first at 27 ml and 8-
15 WT eluted subsequently, between 30 and 35 ml. Fractions 42-47 were pooled and 
stored at -80 °C. As the concentration of protein was too low (2.5 µM, 0.01 mg/ml in 
1 ml) for SAXS experiments, another sample was prepared (14.2 µM, 0.77 mg/ml in 
1 ml (Figure 5.17). For SPR studies (see chapter 6) the final concentration was 6.4 
µM (0.34 mg/ml) in 1 ml.  
 
Figure 5.17 Final FH 8-15 WT sample for SAXS. Bands appear at the expected molecular weight 




5.3.6 Purification of FH 8-15 3xGLY 
A 10-L fermentation was preformed to produce FH 8-15 3xGLY. A final volume of 
7.7 L of supernatant (after removal of cells) was adjusted to pH 4.0 and diluted 
fivefold for application to a 50 ml SP Sepharose cation-exchange column. The bound 
protein was eluted using a 1 M NaCl gradient and the elution profile (Figure 5.18 
(A)) showed one very large broad peak eluted between 400 and 900 mM NaCl.
 
Figure 5.18 FH 8-15 3xGLY elution from the SP Sepharose column. (A) Elution profile (blue 
line). The green line indicates the NaCl gradient (0-100%). (B) The gradient SDS-PAGE shows 
fractions 50-150 in non-reducing conditions; (C) shows the fractions in reducing conditions. The band 
visible at 75 kDa is Endo Hf. 
Analysis of the fractions by SDS-PAGE showed that protein of the expected sizes 
was present in fractions 60-140 but these contained several impurities including 
possible dimer (100-kDa band in non-reducing conditions). Fractions 50-120 
(approx 200 ml) were pooled and after adjusting pH to 5.6 underwent Endo Hf 
treatment. The next step was to concentrate 50 ml down to ~ 3 ml and buffer 
exchange into 20 mM sodium carbonate, pH 9, for anion-exchange chromatography 
(the remaining protein was frozen). Three separate injections (1.0 m, 1.0 ml and 0.5 
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ml injections) were performed and the column was eluted using the same program as 
8-15 WT. 
 
Figure 5.19 The 8-15 3xGLY construct eluted from a Mono Q column. (A) Elution profiles for all 
three injections overlaid. The green line is the concentration of NaCl (0-50% over 20 CV and 50-
100% over 3 CV). The gradient SDS-PAGE in (B) shows the fraction indicated on (A) for injection 1 
whilst (C) shows the fractions from injections 2 and 3. Both gels were run in non-reducing and 
reducing conditions.  
The elution profiles (Figure 5.19 (A)) each showed the target protein peak eluting 
between 25 and 33 ml (200 and 300 mM NaCl) followed by smaller peaks that 
contained impurities (gel not shown). Analysis of injection 1 fractions by SDS-
PAGE (Figure 5.19 (B)) showed that fraction 30 contained the 75-kDa and 20-kDa 
impurities so were discarded. Fractions 35 and 40 were mainly 8-15 3xGLY but still 
contained a small amount of impurities (~ 37 kDa)  and fraction 40 still contained 
some dimer protein (100 kDa). Injections 2 and 3 (Figure 5.19 (C)) showed identical 
results to injection 1. Fractions 33-40 were pooled from all injections and buffer 
exchanged into 20 mM potassium phosphate buffer, pH 7.4, with 500 mM NaCl 





Figure 5.20 Size-exclusion chromatography of 8-15 3xGLY using HiLoad 16/60 Superdex 75. 
(A) Elution profile. (B) The gradient SDS-PAGE of the fractions indicated on (A). (elution profile 
was incomplete due to a power cut). 
A broad asymmetrical peak was seen in the elution profile (Figure 5.20 (A)) eluting 
between 45 and 70 ml. Analysis of the fractions by SDS-PAGE indicated that 
fraction 33 was mostly dimer (100 kDa) which was also present (~ 5-10%) in 
fractions 38 and 40. Fractions 42 and 44 contained pure 8-15 3xGLY so along with 
Fractions 41 and 43 were pooled. The final concentration of the sample was 21.6 µM 
in 1 ml and this sample was used for SAXS analysis 
The purification process also generated a sample for SPR binding studies (see 
chapter 6) at 11 µM (0.5 mg/ml) in 1.5 ml. 
5.3.7 Purification of FH 8-15 SL 
As for 8-15 3xGLY, a 10-liter fermentation was carried out to produce 8-15 SL. The 
resulting supernatant (7 L) was adjusted to pH 4, diluted six-fold and then the 




Figure 5.21 Elution of 8-15 SL from SP Sepharose. (A) Elution profile. The blue line is the UV 
absorbance at 280 nm and the green line indicates the NaCl gradient (0-100% over 4 CV). (B) The 
gradient SDS-PAGE for the fractions from the elution.  Lane number corresponds to the fraction 
number. Target protein bands are indicated by arrows.  
The protein that had bound to the column eluted between 400 and 800 mM NaCl 
(150-300 ml). Analysis of the fractions by SDS-PAGE revealed that most of the 
target protein had eluted in fractions 40-60. These fractions were pooled, 
deglycosylated and 30 ml (out of 120 ml) was buffer exchanged for application to a 
Mono Q anion-exchange chromatography column. Figure 5.22 shows the elution 
profile and SDS-PAGE for one of the injections (3 ml loaded out of 30 used, each 
injection ~ 500 µl). 
 
Figure 5.22 Elution of FH 8-15 SL from the Mono Q column. (A) The elution profile (blue line); 
the green line is the concentration of NaCl (0-50% over 20 CV and 50-100% over 3 CV).  (B) The 




Two overlapping peaks were visible on the elution profile (Figure 5.22 (A)) and 
SDS-PAGE analysis (Figure 5.22 (B)) revealed that fraction 30 gave a double band 
(the expected one at ~50 kDa, and one running slightly higher) under non-reducing 
conditions, which under reducing conditions appears as a single band suggesting that 
the higher band is a modified version of 8-15 SL. Fractions 40-50 contained dimer. 
Fractions 33-37 were buffer exchanged and concentrated to 1.0 ml to allow two 
injections of 0.5 ml onto a size-exclusion chromatography (Figure 5.23). 
 
Figure 5.23 Size exclusion chromatography of FH 8-15 SL using a Superdex 200 HR 10/30 
column. (A) Two profiles overlaid. (B) The gradient SDS-PAGE of the fractions indicated on (A) for 
injection one. 
Both injections showed a single peak eluting between 8 and 13 ml. The fractions 
form the first injection showed that 18-19 still contained a very small amount of 
dimer and fractions 20-24 contained the cleanest protein. Fractions 18-19 from both 
injections were pooled as were fractions 20-24. The latter fractions (20-24) were 
concentrated (to 30 µM, 1.5 mg/ml in 1.0 ml) to provide a sample for SAXS analysis 
The purification process was repeated using the remaining 27 ml (remaining from 
the initial Mono Q chromatography step) to generate a sample for SPR binding 
studies at a final concentration of 4.5 µM (0.2 mg/ml) in 9 ml. 
5.3.8 Purification of FH 10-15 WT 
FH 10-15 WT production was carried out in shaker flasks (see Methods, section 
2.2.5). The supernatant was adjusted to pH 6 and diluted fivefold for application to a 
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30 ml SP Sepharose column (GE Healthcare). Bound protein was then eluted using a 
1 M NaCl gradient. 
 
Figure 5.24 10-15 WT SP Sepharose elution. (A) Elution profile.  The blue line is the UV 
absorbance at 280 nm and the green line indicates the NaCl gradient (0-100% over 4 CV). (B) 
Gradient SDS-PAGE gel of the fractions indicated on (A). Target protein bands are indicated by 
arrows. 
The elution profile (figure 5.24 (A)) showed a small sharp peak eluting between 100 
200 NaCl followed by many overlapping peaks. The SDS-PAGE analysis of the 
fractions (Figure 5.24 (B)) showed that the protein was present mainly in fraction 20 
that corresponds to the top of the main peak. Fractions 15-25 were pooled, 
deglycosylated and buffer exchanged prior to concentration to 1.5 ml for anion-




Figure 5.25 FH 10-15 WT eluted from a Mono Q column. The injection profiles (blue and red) are 
shown overlaid in (A) whilst the gradient SDS-PAGE gels show the fractions indicated with (B) 
corresponding to the first injection and (C) to the second. 
Both injections showed a sharp peak eluting between 200 and 250 mM NaCl (Figure 
5.25 (A)) and analysis of the fractions by SDS-PAGE for the first and second 
injections showed that fractions 36-40 contained nearly all the protein (Figure 5.25 
(B)). Fraction 34 was discarded from each run due to the diffused band seen above 
the protein band whilst fractions 36-40 were pooled, buffer exchanged and 




Figure 5.26 Size-exclusion chromatography of FH 10-15 WT using HiLoad 16/60 Superdex 75. 
(A) shows the elution profile and (B) shows the final purified sample. 
A single peak was eluted between 55 and 65 ml (Figure 5.26 (A)) and when fractions 
38-42 were analyzed by SDS-PAGE all contained clean protein (data not shown). 
The fractions were then pooled and concentrated, and as a final purity check, 5 µl 
was loaded onto SDS-PAGE (Figure 5.26 (B)). 
The sample used for SAXS analysis was 43 µM (1.8 mg/ml) in a final volume of 1.0 
ml). From 1 L of BMMY media the approximate yield is is 2 mg/L. 
5.3.9 Purification of FH 10-15 3xGLY 
A 10-litre fermentor was used to express 10-15 3xGLY. The final volume of 
supernatant (after cell removal) was 6.3 L and purification was carried out as 
described for 8-15 3xGLY (see section 5.36 above). Elution of the SP Sepharose 
column showed a broad peak eluting between 350 mM and 1 M NaCl (Figure 5.27 
(A)). Analysis of the fractions by SDS-PAGE (Figure 5.27 (B) and (C)) showed that 
fractions 60-150 contained the protein at the expected sizes. Fractions 70-150 were 




Figure 5.27 Elution of FH 10-15 3xGLY from SP Sepharose. (A) The elution profile (blue line).  
The green line is the NaCl gradient. (B) and (C) Gradient SDS-PAGE gels show the fractions 
indicated on (A) in non-reducing conditions (B), and reducing conditions (C). 
After digestion, 50 ml was concentrated and buffer exchanged for anion-exchange 
chromatography (Figure 5.28) whilst the remaining ~150 ml was frozen and stored 
for future work. Three separate injections of between 0.5 and 1.0 ml were performed. 
 
Figure 5.28 Elution of 10-15 3xGLY from Mono Q column. (A) The three elution profiles overlaid. 
(B) Gradient SDS-PAGE of injection one for the fractions indicated on (A).  
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The three injections each showed a peak eluting between 200 and 300 mM NaCl (25-
30 ml) followed by a shoulder (30-40 ml). The SDS-PAGE showed that fractions 35-
40 contained the protein and fractions 45-55 contained mainly dimer or trimer. 
Fractions 33-39 from each injection were pooled and prepared for size-exclusion 
chromatography (Figure 5.29). A final volume of 1.5 ml was injected onto the 
column.  
 
Figure 5.29 Size-exclusion chromatography of FH 10-15 3xGLY using HiLoad 16/60 Superdex 
75. (A) Elution profile. (B) Gradient SDS-PAGE for the fractions indicated on (A). 
A single main peak was seen between 55-65 ml and analysis of the fractions showed 
a single band under non-reducing conditions, but under reducing conditions a trace 
amount of clipped protein was detected. 
For SAXS analysis the sample was 39.8 µM (1.62 mg/ml) in a final volume of 1.0 
ml.  
5.3.10 Purification of FH 10-15 SL 
Expression and purification of 10-15 SL was carried out in an identical manner to 
that of 10-15 3xGLY. The elution profile from the SP Sepharose column (Figure 
5.30 (A)) again showed a broad peak eluting between 400 mM and 1 M NaCl. 
Analysis of the fractions by SDS-PAGE (Figure 5.30 (B)) showed a protein band at 
the expected position and in reducing conditions revealed a high proportion of lower-
molecular weight proteins. Fractions 20-44 were pooled (~200 ml) and treated with 
Endo Hf. As before, a 50 ml portion of this was concentrated and buffer exchanged 
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for anion-exchange chromatography while the remaining protein was frozen for 
future use. 
 
Figure 5.30 Elution of FH 10-15 SL from SP Sepharose. (A) Elution profile (blue line) is shown 
with the NaCl gradient indicated by the green line. (B) Gradient SDS-PAGE in reducing conditions 
for the fractions indicated on (A). 
Three 1 ml injections were performed (only the data for the first injection is shown). 
The elution profile showed the main protein peak, with a shoulder, eluting between 
200 and 300 mM NaCl and a smaller peak eluting later (400 mM NaCl). Analysis by 
SDS-PAGE confirmed that the fractions from the main peak contained the target 
protein whilst the smaller peak contained mainly dimer (75 kDa). Fractions 30-45 
were pooled from each injection, buffer exchanged and concentrated to 1.5 ml for 
size-exclusion chromatography. 
 
Figure 5.31 FH 10-15 SL eluted from the Mono Q column. (A) The elution profile (blue line) and 
NaCl gradient (green line). (B) The gradient SDS-PAGE from injection one for the fractions indicated 
on (A).  
143 
 
For size-exclusion chromatography, two injections of ~0.75 ml were performed. 
Each injection gave a single peak eluting between 9 and 13 ml (Figure 5.32 (A)). 
The SDS-PAGE for the fractions indicated showed that the protein was clean (gel 
not shown) and after being pooled and concentrated, 5 µl was run under non-
reducing and reducing conditions as a final purity check (Figure 5.32 (B)). 
 
Figure 5.32 Size-exclusion chromatography of FH 10-15 SL on Superdex 75 HR 10/30. (A) Two 
elution profiles (red and blue) overlaid; (B) SDS-PAGE for the final check of purity.  
The final concentration of the sample for SAXS analysis was 44 µM (1.78 mg/ml) in 
a final volume of 1.0 ml. 
5.3.11 Purification of FH SL 
For production of FH SL, a ten-litre fermentation was performed resulting in 7.4 L 
of supernatant after removal of cells. The supernatant was then diluted fivefold and 
applied to a 30 ml SP Sepharose equilibrated with 20 mM potassium phosphate plus 
50 mM NaCl, pH 6.0. Bound protein was eluted using a salt gradient with the elution 
buffer being 20 mM potassium phosphate plus 1 M NaCl, pH 6.0. The elution profile 
(Figure 5.33 (A)) showed two overlapping peaks with a trailing-edge shoulder 
eluting between 100 and 900 mM NaCl. Analysis of the fractions by SDS-PAGE 
indicated that a protein of the expected size had eluted between fractions 17 and 21, 
although these fractions also contained impurities; fractions 17-20 were pooled (final 




Figure 5.33 Elution of FH SL from SP Sepharose. (A) Elution profile using a 1 M NaCl gradient 
(0-100% over 3 CV, green line). (B) The gradient SDS-PAGE for the fraction indicated on (A), the 
upper arrow marks the expected position for reduced protein (R) and the lower for non-reduced (NR). 
After Endo Hf digestion, the pooled fractions were passed over a 1.0 ml 
Concanavalin A (Con A, Ge Healthcare) bench-top column to remove the digested 
sugars (and any protein that was not deglycosylated). The resulting flow-through was 
then concentrated to 5.0 ml for application to a size-exclusion chromatography 
column. Multiple injections of between 0.5 and 0.7 ml were performed and the 
elution profiles are shown overlaid in Figure 5.34 (A). 
 
Figure 5.34 Sample of FH SL purified by size-exclusion chromatography using a Superdex 200 
HR 10/30 column. (A) The overlaid profiles. (B) A zoomed-in view of (A) highlighting where FH 
SL eluted. (C)  The gradient SDS-PAGE-based analysis of the fractions indicated on (B). 
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Multiple peaks were eluted. The peak eluting at 8-10 ml (fractions 12-16) contained 
no protein whilst the overlapping peaks between 15 and 20 ml contained the lower-
molecular weight proteins seen on the SP elution gel when analyzed by SDS-PAGE. 
The SDS-PAGE suggested that FH SL eluted between 11 and 13 ml (fractions 18-
23). Though the non-reduced samples gave only a very promising single band with a 
small amount of contaminant in fraction 22 and 23, the reduced samples showed that 
while FH SL was present there was, unfortunately, a large percentage of clipped 
protein.  
Fractions 18-20 contained the least clipped protein, so these were pooled and 
concentrated to a final volume of 1.5 ml with a concentration of 0.87 µM. Fractions 
21-23 were frozen and stored separately. 
5.3.12 Purification of FH 3xGLY 
Production and purification of FH 3xGLY was carried out via an identical procedure 
to that used for FH SL. After cell removal the final volume of supernatant was 7.8 L. 
The profile for the SP Sepharose elution gave a single peak eluting between 300 and 
600 mM NaCl. Analysis of the fractions by SDS-PAGE strongly suggested that the 
target protein had eluted in fractions 15-21 but contained many lower-molecular 
weight impurities. 
 
Figure 5.35 Elution of FH 3xGLY from SP Sepharose. (A) The elution profile (blue line) using a 1 
M NaCl gradient (0-100% over 3 CV, green line). (B) Gradient SDS-PAGE in for the fractions 
indicated on (A), the upper arrow marks the expected position for reduced protein (R) and the lower 
for non-reduced (NR). 
146 
 
Fractions 15-21 were pooled (final volume of 32 ml) and treated with Endo Hf and 
applied to the Con-A column as before. The flow-through from the Con-A column 
was concentrated to 10 ml and then loaded onto the size-exclusion chromatography 
column with injections ranging between 0.5 and 0.8 ml. Figure 5.36 (A) shows six of 
the injections overlaid. 
 
Figure 5.36 Size-exclusion chromatography of FH 3xGLY using a Superdex 200 HR 10/30 
column. (A) The overlaid profiles; (B) The gradient SDS-PAGE for the fractions indicated on (A). 
As expected, multiple peaks were obtained. The first major peak eluting between 10 
and 13 ml corresponds to FH 3xGLY according to SDS-PAGE with a single band 
obtained under non-reducing conditions but the reducing conditions confirmed that 
like FH SL, FH 3xGLY also suffered from a large amount of clipping that yielded 80 
and 60-KD fragments. Fractions 18-21 were pooled and concentrated to yield a final 
concentration of 4.6 µM in 1.5 ml. 
5.4 Biophysical analysis  
The 
15
N HSQC for the sample of FH 12-13 WT (Figure 5.37) produced, in the 
current study, from codon-optimized DNA was initially compared to the assigned 
15
N HSQC for the previously prepared FH 12-13 sample that had been used for 
structure determination [55]. The two spectra were almost identical, with slight 






N HSQC of FH 12-13 WT. Spectrum shows good dispersion with well resolved peaks. 
NMR sample is 200 µM in 20 mM potassium phosphate buffer pH 6.6. The purple peaks are 




N HSQC of the FH 12-13 WT sample prepared in the current work overlaid on 
the 
15
N HSQC of FH 12-13 sample prepared previously. New FH 12-13 sample is shown in cyan; 
previous FH 12-13 sample shown in pink.  
In the case of FH 12-13 3xGLY, the 
15
N HSQC (Figure 5.39) again showed well-
defined peaks indicating both of the CCPs were properly folded. When the spectrum 
was overlaid with the original WT data (Figure 5.40) there were again small shifts 
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observed, presumably due to pH or salt differences, but there are also bigger 
difference visible for some peaks, suggesting that the environment around these 




N HSQC of FH 12-13 3xGLY. NMR sample is ~50 µM in 20 mM potassium 
phosphate buffer pH 6.6.  
 
Figure 5.40 Overlaid 
15
N HSQC spectra of FH 12-13 3xGLY and FH 12-13 WT. 12-13 3xGLY is 





N HSQC for FH 12-13 SL (Figure 5.41) also showed well-dispersed and well-
resolved cross-peaks, consistent with properly folded modules. When overlaid with 
the equivalent spectrum of FH 12-13 WT (Figure 5.42), the majority of peaks 




N HSQC of codon optimized FH 12-13 SL. Spectrum shows good dispersion with 
well resolved peaks. NMR sample is 200 µM in 20 mM potassium phosphate buffer pH 6.6. The red 




N HSQC of FH 12-13 SL overlaid on the 
15
N HSQC of FH 12-13 WT. 12-13 SL is 
shown in blue and green; FH 12-13 WT in cyan.  
150 
 
The differences between spectra for mutant and wild-type FH 12-13 were anticipated 
to coincide with residues in or close to the intermodular linker. Linker residues 
Val745, Lys751 and Lys752 had not been mutated. As expected, no cross-peaks could 
be detected (in the spectrum of either mutant) for these three residues at their 
chemical shift, as previously assigned in FH 12-13 WT. Likewise, no cross-peaks 
appeared in the 3xGLY spectrum for remaining linker residues Ala746 or Asp748 at 
their previously assigned chemical shifts (Figure 5.43). 
 
Figure 5.43 HSQC cross-peaks for linker residues. The pink and cyan peaks (and cyan one-letter 
code) correspond to the original and new WT samples, respectively. Purple peaks and one-letter code 
correspond to 3xGLY, while lime green peaks and one-letter code correspond to SL. X means these 
residues have been deleted. 
5.4.1 Chemical shift perturbation of FH 12-13 3xGLY and SL 
In order to investigate further if the structural changes caused by modifying the 
intermodular linker are confined only to residues within the interface between the 
CCPs chemical shift perturbations were calculated. The caluculations were 
performed using the 
15
N-HSQC of FH 12-13 WT alongside either the 
15
N-HSQC of 
FH 12-13 3xGLY or SL and the “shift differences” function in CCPN Analysis. 
Chemical shift values above the baseline (Δδ > 0.04 ppm) were represented as putty 
models based on the NMR solution structure of FH 12-13 (PBD: 2KMS). 
For FH 12-13 3xGLY (Figure 5.44) the largest changes in chemical shifts are only 
located within the interface between the CCPs (CCP 12 residues 720-727, CCP 13 
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residue 792-797). Again for FH 12-13 SL (Figure 5.45) the largest differences are 
within in the interface (CCP 12 residues 724-727, CCP 13 residue 793-797) but there 
are also some minor differences within CCP 12. In order to understand further the 





H) of 3xGLY and SL would be required which would allow the linker 
residues to be included and thus fully calculate any changes that are specific to the 






N Chemical shift differences for FH 12-13 3xGLY. The combined chemical shift 
differences for each residue are plotted as a function of residue number. The largest shift changes (Δδ 
> 0.04 ppm) are mapped onto the FH 12-13. The bale blue peaks correspond to residues between 0.05 
and 0.08 ppm, green for 0.08-0.12 ppm, yellow for 0.12-0.20 ppm and red for above 0.2 ppm. Grey 








N Chemical shift differences for FH 12-13 SL. As above but the orange peaks 
correspond to shifts between 0.12 and 0.24. 
5.4.2 Flexibility of FH 12-13 WT, 3xGLY and SL  
Previous work on the flexibility within FH 12-13 revealed a relatively rigid structure 
[55] with little evidence for intermodular motion. The removal of bulky side-chains 
in 3xGLY was expected to introduce substantially more flexibility. On the other 
hand, the trimming of the linker to three residues (SL) would be expected to disrupt 
the intermodular interface, disallow the folded back structure of FH 12-13 WT but 
restrain flexure between modules. 




N (heteronuclear) NOEs were recorded (Table 
5.2 and Figures 5.46 – 5.48). Note that for FH 12-13 3xGLY, the data quality was 






Table 5.2 Mean values of the relaxation times for all three FH 12-13 constructs. 
  Mean T1 (±SD) 
[ms] 





Both CCPs 620 ± 79 76 ± 13 0.74 ± 0.11 
CCP 12 alone 630 ± 68 75 ± 7 0.75 ± 0.14 
CCP 13 alone 601 ± 92 75 ± 10 0.72 ± 0.05 
SL 
Both CCPs 658 ± 93 106 ± 25 0.64 ± 0.12 
CCP 12 alone 700 ± 86 99 ± 21 0.56 ± 0.07 
CCP 13 alone 606 ±70 112 ± 25 0.71 ± 0.11 
3xGLY 
Both CCPs - 127 ±12 - 
CCP 12 alone - 122 ± 25 - 
CCP 13 alone - 130 ± 31 - 
For each data set, the mean value and standard deviation (SD) was determined for the individual 
CCPs as well as the pair.  
The mean values for T1, T2 and heteronuclear NOE for FH 12-13 WT are similar for 
both CCPs 12 and 13. This means there is no evidence for the modules moving 
independently, which is consistent with their being fused together. Similar results 
were obtained previously for FH 12-13 [55] and the NMR-derived solution structure 
supported the conclusion that FH 12-13 has a relatively rigid structure [55].  
In the case of FH 12-13 SL, relaxation values for the two modules appear to differ 
suggesting that the CCPs move independently of one another. Thus despite having 
only a three-residue linker, this mutant is more flexible presumably because – as 
anticipated - there is no longer an extensive set of intermodular and module-linker 
interactions present in the structure. The lower NOE values for CCP 12 could also 
reflect loss of rigidity within this module that is normally stabilized by its interface 
with CCP 13. Looking at the distribution of decreased heteronuclear NOE values in 
the structure does not really support this hypothesis since they are not concentrated 
near the interface but a fuller assignment would be needed to draw firm conclusions. 
Only T2 data were available for FH 12-13 3xGLY. The average values for the CCPs 
12 and 13 appear to differ in this mutant, so this could hint at more intermodular 
flexibility; but this would need to be confirmed by preparing another sample to re-
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record the T1 and heteronuclear NOE experiments. Note that FH 12-13 3xGLY has 
significantly higher T2 values than does FH 12-13 wt. Overall, the T2 values suggest 
that FH 12-13 3xGLY has the most intermodular, and/or intramodular, flexibility, 
followed by FH 12-13 SL, with FH 12-13 WT being the least flexible.   
 
Figure 5.46 12-13 WT, T1, T2 and NOE values. The broken green lines indicate one SD either side 
of the mean. The corresponding putty diagrams are based on PDB model 2KMS. Thickness and color 
of the backbone traces corresponds to the putative flexibility suggested by the data. Green signifies 
more flexible, blue indicates more rigid. Grey indicates residues for which data is unavailable due to 
spectral overlap, the presences of prolines, or very high peak broadening leading. Figures prepared 




Figure 5.47 T1, T2 and NOE values for 12-13 SL. Red and blue dashed lines indicate one 1 SD on 
either side of the means for CCPs 12 and 13 respectively. The grey box in each plot represents the 
linker region, which could not be assigned due to the sequence difference with respect to WT. The 
residue numbers match those of WT in order to allow comparisons to other constructs. The putty 
models shown are based on a model of the SL variant constructed using Modeller v9.10 using PDB 
model 2KMS. The color coding of the models is identical to that used for FH WT in Fig. 5.44. 




Figure 5.48 12-13 3xGLY T2 values. The dashed green line limits the range of the T2 values within 1 
SD of the mean. The shaded region represents the linker region which could not be assigned. The 
putty model was constructed using PDB 2KMS as the base via Modeller v 9.10. The color coding of 
the model is the same as the WT construct. Figure prepared by Dr Mateusz Maciejewski.  
Diffusion tensor for WT and SL 
In order to determine the diffusion tensor of a protein, the minimum data required 
are the T1 and T2 values; as the T1s are not available for FH 12-13 3xGLY, this 
protein will not be considered any further. 
Initially T1/T2 ratios were used to approximate the elements of the diffusion tensor 
for both FH 12-13 WT and FH 12-13 SL [177]. The ratios suggest that the diffusion 
tensors are either asymmetric or fully anisotropic because they are spread over a 
range of values (Figure 5.49). 
 
Figure 5.49 T1/T2 ratios for FH 12-13 WT and FH 12-13 SL. Blue bars are for SL and red for WT. 
(bin size for both was 0.25). Figure prepared with help of Dr Mateusz Maciejewski. 
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The data were then fitted to three different diffusion tensor models [178] to 
determine which was best. Models used were: the fully isotropic tensor, which is 
characterized using just the overall rotational correlation time (τc) (even though this 
looks unlikely as alluded to above); the axially symmetric tensor which requires four 
parameters - the overall rotational correlation time (τc), the tensor anisotropy (Dǁ/D) 
and the Euler angles θ and ϕ; and finally the fully anisotropy tensor characterized by 
six parameters - the overall rotational correlation time (τc), the tensor anisotropy, the 
tensor asymmetry (Dyy/Dxx) and the Euler angles ψ, θ and ϕ. Throughout the fitting 
for FH 12-13 WT, the closest-to-mean structure of PDB:2KMS was used, and for SL 
structure 9 was used as it gave the lowest E/N values of all the models present in 
2KMS. The results for each of the tensor models are shown in Table 5.3 for FH 12-
13 WT and Table 5.4 for FH 12-13 SL. 
Table 5.3 WT diffusion tensor fitting. 
 Isotropic Axially symmetric Anisotropic 
τc 8.46 ± 0.11 8.68 ± 0.03 8.60 ± 0.02 
Anisotropy 1 1.46 ± 0.01 1.41 ± 0.03 
Asymmetry 1 1 1.21 ± 0.01 
θ (°) - 111.40 ± 0.11 108.79 ± 0.16 
ϕ (°) - 177.85 ± 0.10 176.40 ± 0.19 
ψ (°) - - 136.05 ± 0.26 
F statistic - 7.61 1.66 








Table 5.4 SL diffusion tensor fitting. 
 Isotropic Axially symmetric Anisotropic 
τc 7.23 ± 0.15 7.23 ± 0.01 7.20 ± 0.02 
Anisotropy 1 1.80 ± 0.01 1.71 ± 0.01 
Asymmetry 1 1 1.39 ± 0.01 
θ (°) - 118.10 ± 0.02 120.70 ± 0.04 
ϕ (°) - 227.45 ± 0.01 225.61 ± 0.03 
ψ (°) - - 261.53 ± 0.01 
F statistic - 4.97 1.93 
p value - 0.004 0.15 
 
The F statistic and rejection probability (p value) for both WT and SL indicate that 
the axially symmetric tensor was preferred over the anisotropic and isotropic tensors. 
However for SL even though the axially symmetric model was preferred the fitting 
of the data to this model resulted in a very large E/N score of 94.6 (N is the number 
of residues used for the calculation, E is the total error) in comparison to the WT 
score of 7.8. As only the linker differs between the two it was thought that the high 
E/N score was due to an alteration in interdomain orientation. In order to improve 
this issue the data for each CCP was fitted separately. Whilst this improved the score 
for CCP 12 (6.5), the value for CCP 13 remained too high (47.4). There are two 
possible explanations for why this might be occurring: the first is that the CCPs of 
FH 12-13 SL do not – in fact - diffuse independently of each other and the other is 
that the CCPs in FH 12-13 SL diffuse together but with some interdomain flexibility. 
To investigate if the second explanation could be true the diffusion tensor required 
some refinement. The parameters for the axially symmetric tensor were used (see 
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above) along with the slow-motion order parameter (SS
2
) and the slow-motion 
correlation time (τs) for each CCP – these parameters describe interdomain motion. 
The calculation was also supplemented with averages of the fast internal motion 
order parameter (Sf 
2
) and the fast internal motion correlation time (τf) averaged for 
all residues in both CCPs. A refinement of the WT diffusion tensor was also 
performed though it did not include parameters for interdomain motion (τs and SS
2
). 
Table 5.5 summarizes the results for the calculations.  
Table 5.5 Refined tensor parameters for WT and SL. 
 WT SL 
τc 
8.40 ± 0.07 10.01 ± 0.54 
Anisotropy 
2.09 ± 0.07 1.76 ± 0.11 
θ (°) 
117.13 ± 1.72 128.96 ± 13.82 
ϕ (°) 
174.73 ± 2.82 232.99 ± 13.29 
Sf 
2
 0.95 ± 0.01 0.085 ± 0.02 
τf (ps) 184 ± 7 25 ± 15 
SS
2
 [12] - 0.72 ± 0.05 
τs [12] (ns) - 1.54 ± 0.26 
SS
2
 [13] - 0.65 ± 0.05 
τs [13] (ns) - 3.31 ± 0.51 
E/N 0.23 0.57 
Table 5.5 Refined tensor parameters for WT and SL. 12 and 13 inside square brackets represent 
CCP 12 or CCP 13. 
The result of the refinement process for SL has greatly improved the E/N score to 
0.57 (initially was 94.6) and the WT score has also improved (0.23 compared to 7.8 
initially). The new parameters recorded for SL indicate a large range of interdomain 
mobility and this is supported by the slow motion order parameters of 0.72 and 0.65 
which correspond to semi-cone angles of 39° and 44° respectively. The ranges are 
relative to the mean orientation in the diffusion frame and thus should be treated as 
the maximal ranges of tilt of the CCPs.  Thus these data support our hypothesis that 
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shortening the linker by deleting residues with bulky side chains prevents the 80-
degree tilt seen in FH 12-13 WT and at the same time disrupts intermodular rigidity, 
resulting in a more elongated and flexible interdomain arrangement. 
Model-free and extended model-free analysis of relaxation data for WT and SL 
The diffusions tensors in Table 5.5 were used to calculate Model free (MF) and 
extended model free (EMF) parameters for WT and SL. An approach similar to that 
assumed in the Modelfree software was used. In brief, the data for each residue was 
fitted to five different models. Model 1 was characterized by Sf 
2
, model 2 by Sf 
2
 and 
τf. Model 3 was Sf 
2
 and the chemical exchange rate Rex, for model 4 it was Sf 
2
, τf and 
Rex. Finally model 5 was characterized by Sf 
2
, τf and SS
2
. For SL only models 1-3 
will be considered due to the slow motion parameters already being included in the 
diffusion tensor for SL. 
Model 1 was used when the E value from the fitting of the relaxation data to this 
model was within the 10% confidence interval; models 2 or 3 were used if E from 
the fittings was again within the 10% confidence range but also was shown by an F-
test to fit the data better than model 1. Models 4 and 5 were considered if the E value 
was larger than the 10% confidence interval. As the number of experiments for each 
residue was 3 (T1, T2 and NOE) and the number of parameters in models 4 and 5 was 
also 3 the number of degrees of freedom was set at 0. It was therefore expected that 
the E values would be approximately 0 but if this was not true for both models 4 and 
5 then it was concluded that no model provided an appropriate description of the 
dynamics for that given residue.  
The results for the dynamic parameters for WT and SL are shown in Figures 5.50 
and 5.51. The large errors seen in plots of τf and Rex for WT show that the values 
only reflect the rough order of the timescale of these parameters for the relevant 




Figure 5.50 MF parameters for WT. The error bars designate the distance one SD away from the 
mean. 
 
Figure 5.51 MF parameters for SL. The error bars designate the distance one SD away from the 
mean. The shaded box represents the linker region. 
In conclusion the results for the analysis of the interdomain flexibility within the 
three FH 12-13 constructs confirmed that WT did indeed have limited flexibility as 
previously observed. The results for the SL mutant suggest that there is movement 
between the domains.  
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5.4.2 SAXS analysis of 8-15 and 10-15 linker constructs 
5.4.2.1 Introduction 
SAXS is an established technique for the analysis of biological macromolecules in 
solution. A typical biological experiment involve the macromolecules being 
randomly order in a solution which are then illuminated by a monochromatic and 
collimated X-ray beam, the resulting scattering pattern is then recorded by an X-ray 
detector. The scattered intensity I is recorded by the dector as a function of the 
scattering angle, 2θ (Figure 5.52).Scattering from the solvent (e.g. dialysis buffer) is 
also recorded and then subtracted from the measured sample. The resulting scattering 
profile is generally expressed as a function of the momentum transfer (s=4πsinθ/λ, λ 
is wavelength) and is proportional to the average scattering from a single molecule in 
all available orientations as well as to the concentration of the solute.  
 
Figure 5.52 Schematic representation of a biological solution SAXS experiment. Image from 
[179] 
Information that can be extracted from the scattering profile includes molecular 
weight (MWt), radius of gyration (Rg), hydrated particle volume (V) and the 
maximum particle diameter (Dmax) [179, 180]. The experiments required to obtain 





Table 5.6 Details of SAXS experiments used. 
SAXS Experiment Characteristics of sample 
Guinier plot (calculate Rg and I(O)) Purity 
Pairwise interatomic distance distributions, 
p(r) 
Changes in shape (displayed graphically) 
Kratky plot Flexibility (initial look) 
Multiple conformations (EOM) Flexibility 
Ab initio models Shape (displayed using models) 
Overall parameters (Rg, Dmax and MWt) Validation of structure 
 
Prior to sending the samples for SAXS analysis, they were checked for the presence 
of oligomers or aggregates using dynamic light scattering. According to the size-
distribution by intensity analysis for the FH 8-15 mutants, the 3xGLY and SL 
protein samples appeared to be monodisperse but the native-sequence (WT) protein 
contained very minor amounts of aggregates (although these were not detected in the 
less sensitive size-distribution by volume analysis). The results for the FH 10-15 
proteins, for both types of analysis, showed that no oligomeric impurities were 
detectable (Figure 5.53). 
 
Figure 5.53 DLS data for FH 8-15 and FH 10-15 protein constructs. The top plots are for the 8-15 
proteins and the lower ones are for 10-15 proteins.  
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5.4.2.2 SAXS results for FH 8-15 and FH 10-15 linker constructs 
The scattering profiles obtained for all the constructs are shown in Figure 5.54 (FH 
8-15) and Figure 5.55 (FH 10-15). Both sets of curves yielded a linear Guinier plot 
for each construct, which is a good indication that the samples are of good quality 
and therefore a range of parameters could be legitimately extracted (Table 5.7). 
 
Figure 5.54 SAXS profile for FH 8-15 linker constructs. The green scattering curve represents WT, 
orange represents 3xGLY and blue represents SL. Inserted are the corresponding linear Guinier plots. 
The y-axis has been adjusted to show all three plots in a non-overlapping way for display. 
 
Figure 5.55 SAXS scattering curves for FH 10-15 linker constructs with linear Guinier plot 




Table 5.7 SAXS parameters of FH 8-15 and 10-15 linker constructs. 
FH Construct Rg, A I(0), cm
-1









29.3 ± 0.1 0.05 ± 0.01 103 ± 5 68 ± 10 42.5 ± 5 
10-15 3xGLY 
(41.1 kDa) 
30.3 ± 0.3 0.04 ± 0.01 106 ± 5 69 ± 10 43.5 ± 5 
10-15 SL 
(41.1 kDa) 
28.5 ± 0.1 0.05 ± 0.01 98 ± 5 59 ± 5 36.8 ± 5 
8-15 WT 
(54.7 kDa) 
36.2 ± 0.1 0.06 ± 0.01 127 ± 5 115.2 ± 10 74.5 ± 10 
8-15 3xGLY 
(54.7 kDa) 
42.6 ± 0.1 0.09 ± 0.01 136.4 ± 5 131.8 ± 10 82.4 ± 10 
8-15 SL 
(54.7 kDa) 
44.2 ± 0.1 0.10 ± 0.01 148 ± 5 147.5 ± 10 92.2 ± 10 
Radius of gyration (Rg), forward scattering intensity (I(0)) determined from Guinier analysis. 
Maximum particle dimension (Dmax) determined via indirect Fourier transformation. 
a
Molecular 
weight (MWt) estimated based upon the hydrated particle volume (Vp). 
The parameters extracted for FH 10-15 WT were compared against those already 
published in [55] and were found to be in good agreement. Analysis of the 
parameters extracted for all three FH 10-15 constructs suggested that there was little 
difference between the three and the distance distribution function p(r) for each 
(Figure 5.56) also showed only very small differences. 
 
Figure 5.56 Pairwise interatomic distance distributions, p(r) for the FH 10-15 constructs. 
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As for the FH 10-15 constructs there were only very small differences between the 
FH 8-15 constructs apparent from SAXS analysis (Table 5.7 and Figure 5.57).  
 
Figure 5.57 distance distribution function p(r) for FH 8-15 constructs. FH 8-15 WT is represented 
by the green line, for 3xGLY the orange line and SL is the blue line.  
The results so far indicate that there are very few differences between the three 
constructs for both FH 10-15 and FH 8-15. The next step was to investigate if there 
was a change in flexibility between the constructs as had been seen in the NMR-
based comparisons of the FH 12-13 proteins. First a Kratky plot was used to have an 
initial look at the flexibility within all the proteins. For FH 8-15 WT (green line, 
Figure 5.58) there is the peak from the low-angle scattering followed by a continuous 
increase as the scattering angle increases, which is the expected result for a multi 
domain protein [180]. On the other hand, with the 3xGLY (orange line) and SL (blue 
line) samples, as the scattering angle increases there is a decrease in scattering angle. 




Figure 5.58 Kratky plot for FH 8-15 constructs. As before green is WT, orange 3xGLY and blue 
SL.  
The Kratky plot results for FH 10-15 constructs (Figure 5.59) was much better as all 
three behaved as would be expected for a multi-domain protein. 
 
Figure 5.59 FH 10-15 constructs Kratky plot. 
As the results for the FH 10-15 constructs were good it was possible to use the 
SAXS-based ensemble optimization method (EOM) in an attempt to investigate if 
there were any differences in flexibility within the three constructs. The method 
works by using a large pool of random configurations from which ensembles are 
selected using a genetic algorithm [181]. For all three constructs the data was 
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confined to the left side of the pool (Figure 5.60), this indicates that there is similarly 
limited flexibility within all three constructs. Thus the extra flexibility between 
CCPs 12 and 13 allowed by the mutated linker is not manifested in these longer 
constructs. 
 
Figure 5.60 EOM analysis of FH 10-15 constructs. 
As a final approach to see if there were any SAXS-detectable differences between 
the FH 10-15 constructs, an ab initio approach was used. The bead modeling 
program DAMMIF was employed to reconstruct an average structural model for 
each construct [182]. The results from this exercise (Figure 5.61) suggest that all 
three form similar compact structures. This is interesting since it means that the more 
extended conformation of CCPs 12-13 induced by the (engineered) short linker 
between these modules does not cause a loss of the compact overall arrangement of 
the longer construct. This implies that there are sufficient intermodular interactions 
within FH 10-15 – most likely between non-neighbouring modules - to 
accommodate the mutations and resist an opening out or “springing open” effect of 




Figure 5.61 Ab initio DAMMIF models for FH 10-15 constructs. The yellow models are for 
3xGLY, blue for SL and green for WT.  
5.5 Conclusions 
The work described in this Chapter was performed to investigate the hypothesis that 
the long linker located between CCPs 12 and 13, which forms a “mini-domain” 
resulting in a relatively rigid and bent intermodular orientation, is important for FH 
architecture. An investigation of functional repercussions is reported in the next 
Chapter.  
The initial work focused on FH 12-13 because detailed structural data were already 
available for the native-sequence (WT) construct and therefore any changes that 
resulted from mutagenesis of the linker sequence could be easily identified [55]. In 
this part of the work, 
15
N HSQC spectra were recorded since chemical shifts allow 
small differences in structure to be inferred. The results showed, importantly, that 
radical engineering of the linker residues did not perturb the compact folding of the 
modules on either side. On the other hand, NMR-based 
15
N-relaxation measurements 
showed significant differences in dynamic properties of the mutants.  Although a 
complete data set for FH 12-13 3xGLY was not obtained, this mutant has much 
longer T2 values than WT consistent with less overall rigidity. It would be 
fascinating to explore this observation further by recording more data on a new 
sample. The FH 12-13 SL mutant was also more dynamic and in this case a more 
rigorous analysis was possible. This implied that, consistently with intuition, 
removal of the residues forming the mini-domain between CCPs 12 and 13 resulted 
in a module pair that was less tilted and more flexible, leading to the expectation of a 




As it is difficult to interpret SAXS data in terms of individual modules and module-
module orientations for a protein as large as full-length FH, the same linker 
mutations were also made in the contexts of the shorter, more tractable constructs, 
FH 10-15 and FH 8-15, which encompass the central region of FH. According to 
SAXS, the FH 10-15 WT construct has a relatively rigid and compact structure (as 
observed previously) but, interestingly and unexpectedly, so did the FH 10-15 SL 
and FH 3xGLY constructs. As no real differences between FH WT, SL and 3xGLY 
were observed in terms of overall shape, it follows that interactions between non-
contiguous CCPs must dominate these compact structures that can therby 
accommodate differences in one linker. Unfortunately the SAXS data for FH 8-15 
were of lower quality due to poor buffer matching and degradation of this protein in 
the X-ray beam. Very recent SAXS data (not shown) with better buffer matching 
indicated that FH 8-15 SL (although still subject to degradation) had a significantly 
greater Dmax than FH 8-15 WT. This is intriguing and not necessarily incompatible 
with our interpretation of the SAXS data for FH 10-15 WT versus FH 10-15 SL. The 
resolution of SAXS is insufficient to uncover differences in the relative positions of 
specific modules within similar compact arrangements present within both FH 10-15 
WT and FH 10-15 SL, but these might on the other hand be revealed by the 
additional presence of CCPs 8-9 that in FH 8-15 WT appeared to project away from 
the core formed by CCPs 10-15. These hypothesis could be tested by further SAXS 
data collection on fresh samples (of FH 8-15 but also on full-length FH) or could be 
tested by an orthogonal methods such as the use of chemical cross-linking combined 
with mass spectrometry to identify cross-linked peptides, as has proved successful 
recently (unpublished) with samples of intact FH. 
In summary, engineering the CCPs 12-13 linker provides a route to versions of FH 
that have intact CCP modules and maintain a compact arrangement of their central 
modules but could have differences in flexibility and overall architecture. These 
make intriguing subjects for functional studies as explored in the next Chapter. 
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Chapter 6 Investigating the functional role of the central 
region of FH 
The previous chapter described a study of the extent to which mutations of a linker 
within the central region of FH alter its flexibility and architecture. This chapter 
describes the functional analysis of the 3xGLY and SL mutants in the context of FH 
8-15 and full-length FH. 
Surface plasmon resonance (SPR) was used to measure the affinities of plasma-
purified and recombinant FH (wild-type, plus the SL and 3xGLY mutants) for the 
following fragments of C3 immobilized on a sensor chip: the large (180 kDa), 
opsonic, activation-specific fragment, C3b, which binds covalently to surfaces; the 
soluble and seemingly inert product of iC3b cleavage (by factor I) C3c; and C3d - 
equivalent to the thioester domain (TED) of the original C3b - which is the final 
product of C3b cleavage, and remains tethered to the surface. In addition, an SPR-
based assay was used to compare decay-accelerating activity, i.e. the enhancement of 
the rate of dissociation of C3b.Bb, between wild-type and mutant versions of FH. 
Recent work in the lab had also created the possibility of performing binding studies 
for the recombinant FH 8-15 segment since this encompasses a binding site for the 
bacterial protein PspC. Furthermore, binding of PspC to central modules of full-
length FH alters its overall architecture and boosts the regulatory activity of FH, 
providing further opportunities for functional characterization of the full-length FH 
mutants. 




Figure 6.1 Summary of proteins used in the study. Full-length FH (FH) and FH 8-15 are shown 
with each oval representing a CCP module; the 12-13 linker modifications are shown above CCPs 12 
and 13. Representation of the C3 fragments used; C3b, C3c and C3d. PspC is represented with the N-
terminal, R1 and R2 repeats, proline rich region (P) and choline binding domain (CBD) highlight. The 
approximate boundaries of the fragment PspCN are indicated. 
6.1 Binding of full-length FH linker constructs to C3b, C3c and 
C3d 
The interaction between FH and C3b is key to regulation of the alternative pathway 
of complement. It is thought to involve CCPs 1-4 and CCPs 19-20 binding to 
adjacent sites on C3b, with intervening FH modules playing an architectural or 
hinge-like role as discussed in Chapter 1. It was therefore of interest to compare the 
binding of FH WT with that of the two linker mutants, SL and 3xGLY.  
6.1.1 Binding to C3b 
An initial experiment using plasma-purified FH (purchased from Complement 
Technology) was performed as a bench mark (Figure 6.2). A concentration series of 
0, 0.0313, 0.0625, 0.125, 0.25, 0.5, 1.0 and 2.0 µM FH was flowed over immobilized 
C3b (see Methods, section 2.6.2) with dual injections for each concentration. A KD 
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value of 0.5 ± 0.06 µM was obtained by fitting steady-state binding levels derived 
from the background-subtracted traces to a one-to-one steady-state binding model, in 
line with previously obtained values (0.59 ± 0.04 µM) [63].  
 
Figure 6.2 Binding of plasma-purified FH to C3b. In (A) is the background-subtracted sensorgram 
with each of the concentration coloured according to the key. (B) The plot of response obtained vs. 
concentration with the calculated KD indicated by the dashed line. 
Having established that the assays was working by obtaining a KD for plasma-
purified CFH that was in line with expectations, the SPR experiment was repeated 
with recombinantly produced WT FH (Figure 6.3) instead of plasma-purified 
material. An identical concentration series was used. A KD value of 0.58 ± 0.09 µM 





Figure 6.3 Binding of rFH to C3b. In (A) is the background-subtracted sensorgram with each of the 
concentrations coloured according to the key. (B) shows the plot of response obtained vs. 
concentration with the calculated KD indicated by the dashed line. 
The comparable KD value for FH 3xGLY (Figure 6.4) was estimated at 1.05 ± 0.18 
µM. Due to the low concentration of the FH SL stock protein solution, a 
concentration range of 0, 0.0313, 0.0625, 0.125, 0.25, 0.5 and 1 µM was used and 
only single injections were performed for each. Despite this, the data fit very well to 
the one-to-one binding model (Figure 6.5) and the KD value was reliably estimated at 
2.2 ± 0.24 µM.  
These affinities of the mutants for C3b are significantly, but not dramatically, 
different from that of FH WT (~ 0.5 µM) and therefore replicate experiments would 
be needed to confirm that FH 3xGly and FH SL really do bind two-fold and four-
fold, respectively, more weakly to C3b. It is, nonetheless, intriguing that the KD 
value estimated for FH SL:C3b is very similar to that (~ 2 µM) of FH 19-20:C3b 
reported previously (FH 1-4:C3b has a weaker KD of ~ 10 µM); so it could be that 





Figure 6.4 Binding of FH 3xGLY to C3b. In (A) is the background-subtracted sensorgram with each 
of the concentrations coloured according to the key. (B) shows the plot of response obtained vs. 
concentration with the calculated KD indicated by the dashed line. 
 
Figure 6.5 Binding of FH SL to C3b. In (A) is the background-subtracted sensorgram with each of 
the concentrations coloured according to the key. (B) shows the plot of response obtained vs. 
concentration with the calculated  KD value. 
176 
 
6.1.2 Binding to C3c 
Previous work showed that FH does not bind to C3c, presumably because FI has 
ablated both the binding site for CCPs 1-4 (due to cleavage within the CUB domain) 
and for CCPs 19-20 (due to removal of the TED). Using the same concentration 
series as used for C3b (and a different channel of the same SPR chip – see Methods, 
section 2.6.2) it was found that none of the versions of FH in the current study bound 
significantly to C3c (Figure 6.6). 
 
Figure 6.6 Binding of FH linker constructs to C3c. Each sensorgram shows the background-
subtracted curves with the concentrations used coloured according to the keys. (A) Plasma-purified 
FH, (B) FH 3xGLY, (C) recombinant FH (WT) and (D) FH SL. 
6.1.3 C3d binding 
Previous work from several laboratories suggested that FH binds only weakly to 
C3d, unlike the FH fragment FH 19-20 that binds to both C3b and C3d with an 
affinity of ~ 2 µM. An identical concentration series of FH as employed for C3b 
binding was flowed over a different channel of the same chip that had been loaded 
with 69 RUs of C3d. 
Initial experiments with commercially prepared, C3b-derived C3d (from 
Complement Technology) and plasma-purified FH showed (Figure 6.7) a very small 
response. A very rough estimate of the KD value (13 ± 5 µM) could be extracted 
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from the data, but the very low number of response units obtained might reflect 
binding of FH to a small quantity of contaminant on the chip (such as iC3b as might 
arise from incomplete digestion during the preparation of C3d). Alternatively, the 
slight leveling off of the curve perceptible in Figure 6.7B might be an artifact and 
hence the KD could in fact be much higher than 13 µM.  
 
Figure 6.7 Binding of plasma FH to C3d. In (A) is the background-subtracted sensorgram with each 
of the concentrations coloured according to the key. (B) shows the plot of response obtained vs. 
concentration with the estimated KD value that cannot be considered reliable in this case due to the 
low responses obtained and the maximum concentration of FH used. 
The three recombinant versions of FH (WT, SL and 3xGLY) all yielded higher 
responses (than plasma-purified FH) when flowed over immobilized C3d. Yet in 
none of the response vs. concentration curves is there any sign of saturation being 
approached (Figure 6.8). Thus, no meaningful KD values could be obtained.  The 
interactions appear, therefore, to be non-specific and one suggestion is that these 




In summary, the current results are in full agreement with previous observations that 
full-length FH, whether recombinant or derived from plasma, binds at least a couple 
of orders of magnitude less well to C3d than does the C-terminal fragment FH 19-20. 
 
 
Figure 6.8 FH WT and FH with mutations in the 12-13 linker do not bind significantly to C3d. 
Each sensorgram shows the background-subtracted curves with the concentrations used coloured 
according to the keys. The plots of response obtained vs. concentration, with estimated KD values (that 




6.2 Decay acceleration by full-length FH and linker mutants 
The results of the above-described study indicate that all of the tested versions of 
full-length FH bound to C3b with KD values in the range of 0.5 to 2 M. It was 
important to establish whether mutating the linker had any influence on the C3b.Bb 
decay-accelerating activity of FH, which is assumed to depend upon initial 
engagement of FH with C3b (as well as Bb). It was hypothesized that if the SL 
mutant genuinely binds to C3b twofold less well than FH 3xGLY, and fourfold less 
well than FH WT, a matching deficiency in DAA might occur. 
At 2.5 nM FH (or 2.5 nM FH mutant) the results showed (Figure 6.9; see Methods, 
section 2.6.3, for a description of how this experiment was preformed and the data 
processed) that SL was indeed the poorest of the recombinant proteins tested while 
the recombinant FH WT and FH 3xGLY appeared to have virtually indistinguishable 
activities. The plasma-purified FH performed less well in this assay than 
recombinant FH as was observed previously [140]. 
When the concentrations of the FH constructs were increased to 5 nM and then 10 
nM this trend persisted, with FH SL displaying the lowest activity of the four 
proteins tested. As at the lower concentration, there is only a small difference in the 





Figure 6.9 Decay-accelerating activities of various versions of full-length FH. The sensorgrams 
were obtained according to the procedures outline in the Methods (section 2.6.3) and show initial 
assembly of the C3 convertase (C3b.Bb) followed by its natural decay and then (first spike) addition 
of FH that gives rise to a faster dissociation rate. Finally (second spike) injection of FH ceases and the 
inherent rate of decay resumes. 
6.3 Interaction of FH linker constructs with PspC of S. 
pneumoniae 
In order not to be destroyed by the complement system, many pathogens have 
developed means of avoiding deposition of C3b on their surfaces [110] (as outlined 
in the Introduction). For example, one of the ways S. pneumoniae avoids 
complement-mediated destruction is by expressing the gene for the surface-exposed 
protein PspC, which is a virulence factor that can bind to FH [112]. Previous work 
on the N-terminal segment of PspC (called PspCN) has shown that this is the region 
required to bind FH [183], and that within FH the binding site of PspCN is located 
within the central CCPs 8-10 [184], i.e. well away from the C3b-binding sites in 
CCPs 1-4 and 19-20. It is therefore possible that PspC binding alters the architecture 




As reported below, the various versions of FH 8-15 and full-length FH described in 
the previous Chapter were used to study how mutations in the CCPs 12-13 linker 
affect the binding of PspCN.  In further studies, the effects of PspCN on the 
functions of the FH linker mutants were investigated. 
6.3.1 Binding of linker constructs to PspCN 
Previous work had shown that native-sequence FH 8-15 (WT) binds tightly to 
PspCN with a KD of 1.7 nM [184], and so initial experiments aimed to replicate this 
result. A concentration range of 1, 2, 4, 8, 16, 32 and 64 nM FH 8-15 WT was 
flowed over His-tagged PspCN attached to the chip (see Methods, section 2.6.1) with 
a double injection being performed at 64 nM.  
 
Figure 6.10 Binding of FH 8-15 WT to His-tag PspCN. Background-subtracted traces are shown 
for all concentrations and are coloured as indicated in the key. The dashed lines represent the fitted 
data for each concentration. 
The sensorgrams for FH 8-15 WT (Figure 6.10) showed a rapid association rate (kon) 
and a very slow dissociation rate (koff), as was observed in previous work. When the 
kinetics data from the subtracted traces was fitted to a 1:1 Langmuir model, a KD 
value of 1.3 nM was obtained that is in very good agreement with the previously 
obtained value [184]. A further study was performed to ascertain how the linker 
modifications affected the affinity of FH 8-15 for PspCN. 
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Using identical concentrations of FH 8-15 3xGLY the sensorgrams (Figure 6.11) 
again showed fast association and slow dissociation. The KD value obtained (from 
fitting the subtracted traces to a 1:1 Langmuir model) was 0.7 nM, indicating that 
binding of this mutant to PspCN was at least as good as that of FH 8-15 WT.  
 
Figure 6.11 Binding of FH 8-15 3xGLY to His-tag PspCN. Background-subtracted traces are 
shown for each concentration and are coloured as indicated in the key. The dashed lines represent the 
fitted data for each concentration. 
In a further SPR experiment, an identical concentration series of FH 8-15 SL was 
flowed over PspCN. Again, rapid association and slow dissociation were observed 
(Figure 6.12), with an estimated KD of 0.5 nM. Although the data does not fit quite 
as well to the binding model as for the other constructs, it is reasonable to conclude 
that this mutant binds at least as well as FH 8-15 WT and FH 8-15 3xGLY to 
PspCN.  
In summary, these results are consistent with the binding of PspCN to CCPs 8-10 
within FH 8-15 independently of the CCPs 12-13 linker. The results are inconsistent 
with a model in which CCPs 8-15 wrap around PspCN to form the stable complex. 
The observation that FH 8-15 binds about 30-fold better than FH 8-9 [184] therefore 
suggests that CCP 10 additionally interacts with PspCN (and this was supported by 
cross-linking studies performed by Zhou Chen, University of Edinburgh, personal 
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communication.) while participation of CCPs 11 or 12 is also possible; a FH 8-10 
construct is needed to test these possibilities. 
 
Figure 6.12 Binding of FH 8-15 SL to His-tag PspCN. Background-subtracted traces are shown for 
each concentration and are coloured according to the legend. The dashed lines represent the fitted data 
for each concentration. 
To examine the effects of the linker mutations in full-length FH, initial SPR 
experiments were performed with plasma-purified FH (purchased from Complement 
Technologies). The concentration series used in this case was 0.25, 0.5, 1, 2, 4 and 8 
nM FH with 8 nM FH being injected twice.  
As expected (Figure 6.13) rapid association is followed by barely detectable 
dissociation. The KD was estimated, by fitting the background-subtracted data to a 
1:1 Langmuir model, at 0.05 pM which is outside the range that can be accurately 





Figure 6.13 Binding of plasma-purified FH to His-tag PspCN. Background-subtracted traces are 
shown for each concentration and are coloured according to the key. The dashed lines represent the 
fitted data for each concentration. 
Virtually identical results were obtained with recombinant FH (Figure 6.14), 
although the fit of the data to the model was poor, particularly for the highest 
concentration of FH. This is the appropriate control protein for the mutants of FH 
produced in the current study. 
 
Figure 6.14 Binding of recombinant FH WT to His-tag PspCN. Background-subtracted traces are 
shown for each concentration and are coloured according to the key. The dashed lines represent the 
fitted data for each concentration. Poor fits were obtained for some of the traces but this did not affect 
the overall conclusion that recombinant FH binds to PspCN with approximately the same affinity as 
plasma-purified FH does. 
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The sensorgrams (Figure 6.15) for the equivalent experiment carried out with FH 
3xGLY again showed effectively irreversible binding to PspCN. The KD value 
obtained was 10-fold weaker at 0.45 pM, but it is hard to ascribe much meaning to 
such a value since these affinities are outside the range that can be accurately 
determined by SPR. 
 
Figure 6.15 Binding of FH 3xGLY to His-tag PspCN. Background subtracted traces are shown for 
each concentration and are coloured as indicated in the key. The dashed lines represent the fitted data 
for each concentration. 
The results for FH SL (Figure 6.16) suggested an increase in the dissociation rate 
compared to that seen for FH WT and FH 3xGLY. The complex formed with PspCN 
by this linker mutant is not irreversible; dissociation is perceptible over the 30-
minute course of data collection. In this case a KD of 80 nM was estimated although 
the data does not fit particularly well to the binding model so there is a large error 




Figure 6.16 Binding of FH SL to His-tag PspCN. Background-subtracted traces are shown for each 
concentration and are coloured as indicated in the key. The dashed lines represent the fitted data for 
each concentration.  
In summary it can be concluded that making the FH 12-13 linker more flexible by 
substituting bulky residues with glycine residues does not prevent FH from binding 
very tightly to PspCN, and much more tightly than FH 8-15. This implies that 
modules other than CCPs 8-15 stabilize the FH:C3b complex. Since PspCN is quite 
small (~110 residues) it seems unlikely that more than three or four CCPs (60 
residues each) make simultaneous direct contact with the bacterial polypeptide.  
More likely is that the PspCN stabilizes a conformation of FH in which non-
sequential CCPs participate in complex-stabilizing interactions.  This confirmation is 
unavailable to FH SL that binds no better than FH 8-15 SL. 
Table 6.1 Summary of KD values obtained for FH binding to PspCN 










Full length WT 0.05x10
-12
 
Full length 3xGLY 0.45x10
-12
 





6.3.2 Binding of PspCN:FH complexes to C3b, C3c and C3d. 
Previous work had suggested that the FH:PspCN complex has a higher affinity for 
C3b and C3d than FH alone [184]. Using this observation as a starting point it was 
decided to investigate how PspCN could alter the binding to the C3 fragments of the 
full-length FH linker mutants. 
C3b binding 
A complex of FH and PspCN (FH:PspCN) was formed, using a 2:1 molar mixture of 
the bacterial protein and plasma-purified FH, and this was flowed over the same 
C3b-loaded sensorchip surface (Figure 6.17) that was used for studies of FH in the 
absence of PspCN (section 6.1.1, Figure 6.2). The KD value obtained was 0.16 ± 0.02 
µM, which is approximately three times stronger than that observed for FH alone 
(i.e. no PspCN) binding to C3b. This is entirely consistent with previous 
(unpublished) observations made by other members of the Barlow lab. 
 
Figure 6.17 Binding of plasma-purifed FH:PspCN complex to C3b. In (A) is the background-
subtracted sensorgram with each of the concentrations coloured according to the key. (B) shows the 
plot of response obtained vs. concentration with the calculated KD indicated by the dashed line. 
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The KD value for recombinant FH:PspCN complex binding to C3b (Figure 6.18) was 
determined in the same way, and found to be 0.16 ± 0.02 µM - identical to the 
plasma-purified:PspCN complex and 3.5 times stronger than recombinant FH alone 
(Figure 6.3). 
 
Figure 6.18 Binding of recombinant FH:PspCN complex to C3b. In (A) is the background-
subtracted sensorgram with each of the concentrations coloured according to the key. (B) shows the 
plot of response obtained vs. concentration with the calculated  KD indicated by the dashed line. 
FH 3xGLY:PspCN and FH SL:PspCN complexes were prepared in the same way as 
the wild-type FH:PspCN complexes and flowed over the same C3b-loaded 
sensorchip surface. Note that in the case of FH SL, the injections at the lower 
concentrations (~31, 62 and 125 nM) may in fact contain a mixture of free FH and 
PspcN-complexed FH due to the higher KD for the FH SL:PspN complex (~ 90 nM). 
FH 3xGLY:PspCN (Figure 6.19) and the FH SL:PspCN bound to C3b (Figure 6.20) 
with KDs of 0.24 ± 0.04 µM and 0.42 ± 0.06 µM, respectively. These values 
correspond to a very roughly fourfold increase in affinity for C3b compared to FH 
3xGLY or FH SL on their own. Note that the data for FH SL:PspCN fit well to the 




Figure 6.19 Binding of FH 3xGLY:PspCN complex to C3b. In (A) is the background-subtracted 
sensorgram with each of the concentrations coloured according to the key. (B) shows the plot of 
response obtained vs. concentration with the calculated KD indicated by the dashed line. 
 
Figure 6.20 Binding of FH SL:PspCN complex to C3b. In (A) is the background-subtracted 
sensorgram with each of the concentrations coloured according to the key. (B) shows the plot of 
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response obtained vs. concentration with the KD indicated by the dashed line. 
In summary (Table 6.2) these results deliver a remarkably consistent story in which 
the binding of PspCN brings about an approximately fourfold improvement in 
affinity for C3b. The lower affinity of FH SL for PspCN did not seem to have an 
impact here, perhaps because the FH SL:PspCN KD was overestimated in the 
previously described SPR-based calculation (Figure 6.5); visually those data look 
similar to the date for FH 8-15 SL:PspCN ( KD = ~1 nM, Table 6.1) 
Table 6.2 Summary of KD values obtained for all FH construct binding to C3b with and without 
the presence of PspCN. 
FH construct FH only (µM) FH:PspCN complex (µM) 
Plasma 0.5 ± 0.06 0.16 ± 0.02 
WT 0.58 ± 0.09 0.16 ± 0.02 
3xGLY 1.05 ± 0.18 0.24 ± 0.04 
SL 2.2 ± 0.24 0.42 ± 0.06 
 
C3c binding 
The C3c-binding experiments performed on the FH variants were repeated for the 
equivalent FH:PspCN complexes (Figure 6.21). There was some evidence of binding 
to the immobilized C3c on the chip, but it was characterized by fast off and on rates 
and low responses, suggesting weak or non-specific binding.  There were significant 
differences between the proteins tested, with FH SL:PspCN showing the smallest 
response, while recombinant FH:PspCN produced the biggest response. It is possible 




Figure 6.21 Binding of FH:PspCN complexes to C3c. Each sensorgram shows the background-
subtracted curves with the concentrations used coloured according to the keys. (A) plasma-purified 
FH:PspCN, (B) FH 3xGLY:PspCN, (C) FH WT:PspCN and (D) FH SL:PspCN. 
C3d binding 
Upon the addition of PspCN to form the FH:PspCN complex (Figure 6.22) a KD 
value of 2.3 ± 0.2 µM was obtained for C3d. This exceeds the highest concentration 
used for the SPR experiment (2 µM) but the data fit well to the model and this 
calculated value is probably quite reliable. This is dramatically better than the 
binding of FH alone (for which only a tiny response was recorded and no KD could 
be accurately determined). This is in line with previously obtained results, and is 
consistent with the aforementioned enhanced affinity of FH:PspCN for C3b. 
Importantly, it suggests that PspCN reveals a previously masked or cryptic C3b/d-




Figure 6.22 Binding of plasma FH:PspCN complex to C3d. In (A) is the background-subtracted 
sensorgram with each of the concentrations coloured according to the key. (B) shows the plot of 
response obtained vs. concentration, with the calculated KD. Despite this being greater than the 
maximum concentration used in the series, the data fit well to the curve, and the calculation of KD. is 
probably reliable. 
The recombinant FH:PspCN complexes all showed an improvement in binding to 
C3d. For FH WT (Figure 6.23) the KD was 2.1 ± 0.2 µM which is very similar to the 
result seen for the plasma-purified FH:PspCN complex, although the response 




Figure 6.23 Binding of WT FH:PspCN complex to C3d. In (A) is the background-subtracted 
sensorgram with each of the concentrations coloured according to the key. (B) shows the plot of 
response obtained vs. concentration along with the calculated KD. 
For the FH 3xGLY:PspCN complex binding to C3d, the response was high, but the 
calculated KD suggested weaker binding (compared to WT) at 4.5 ± 0.7 µM (Figure 
6.24) that was well in excess of the highest FH concentration used in the series and 
therefore cannot be regarded as wholly reliable. It is however about half as strong as 
the value for WT, which is in line with the relative values for FH WT and FH 




Figure 6.24 Binding of FH 3xGLY:PspCN complex to C3d. In (A) is the background-subtracted 
sensorgram with each of the concentrations coloured according to the legend. (B) shows the plot of 
response obtained vs. concentration with the calculated KD. 
Interestingly, in the case of the FH SL:PspCN complex (Figure 6.25) (unlike FH WT 
and 3xGLY) binding to C3d was much weaker with no sign of approaching 




Figure 6.25 Binding of FH SL:PspCN complex to C3d. In (A) is the background-subtracted 
sensorgram with each of the concentrations coloured according to the key. (B) shows the plot of 
response obtained vs. concentration with the calculated KD. This number is meaningless due to the 
lack of any sign of saturation at 2 M.   
In summary (Table 6.3), FH on its own does not bind with a physiologically 
meaningful KD to C3d. In contrast when PspCN is present both the WT and 3xGLY 
samples bind to C3d about as well as FH 19-20.  
Table 6.3 Summary of KD values obtained for all FH construct binding to C3d with and without 
the presence of PspCN. 
FH construct FH only FH:PspCN complex 
Plasma 12.6 ± 4.27 µM 2.32 ± 0.16 µM 
WT -
A
 2.10 ± 0.20 µM 
3xGLY -
A












6.3.3 Decay-accelerating activity of FH:PspCN complexes. 
From studies of FH and its linker mutants binding to C3b and its fragments, it is 
clear that PspCN enhances the affinity between these proteins. The next step was to 
investigate whether the FH:PspCN complexes also increased the rate of decay of the 
C3 convertase more than FH in isolation. As before, the complexes were formed 
using a 2:1 ratio (PspCN:FH). At the lowest concentration of 2.5 nM (Figure 6.26) it 
is clear that the rate of decay for all of the FH variants has increased compared to 
just FH SL alone. The enhancements seen at 2.5 nM were also evident in assays with 
5 nM and 10 nM FH:PspCN complex. The presence of PspCN clearly boosts the 
ability of all the FH constructs to decay the C3 convertase. 
 
Figure 6.26 Decay-accelerating activity of FH:PspCN complexes. The sensogram have each had 
the background subtracted and proteins are coloured according to the keys. The FH-only sensograms 
(2.5 nM etc) are shown alongside (and to the left of) those for the FH:PspCN complexes (2.5 nM etc. 




Both plasma-purified and recombinant, native-sequence, full-length FH bound to 
amine-immobilized C3b with SPR-derived KD values in the range of 0.5-0.6 µM. 
Both versions of FH had very low affinities for C3c and C3d. Thus the C3d-binding 
site of FH in CCPs 19-20 must be hidden or “cryptic”.  
Both CCPs 12-13 linker mutants (FH 3xGLY and FH SL) bound significantly less 
well to C3b although the differences in affinities (twofold and fourfold, respectively) 
were not radical. This is not surprising given that the C3b-binding regions at either 
terminus of FH remain intact and are at least five modules away from the engineered 
linker. Like wild-type FH, neither mutant bound significantly to C3d or C3c. It was 
notable that the affinity of FH SL for C3b equates with that of CFH 19-20 alone. 
This may indicate that a version of FH with a short, relatively stiff linker between 
CCPs 12 and 13 is unable to bind to its two adjacent recognition sites on C3b 
simultaneously and thus there is no avidity effect. Such a notion is consistent with a 
“sprung open” conformation of FH SL, and it is in agreement with the SAXS and 
NMR data for FH 8-15 SL presented in the previous chapter. On the other hand, the 
low affinity of FH SL for C3d indicates that the C-terminal C3d binding site remains 
cryptic as it is in the wild-type protein 
All variants of FH 8-15 bound tightly (~ 1-2 nM) to PspCN, consistent with a model 
(based on additional evidence, not shown) in which PspCN (~12 kDa) contacts CCPs 
8-10 only. Full-length native-sequence FH (recombinant or plasma-purified) bound 
several orders of magnitude more strongly than FH 8-15 to produce complexes that 
are irreversible on a biological time scale. The actual KD values for these complexes 
of native-sequence FH with the bacterial protein are hard to assess due to their 
extremely slow decay rates. A working hypothesis is that the additional CCPs in full-
length FH (CCPs 1-7 and 16-20) participate in intermodular contacts that favor 
complex formation and stability. A similar observation was made for FH 3xGLY but 
on the other hand it was striking that FH SL did not form an irreversible complex 
with PspCN and its affinity for the bacterial protein was no better than that of FH 8-
15 SL (the calculated KD for FH SL:PspCN was in fact 40-fold weaker than that for 
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FH 8-15 SL:PspCN although visually, the sensorgrams were very similar). Thus, in 
this mutant, the contracted CCPs 12-13 linker prevents the formation of a stable 
complex with PspCN, presumably by disfavoring a conformation that allows the 
intermodular interactions alluded to earlier.  
All of the variants, when in complex with PspCN, bound approximately threefold to 
fourfold better to C3b. Strikingly, PspCN enhances the affinity of plasma-purified 
and recombinant FH for C3d by two orders of magnitude.  A similar result was 
obtained for FH 3xGLY but – interestingly - not for FH SL that displayed little 
affinity for C3d.  In line with the previously suggested hypothesis (above) these 
observations suggest that in the PspCN-stabilized complex. FH has adopted a 
conformation that binds well to C3b. An obvious possibility is that in the complex 
(with FH WT or FH 3xGLY), N-terminal and C-terminal C3b-binding sites are fully 
revealed and juxtaposed appropriately for simultaneous engagement with the two 
adjacent recognition regions on C3b. The revelation of the TED/C3d-binding site is 
not possible in FH SL because the engineered linker prevents the required orientation 
of the modules (CCPs 12 and 13) on either side and this has repercussions for the 
overall dynamic architecture of the FH molecule. Nonetheless (see above) FH 
SL:PspCN is still a better C3b binder than FH SL alone, so some aspects of the 
PspCN-induced “active” conformation must still be achievable despite the short 
linker. 
The rate of decay of the C3 convertase in the presence of FH and FH mutants, with 
and without PspCN, was tested in an SPR-based approach that allowed the formation 
and decay of the C3b.Bb complex to be monitored in real time. The results (in 
absence of PspCN) showed that FH SL had the lowest activity while recombinant 
FH WT and FH 3xGLY had similar rates of decay. In these experiments, plasma-
purified FH underperformed recombinant FH and was almost as poor as FH SL. 
Upon addition of PspCN, decay-accelerating activities were enhanced in all four 
versions of FH but to different extents such that plasma-purified FH and 
recombinant FH as well as FH 3xGLY all had similar activities, while SL now 
stands out for its much poorer performance. These results are again consistent with 
the hypothesis of PspCN stabilizing an active conformation of FH that can bind 
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optimally to C3b within the C3b.Bb complex to displace Bb (that has an overlapping 
binding site on C3b). The short linker between CCPs 12 and 13 presumably 
disfavours adoption of this conformation by FH SL. 
Previous work using SPR has narrowed the binding site for PspCN to CCPs 8 and 9 
of FH and showed that FH 8-15 has a very tight binding affinity for PspCN with a 
very slow off-rate. The results reported here showed that complexes of PspCN with 
the mutants also dissociated very slowly although intriguingly the complex with FH 
8-15 SL did appear to decay more rapidly than WT or 3xGLY and the estimated KD 
for FH 8-15 SL binding to PspCN was accordingly weaker. The poorer fits of the 
data to the binding model in the case of SL provides grounds for caution and suggest 
that these experiments need to be repeated.  
Next, the engineered linkers were characterized in the context of full-length FH. 
Again, FH WT and FH 3xGLY both bound effectively irreversibly to PspCN with 
KD values that were too tight to measure reliably (due to virtually in detectable 
dissociation rates). In the case of the FH SL:PspCN complex, some dissociation was 
evident over the course of the sensogram and a KD in the region of 80 nM was 
calculated. This result is anomalous given that the FH 8-15 SL construct yielded a 2 
nM KD. But it clearly highlights the need for preparation of a fresh sample of FH SL 
and re-recording of the data. In the meantime it remains possible that the SL, despite 
not disturbing the overall compact nature of the central segment of FH, prevents FH 
from binding properly to PspCN.  
The overall conclusion that can be drawn from these experiments is that the 
shortened linker prevents CCPs 12 and 13 from adopting their V-shape. This 
decreases the inherent ability of FH to adopt an active conformation that is stabilised 
by PspCN (to enhance bacterial protection), and which might also be stabilised by 
markers on self-surfaces to afford them the protection they need from C3b 
deposition. These observations are potentially important for understanding the 
mechanism of FH and designing FH-derived therapeutic inhibitors.  
More work, however, is required to firm up the potentially very important reported 
results: most importantly new, bigger, batches the of the full-length FH SL mutant 
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and of FH 8-15 SL should be produced and proteolytic clipping during purification 
(see last chapter) must be avoided. The SAXS data for FH 8-15 WT versus FH 8-15 
SL should be re-collected (using glycerol to avoid radiation damage to the protein) in 
order to firm up the SAXS result suggesting that SL causes FH 8-15 to “spring open” 
and lose its very compact architecture. The SPR data for FH SL and FH 8-15 SL 
need to be repeated several times to obtain accurate, reproducible KD values. It 
would also be important to check the oligomerisation status of both FH SL and FH 
3xGLY using SEC-MALS or AUC, and it would be instructive to conduct cross-


















Chapter 7 Summing up and future work 
The current project was designed to test the hypothesis that the FH molecule adopts a 
dynamic bent-back conformation that allows the binding sites located close to its N 
and C termini to interact simultaneously with their molecular targets on a self (i.e. 
non-complement activating) surface in a selective fashion [49, 65]. 
For the 155-kDa FH to work in this way there must be flexibility within some parts 
of the protein molecule combined with a degree of stability or rigidity elsewhere. 
Flexibility presumably arises mainly through some of the 19 intermodular linkers, 
while stability could derive from interactions between some of the 20 CCP modules 
that are far apart from one another within the FH sequence. The central region of FH 
has been proposed to form a “molecular hinge”-like structure connecting more 
extended “arms” that embrace the target. This model was consistent with studies in 
our lab [52, 55] that were ongoing in the early years of the current project, which 
suggested that CCPs 10-15 are devoid of binding sites but form a compact structure 
in which non-neighbouring (in the sequence) CCPs contact one another. In the 
current project, work focused on a strategy of mutagenesis and structure-function 
studies to probe the functional anatomy of FH with a focus on the role of this 
putative central “hinge” in connecting up two C3b-binding sites.  
First, the ability to produce sited-directed mutants of the N-terminal fragment of FH 
(FH 1-4), and to characterize them using functional assays and biophysical 
techniques, was demonstrated. Two disease-linked mutations were thus shown in the 
current work to be functionally deficient in differing ways.  
Similar techniques were applied to mutants in the linker regions, within the contexts 
both of various fragments and full-length FH. The structures of fragments could be 
studied using NMR and SAXS while the use of EPR for characterizing such mutants 
was explored as a means of determining long-range distance restraints for extended 
and flexible proteins – such as FH and its mutants - that cannot be crystallized and 
are too big for NMR (see below). Functional characterization of full-length FH 
mutants was accomplished using standard assays while some of the shorter 
fragments could be tested for binding to a bacterial protein PspCN. These studies 
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showed for the first time that mutations in the “hinge” and in particular mutations 
that caused the hinge to “spring open” had an effect on the ability of Factor H to bind 
to C3b in a bivalent fashion. 
The well-established EPR method, DEER [135, 139], was the most demanding of 
these techniques since it required the insertion of molecular probes into the protein at 
site-specific positions within the sequence. EPR along with site-directed spin 
labeling (SDSL) allows for distances of between 1.8 and 7 nm to be obtained, but in 
deuterated proteins, measurable distances can be as great as 10 nm [185]; when these 
distance restraints are combined with the short distances obtained from NMR the 
resulting structural information can address hypotheses such as the one outlined 
above. In the current experiments, the EPR spin labels were inserted before the first 
and after the last residues of the natural sequence to minimize the risk of disrupting 
the natural conformation of the protein. Various strategies for SDSL were attempted 
including the incorporation of cysteines and the engineering or proteins to include 
substrates for enzymatic conjugation. The successful derivation of an EPR-derived 
distance in FH 12-13 that matched the equivalent distances in NMR and crystal 
structures was a useful proof of principle. This strategy incorporated two 
transglutaminase tags and, in the case of the double-module construct, FH 12-13 TT, 
as the tag sequence is quite flexible it will be near impossible to gather exact 
distance measurements with this method. 
Initial work presented in this thesis has thus provided a greater insight into how the 
structure and function of FH are related - but further work will be required. 
In order to advance the study on the aHUS mutations located in CCP 1 (Chapter 3) 
full-length versions of FH containing these mutants will be required. A comparison 
of binding of C3b to these mutants, with the anticipation that the presence of the 
second C3b-binding site in CCPs 19-20 could influence the interaction would be 
performed. Also to understand how the mutant full-length proteins would affect cell-
surface interactions, hemolysis assays using sheep erythrocytes coated with C3b 




Three strategies were used for labeling the proteins with the paramagnetic tags 
needed to gather intramolecular distances using EPR, but unfortunately all had 
problems and would benefit from further work (Chapter 4). Whilst the incorporation 
of cysteines did not appear to disrupt the natural disulphides found within FH 12-13 
CC it did appear to cause problems when used in the context of FH 10-13 CC. In 
order to see if there is a limit to the amount of cysteines that can be present a FH 
fragment containing three CCPs (e.g. FH 10-12) could potentially provide some 
answers. 
During the recording of the EPR experiments and mass spectrometry analysis of FH 
12-13 CC it became apparent that only one of the labeling sites was labelled in each 
of the proteins. Adjusting the amounts of reducing agent, excess label and 
transglutaminase enzyme in the reactions may be all that is required to improve the 
labeling efficiency. As mentioned in Chapter 4 the use of unnatural amino acids or 
exploiting the N-glycosylation present in FH may be more logical routes to approach 
but many challenges may also arise. 
In an initial experiment to compare structural changes of the FH 12-13 linker 
mutants it was shown that structurally there are very few changes between the three 
and with regards to flexibility both mutants exhibited more flexibility than the WT. 
SAXS was used to monitor any structural changes that could occur in both FH 8-15 
and FH 10-15 linker fragments. The FH 10-15 fragments all had a similar compact 
structure. For the FH 8-15 constructs it proved difficult to obtain SAXS data as the 
samples were extremely radiation sensitive so conditions will firstly need to be 
optimized to reduce the sensitivity to the x-rays prior to repeating the experiment. 
The second aspect of the linker project focused on the functional changes that the 
modified linkers could cause (Chapter 6). 
Firstly the yields of both FH 3xGLY and FH SL were poor so the use of a P. pastoris 
strain that incorporated the protein disulfide isomerise gene may help improve the 
yields. A further issue that needs addressing is that all the experiments were 
performed using samples that contained clipped protein so all of these experiments 
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need to be repeated using new samples but hopefully adjusting the fermentation 
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Appendix A Media and buffers 
MEDIA COMPOSITION (w/v unless stated otherwise) 
Basal Salts for 15N-labelled fermentor growth 
4% (v/v) glycerol 
0.413% potassium hydroxide 
1.5% magnesium sulphate heptahydrate 
1.82% potassium sulphate 
0.093% calcium sulphate 
2.67% (v/v) ortho-phosphoric acid 
BMGY (Buffered glycerol-complex) 
100 mM potassium phosphate pH 6 
1.34 % YNB 
4x10
-5
 % biotin 
1 % glycerol 
1% yeast extract 
2% peptone 
BMMY (Buffered methanol complex) 
100 mM potassium phosphate pH 6 
1.34 % YNB 
4x10
-5
 % biotin 
0.5 % methanol 




Low-salt LB (Luria-Bertani) 
(low salt is needed for use with zeocin antibiotic) 
0.5 % yeast extract 
1 % tryptone 
0.5 % sodium chloride 
+/- 1.5 % agar 
LB (Luria-Bertani) 
0.5 % yeast extract 
1 % tryptone 
1 % sodium chloride 
+/- 1.5 % agar 
YPD (Yeast extract, Peptone, Dextrose) 
1 % yeast extract 
2 % peptone 
2 % dextrose (D-glucose) 
+/- 1.5 % agar 
EDTA stock solution (ethylenediaminetetraacetic 
acid) 
0.5 M stock adjusted to pH with sodium 
hydroxide 
TAE buffer 50x in distilled H2O 
Tris-acetate (2 M) 
EDTA (100 mM) 








Appendix B vector map and sequencing primers 
 
Sequencing primers: 
Name Sequence (5’ – 3’) 
5’ Sequencing GGGGATTTCGATGTTGCTGTTTTG 





Appendix C Quantification of C3b α and β bands using 
distribution ratios 
As an additional way to quantify the inhibition assay seen in section 3.2.2 was the 
use of distribution ratios. Ratios were calculated using the equation W=X/Y where X 
was the densitometry of the C3b α band and Y the densitometry of the C3b β band.  
For all three experiments the ratios were very similar between 40:0 and 25:15 
followed by a slight increase for the 20:20 and 15:25 samples then an approximate 
linear relationship was seen between 10:30 and 0:40. As the results are very similar 
for each of the experiments it can be concluded that the disease linked mutants R53H 





Appendix D Protein Summary 
In the table below all the constructs are summarized including all the non-native 
sequences found at the N-terminus or C-terminus as well as the FH residue numbers 
that they consist of. The purification method for the proteins used is shown below. 
CONSTRUCT 






1-4 I62 19-263 AGEQKLISEEDL HHHHHH 
1-4 R53H 19-263 AGEQKLISEEDL HHHHHH 
1-4 R78G 19-263 AGEQKLISEEDL HHHHHH 
11-14 CT 628-866 ACG PKPQQFM 
10-15CT 568-927 ACG PKPQQFM 
CODOPT 10-13 WT 567-804 AG - 
CODOPT 10-13 CC 567-804 AGC C 
CODOPT 10-13 TT 567-804 AGPKPQQFM PKPQQFM 
CODOPT 10-13 CT 567-804 AGC PKPQQFM 
CODOPT 10-13 TC 567-804 AGPKPQQFM C 
CODOPT 12-13 WT 690-804 AG - 
CODOPT 12-13 CC 690-804 AGC C 
CODOPT 12-13 TT 690-804 AGPKPQQFM PKPQQFM 
CODOPT 12-13 CT 690-804 AGC PKPQQFM 
CODOPT 12-13 TC 690-804 AGPKPQQFM C 
CODOPT 12-13 3xGLY 690-804 AG - 
12-13 SHORT LINKER 690-804 AG - 
CODOPT 8-15 WT 447-927 AG - 
CODOPT 8-15 3xGLY 447-927 AG - 
223 
 





CODOPT 10-15 568-927 AG - 
CODOPT 10-15 3xGLY 568-927 AG - 





CODOPT FH 3xGLY 1-1217 AG - 





Sequences of FH constructs. Numbering includes the 18 amino acid residues that form the natural 





























































10-15 DNA in 
pPICZαB. 





Trypsin Digest 1D 1H NMR  
11-14 CT 
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